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1.1 Pancreatic ductal adenocarcinoma 
Malignant transformations of the pancreas are classified by the histological origin of the neoplastic cells. 
The most frequent one is the pancreatic ductal adenocarcinoma (PDAC) representing 90% of all pancreatic 
neoplasms (Pelosi et al., 2017). Pancreatic neuroendocrine tumours are the second most common form, 
accounting for 5%, and all tumour subgroups deriving from acinar pancreatic cells (pancreatoblastom, solid-
pseudopapillary neoplasm and pancreatic acinar cell carcinoma) make out less than 5% of pancreatic 
neoplasms (Pelosi et al., 2017). 
1.1.1 Epidemiology 
With less than 4%, the PDAC represents a small share in newly detected cancers but is among the few 
tumour entities with increasing incidence and mortality (Rahib et al., 2014; Q. Zhang et al., 2016). Due to 
demographic changes and the general adoption of a tumour-promoting lifestyle, an annual increase of 1.3% 
on average is estimated in the incidence of PDAC (Rahib et al., 2014). In Germany, more than 18.370 new 
PDAC cases were diagnosed in 2016 (9.180 in men, 9.190 in women) and a total of 19.900 new diagnoses 
are expected for 2020 (10.200 in men and 9.700 in women)(Kaatsch and Spix, 2019). Currently ranked 
fourth in cancer related deaths, it is predicted that PDAC will be the second most lethal neoplasia in the 
United States (US) by the year of 2030 (Figure 1) (Rahib et al., 2014). One reason for this development is 
the lack of specific early symptoms, impeding the introduction of standardised screening methods which 
has considerably contributed to the decline of cancer-induced deaths in other tumour entities (Rahib et al., 
2014; Malvezzi et al., 2018). 80% of all PDAC patients are first diagnosed in late stages of tumourigenesis, 
leaving palliative treatment as only option and leading to an overall 5-year survival rate of less than 10% 
(Q. Zhang et al., 2016; Pelosi et al., 2017; Siegel et al., 2018). The only curative therapeutic approach is the 
chirurgical resection which is eligible for less than 20% of the patients as it requires a localised tumour mass 
(Groot et al., 2018). And even after successful resection, the 5-year survival rate is no more than 17-23% as 
most of the patients develop local recurrence or metastasis causing their death within 18 to 23 months 






Figure 1: Projection of cancer related deaths up to the year of 2030 of the eight most deadliest cancer entities. 
PDAC is estimated to be the second most lethal neoplasia by the year of 2030 in Western countries. Figure modified 
according to (Rahib et al., 2014). 
1.1.2 Pathology 
The pancreas can be divided into an endocrine and an exocrine part. Tumours originating from the 
endocrine cells are less frequent than tumours arising from exocrine cells (Fesinmeyer et al., 2005). The 
latter represent 95% of all pancreatic neoplasms, among which the PDAC is the most frequent entity making 
up 90% of the cases (Han and von Hoff, 2014). It originates from the pancreatic ductal epithelial cells 
(PDEC) and is characterised by a much poorer prognosis than the endocrine and also than other exocrine 
tumours (Fesinmeyer et al., 2005). This is mainly due to its lack of early symptoms impeding timely diagnosis 
and due to its low therapeutic response (Fesinmeyer et al., 2005; Halfdanarson et al., 2009). 
It has long been understood that PDAC develops via precursor lesions, stepwise gaining malignant potential 
and metastatic capacity (Hezel et al., 2006). Most importance is attributed to the Pancreatic Intraepithelial 
Neoplasia (PanIN) which are the most common precursor lesions, albeit not the only ones. Cystic lesions 
such as Intraductal Papillary Mucinous Neoplasms (IPMN) and mucinous cystic neoplasms (MCN) have 
also been reported as early precancerous stages in the development of PDAC (Koorstra et al., 2008; Basturk 
et al., 2015; Pelosi et al., 2017). 
By definition, PanIN are lesions in small pancreatic ducts (Koorstra et al., 2008). They are classified into 
three groups according to their histological and cytological appearance and the grade of dysplasia (Figure 2). 
PanIN-1, further divided into PanIN-1a and PanIN-1b, are low-grade, PanIN-2 intermediate and PanIN-3 
high-grade lesions. Whereas low-grade PanIN are characterised by columnar cells with mucin 
production (1a) or papillary architecture (1b), PanIN-2 are marked by cell crowding, nuclear abnormalities 
and the loss of cell polarity. High-grade lesions show enhanced nuclear atypia, a high mitosis rate and a 
pronounced architectural disorder with cells budding into the ductal lumen. They differ from carcinoma by 
still representing a non-invasive lesion with intact basement membrane (Hruban et al., 2000; Distler et al., 
2014; Pelosi et al., 2017). PanIN-3 are also referred to as carcinoma in situ. 
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Figure 2: PDAC development. Schematic depiction (top) and corresponding histological images (middle) of healthy 
pancreatic ductal epithelium developing to PDAC via precursor lesions with stepwise increasing dysplasia. PDAC 
initiation is accompanied by genetic and epigenetic alterations; the most frequent ones are shown in the lower panel. 
Modified according to (Hezel et al., 2006; Iacobuzio-Donahue, 2012). 
 
The multistep PanIN progression towards PDAC is accompanied by the accumulation of genetic alterations. 
Jones et al. revealed an average of 63 genomic alterations in PDAC, mainly manifested in form of point 
mutations (Jones et al., 2008). Telomerase shortening, an early event observed in 90% of PanIN-1 lesions, 
causes chromosomal instability and predisposes pancreatic lesions to accumulate mutational alterations (van 
Heek et al., 2002; Maitra et al., 2006). 
The most common mutation found in 90% of all PDAC is the activation of the oncogene kras (Kanda et 
al., 2012). The point mutational activation of the GTPase causes permanent signalling via several signalling 
pathways involved in cell proliferation, differentiation, apoptosis and migration (Spaargaren et al., 1995). As 
this alteration is already detectable in many early precancerous lesions (in 36% of all PanIN-1a and 44% of 
all PanIN-1b), it is assumed to be an important contributor not only to the progression but also to the 
initiation of PDAC (Löhr et al., 2005). 
Further frequent mutations are found in other oncogenes and tumour suppressor genes such as 
P16/CDKN2A, TP53 and SMAD4 (found in 90%, 70%, 55% of all PDAC respectively) (Pelosi et al., 2017). 
Together with mutational activation of kras these are commonly referred to as the four driver mutations of 
PDAC (Korc, 2010; Pelosi et al., 2017). Whereas the inactivation of P16/CDKN21 is already detectable in 
PanIN-2 stages, the loss of function of P53 and SMAD4 is a later event in tumourigenesis correlated to 
PanIN-3 stages (Distler et al., 2014).  
Epigenetic alterations also play a meaningful role in PDAC progression. Especially abnormally methylated 
CpG islands, which can lead to the inactivation of certain tumour suppressor genes and metabolic pathways, 
are of importance (Koorstra et al., 2008). Similar to telomerase shortening, hypermethylation is already 
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detectable in early PanIN lesions and shows an increase in prevalence throughout cancer progression. To 
name one example, P16/CDKN21 is not only silenced through genetic alterations (as described above) but 
also by hypermethylation of its promotor region in 15-20% of PDACs (Hruban et al., 2008).  
1.1.3 Risk factors 
With an average age at manifestation timepoint of 75 years in women and 72 years in men, PDAC is a 
disease of elderly people, age featuring as one risk factor (Krebs in Deutschland für 2013/2014, 2017).  
Whereas only 5 to 10% of all PDAC involve a hereditary component, the main proportion of cases is 
associated to lifestyle and environment attributable risk factors (Raimondi et al., 2009). Tobacco 
consumption is shown to increase the risk of PDAC development in an intensity and cumulative dose 
dependent manner, showing an up to 2.2-fold higher risk in smokers than non-smokers. 20 to 35% of all 
PDAC cases are caused by smoking, and even after cessation the risk of PDAC takes 15 to 20 years to adapt 
back to the one of the non-smoking population (Becker et al., 2014). 
Alcohol consumption alone turned out to be not that closely related to PDAC as had long been thought. 
Meta-analyses could show that the consumption of three drinks per day leads to a 1.22 to 1.36-fold elevated 
risk for PDAC (Becker et al., 2014; Rahman et al., 2015). Alcohol in combination with smoking, however, 
significantly increases the risk of PDAC (Rahman et al., 2015). Furthermore, sincere alcohol abuse is 
correlated with pancreatitis which, in its chronic form, is also considered as a risk factor of PDAC with a 
13.3-fold relative risk (Becker et al., 2014). 
Additionally, obesity is linked to an increased probability of PDAC development. A study of the year 2003 
could show that a body mass index (BMI) higher than 40 is associated with a relative risk of 1.49 and 2.76 
for men and women, respectively, assigned to the obesity-induced inflammatory tissue (Calle et al., 2003). 
Moreover, a high fat diet has been connected to enhanced kras activation and increased tumour formation 
(Philip et al., 2013). 
Similarly, a meta-analysis could show that with every 0.56 mmol/L increase in fasting blood glucose, PDAC 
risk is elevated by 14% (Liao et al., 2015), thereby identifying type II diabetes mellitus (T2DM) as a further 
risk factor. Cohort studies stated a 2-fold higher probability for diabetic patients to develop PDAC 
compared to the non-diabetic population (Becker et al., 2014). However, no correlation between the 
duration of diabetic illness and risk magnitude was identified, and in 39% of the cases diabetes and PDAC 
where even diagnosed simultaneously (Hassan et al., 2007). Hence, diabetes is discussed as both 
consequence and risk factor of PDAC. Molecular mechanisms linking T2DM and PDAC will be discussed 
in detail in the following section. 
Dietary changes have led to increased incidence of obesity and T2DM worldwide. It is therefore estimated 
that metabolic diseases associated with impaired glucose tolerance will become important risk factors for 
PDAC in the future (Malik et al., 2010; Matrisian et al., 2012). 
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1.1.4 Type II diabetes mellitus, obesity and PDAC 
T2DM and obesity are considered two important risk factors of PDAC development, even though the 
underlying molecular interactions are not fully understood. As they share several pathological characteristics, 
their individual impacts on PDAC intersect and are not to be clearly distinguished (Chang and Yang, 2016). 
T2DM, which is also referred to as “non-insulin dependent diabetes”, represents the most common form 
of diabetic diseases with 90 to 95% of all cases (Chang and Yang, 2016). It is characterised by an insulin 
resistance with compensatory elevated insulin levels leading to hyperglycaemia. Obesity is characterised by 
chronical low-grade inflammation and correlated to the acquisition of an impaired insulin metabolism and 
the occurrence of T2DM (Wellen and Hotamisligil, 2015). The fact that 86% of diabetic patients are 
overweight or obese (Daousi et al., 2006), underlines the close link between these two diseases. 
As insulin can inhibit the production of insulin-like growth factor (IGF) binding protein in the liver, excess 
in insulin induces elevated levels of active IGF-1. Consequently, downstream signalling of insulin and IGF-1 
(e.g. via the mitogen-activated protein kinase (MAPK) or protein kinase B (AKT)) is promoted, causing 
proliferation, invasion and decreased apoptosis as well as enhanced expression of angiogenesis mediators 
(Pollak, 2009). These pathways are often dysregulated in PDAC (Li and Mao, 2015), suggesting an 
involvement of insulin/IGF-1 signalling in PDAC development. This is encouraged by findings of Duan et 
al. who demonstrated diminished PDAC risk via the reduction of insulin and IGF-1 by metformin treatment 
(Duan et al., 2017). Similar results were also obtained in in vivo experiments: metformin administration was 
shown to inhibit the growth of Panc1 xenografts in nude mice (Kisfalvi et al., 2013). 
A further link between T2DM, obesity and PDAC is inflammation. Both diabetic and obese tissues are 
characterised by chronic low-grade inflammation. Pro-inflammatory cytokines such as Interleukin - 6 (IL-6) 
and Tumour necrosis factor-alpha (TNF-a), transcriptional factors such as Nuclear Factor kappa-light-
chain-enhancer of activated B-cells (NF-kB) and Signal Transducer and Activator of Transcription 3 
(STAT3) as well as adipokines promote tumour growth, migration and invasiveness through interaction 
with tumour-promoting immune cells (Scholz et al., 2003; Sciacca et al., 2013; Chang and Yang, 2016). In 
line with this, Braune et al. recently demonstrated that IL-6 stimulates macrophages in adipose tissue and 
promotes their local proliferation (Braune et al., 2017). Moreover, inflammation-induced abundant reactive 
oxygen species (ROS) production damages cellular components and also contributes to malignant 
progression (D. Li, 2012; Wellen and Hotamisligil, 2015). 
In a KrasG12D mouse model, obesity provoked ample inflammatory signs characterised by a high number 
of infiltrating cells (especially macrophages), an elevated level of inflammatory cytokines and enhanced 
stromal fibrosis. These reactions resulted in an accelerated formation of PDAC precursor lesions (Dawson 
et al., 2014). The group of Lanza-Jacobi demonstrated that calorie restriction in LSL-KrasG12D; Pdc-1/Cre 
mice attenuates PDAC progression by reduction of cell proliferation, IGF-1 levels and expression of the 
glucose transporter Glut1 among others (Lanza-Jacoby et al., 2013). 
In a diabetic mouse model, persistent exposure to hyperglycaemia and inflammatory microenvironment also 
led to accelerated tumour growth. Therapeutic intervention inhibiting inflammatory signalling not only 
decreased the tumour volume in diabetic mice but also led to prolonged survival (Wang et al., 2016). 
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Furthermore, both metabolic disorders encourage a remodelling of the pancreatic microenvironment 
(Mohapatra et al., 2015; Yang et al., 2016). High glucose and insulin levels activate pancreatic stellate cells 
which adopt a proliferative myofibroblast phenotype and produce a bulk of extracellular matrix (ECM) 
proteins and cytokines. This subsequently leads to pronounced fibrosis and desmoplasia and promotes 
PDAC development (Yang et al., 2016). 
It is evident that a better understanding of the molecular interaction linking T2DM, obesity and PDAC is 
of great importance for developing screening methods for detection of high-risk patients and improved 
therapeutic options. And as these metabolic disorders can be positively influenced by the adoption of a 
healthier lifestyle, it also seems important to sensitise the population for the magnitude of the two risk 
factors. 
1.1.5 Inflammatory microenvironment in PDAC 
PDAC progression is characterised by a gradually increasing desmoplastic stroma. First signs of tissue 
remodelling and inflammatory infiltration are already detectable in precursor lesions (Rasheed et al., 2012). 
Whereas desmoplasia is counted among the hallmarks of cancer in various cancer entities (Hanahan and 
Weinberg, 2011), the extent to which it is present in PDAC is unique: up to 90% of the entire tumour mass 
can be made up by dense stroma (Erkan et al., 2012). Within this vast compartment a complex interplay 
takes place between fibroblasts, pancreatic stellate cells (PSC), immune cells, ECM proteins such as collagens 
I and III and fibronectin, blood vessels, hyaluronic acids and various secreted soluble mediators; this 
interplay impacts on tumour progression (Rasheed et al., 2012). An advanced degree of desmoplastic 
reaction has been shown to correlate with poorer clinical outcome (Erkan et al., 2008). 
The major contributors to the desmoplastic reaction are PSC (Pandol et al., 2009; Rasheed et al., 2012). In 
healthy tissue they are present in a quiescent state, characterised by a slow proliferation rate and low 
production of ECM proteins and cytokines (Masamune and Shimosegawa, 2009). In PanIN- and PDAC-
associated stroma, however, they are activated and switch into a myofibroblastic state with an amplified 
secretion rate (Masamune and Shimosegawa, 2009; Pandol et al., 2009). In particular, elevated levels of 
Transforming Growth Factor-b1 (TGF-b1), Fibrocyte Growth Factor (FGF) and Epidermal Growth 
Factor (EGF) have been shown to impact on tumour progression (Masamune and Shimosegawa, 2009; 
Merika et al., 2012). Moreover, increased secretion of Matrix Metalloproteinases (MMP) has been described 
in the context of PSC activation. MMP are able to break down basement membranes, thereby facilitating 
the metastatic spreading of cancer cells (Bergers et al., 2000; Phillips et al., 2003).  
Besides PSC, infiltrating immune cells including mast and plasma cells, macrophages and leucocytes 
contribute to the desmoplastic reaction (Pandol et al., 2009). Especially, tumour-associated macrophages 
(TAM) are of importance (Grivennikov et al., 2011). They encourage tumour initiation by producing ROS 
and reactive nitrogen intermediates (RNI), leading to DNA damage and paving the way for tumour 
promoting mutations (Figure 3). Besides this, macrophages can also promote ROS accumulation inside 




Figure 3: Impact of an inflammatory microenvironment on PDAC progression. A) Inflammatory cells produce 
ROS and RNI leading to mutational alterations in PDEC. Additionally, immune cell derived pro-inflammatory 
cytokines stimulate PDEC to produce ROS and RNI themselves and initiate epigenetic mechanisms resulting in 
tumour initiation. B) Kras mutated PDEC produce cytokines which activate inflammatory signalling cascades via NF-
kB and STAT3 promoting cell survival, proliferation, growth, angiogenesis and invasion. Moreover, immune cells are 
attracted and stimulated to secrete IL-6 and TNF-a which further enforces STAT3 and NF-kB activation in PDEC. 
Tumour progression is promoted. Modified according to (Grivennikov et al., 2011). 
Additionally, mutated kras plays an important role in the inflammatory microenvironment of PDAC 
(Gukovsky et al., 2013). Kras-dependent secretion of inflammatory cytokines activates STAT3 and NF-kB 
in an autocrine manner and simultaneously attracts immune cells which activate STAT3 or NF-kB in a 
paracrine manner by secreting IL-6 or TNF-a and IL-1, respectively. These self-amplifying signals promote 
cell survival, proliferation and invasiveness of PDEC (Lesina et al., 2011; Gukovsky et al., 2013). IL-6 seems 
to play an especially important role: elevated IL-6-serum levels in PDAC patients have been correlated with 
enhanced tumour growth and poorer prognosis (Scholz et al., 2003; Ebrahimi et al., 2004). Similarly, 
deficiency of its downstream effector STAT 3 diminishes PanIN formation (Scholz et al., 2003; Lesina et 
al., 2011). 
Further possible  mechanisms by which inflammatory cells promote tumour progression are the generation 
of an immunosuppressive microenvironment through secretion of IL-8, IL-10 and TGF-b1 (Kleeff et al., 
2007; Rasheed et al., 2012), regulation of angiogenesis via the Vascular Endothelial Growth Factor (VEGF) 
and immune surveillance (Pandol et al., 2009).  
Moreover, enhanced desmoplasia has been shown to promote chemoresistance in PDAC in several studies 
(Müerköster et al., 2004, 2008, Miyamoto et al., 2004). 
1.2 Macrophages 
1.2.1 Origin, polarisation and function 
Macrophages are myeloid innate immune cells occurring throughout the body tissue and are endowed with 
a wide range of functions. The phagocytes are involved in tissue protection and regeneration, in the defence 





against pathogens, in inflammatory processes and in the promotion of tumour cell proliferation and 
dissemination (Shi and Pamer, 2009; Sica et al., 2015). Since their first description by Ilya Metchnikoff there 
were several theories concerning their origin leading up to the current understanding that the majority of 
macrophages are tissue resident ones, formed prenatally and characterised by longevity and the capacity of 
self-renewal (Yona et al., 2013; Epelman et al., 2015). Additional macrophages can differentiate from 
monocytes in the form of a constant replenishment during homeostasis or in an enhanced form to back up 
local macrophages during inflammation (Varol et al., 2015). Monocytes derive from the bone marrow and 
are released into the bloodstream allowing them to circulate throughout the whole body (Serbina et al., 
2008). They can express a broad range of chemokine receptors such as CCR1, CCR2, CXCR2 and CX3CR1 
(Serbina et al., 2008). In case of tissue damage or inflammation, monocytes are attracted to the site by 
chemoattractants such as CCL2 and infiltrate into the tissue. Their further differentiation is strongly 
dependent on the stimuli they receive from the local microenvironment (Geissmann et al., 2010; Sica et al., 
2015). A dichotomic classification of M1- and M2-macrophages has been established, considering the 
expressed cytokine profile and manner of activation (Figure 4). M1-macrophages are also referred to as 
classically activated macrophages and are induced by either lipopolysaccharides (LPS), Interferon-g (IFNg) 
expressed by T-helper cells type 1 (Th1) or the Granulocyte macrophage - colony stimulation factor (GM-
CSF) (Sica et al., 2015). They are characterised by a pro-inflammatory profile with enhanced secretion of 
IL-1b, IL-6, IL-12 and TNF-a and the possibility to attract further immune cells via chemokines such as 
CCL9 and CCL10 (Rőszer, 2015). Moreover, high expression levels of CD11c are a marker of classical 
macrophage activation (Torres-Castro et al., 2016). Due to an amplified expression of the human leucocyte 
antigen DR (HLA-DR), classically activated macrophages have a great capacity to present antigens. Through 
high expression levels of Toll-like receptor 2 (TLR2) and inducible NO synthase (iNOS) as well as an 
increased production of ROS and reactive nitrogen species (RNS), they are capable to react in a bactericidal 
manner upon invasion of pathogens (Tan et al., 2016; Mills et al., 2016). Given these pro-inflammatory 
characteristics M1-macrophages are often classified as tumour suppressive cells (Mantovani et al., 2006). 
M2-macrophages on the other hand are induced by IL-4 and IL-13 expressed by T-helper cells type 2 (Th2) 
or by Macrophage-colony stimulating factor (M-CSF) (Martinez and Gordon, 2014). This is also referred to 
as alternative activation. They are characterised by the secretion of the anti-inflammatory cytokines IL-10 
and IL-1-receptor antagonist (IL-1ra), secretion of the growth factors TGF-b, VEGF, EGF and FGF, which 
are correlated to angiogenesis, tissue remodelling and wound healing (Rőszer, 2015). CCL17, CCL18 and 
CCL22 are chemokines indicating M2-activation (Rőszer, 2015). Furthermore, M2-macrophages are known 
to express high levels of the mannose receptor CD206, the scavenger receptors CD163 and CD204 and 
Arginase-1 (Arg-1) (Sica et al., 2006; Torres-Castro et al., 2016). In the tumour context, alternatively 




Figure 4: Differentiation into M1- and M2-polarised macrophages is dependent of the received stimuli from 
the microenvironment. Schematic overview of macrophages’ polarisation and their distinct surface markers, soluble 
factors and main functions. Figure modified according to (Sica et al., 2006). 
Even though the differentiation between M1- and M2-macrophages is well established in the literature and 
is a useful tool in in vitro experiments, it is not that easily transferrable into in vivo situation. Recent work has 
shown that macrophages cannot always be categorised into one of these two extremes as they often express 
a mixed phenotype (Helm et al., 2014a). Furthermore, they can even exhibit a certain plasticity, showing 
more pro- or anti-inflammatory characteristics depending on the local microenvironment they are exposed 
to (Helm et al., 2014a; Martinez and Gordon, 2014). 
1.2.2 Macrophages, hyperglycaemia and obesity 
M1- and M2-polarised macrophages differ in their primary metabolic pathways. Whereas the pro-
inflammatory macrophages predominantly rely on glycolysis to meet their energetical needs, anti-
inflammatory macrophages metabolise fatty acids via oxidative phosphorylation (Vats et al., 2006). In line 
with this, in vitro and in vivo experiments have shown that LPS-triggered M1-polarisation of macrophages 
leads to metabolic reprogramming with consecutive enhanced glycolysis (Blagih and Jones, 2012; Haschemi 
et al., 2012). 
However, several other studies promote the idea that it is the glucose metabolism that shapes the phenotype 
of macrophages. The group around Freemerman could show that macrophages in inflammatory tissues 
express enhanced levels of Glut-1 transporters. The resulting pronounced glucose uptake into the cells leads 
to a metabolic switch towards glycolysis with resulting lactate and ROS accumulation and enhanced pro-
inflammatory phenotype of macrophages (Freemerman et al., 2014). 
High glucose levels also alter the cytokine expression profile of macrophages promoting a pro-inflammatory 
M1-associated phenotype. Enhanced levels of TNF-a, IL-1b, IL-6, IL-8 and IL-12 among others were 







































exposure to hyperglycaemia. These transcriptional upregulations were partially dependent of NF-kB 
activation (Pan et al., 2012; Cheng et al., 2015). Similarly, increased levels of CD11c and iNOS and decreased 
levels of Arg-1 and IL-10 also imply a polarisation towards an M1-phenotype in a hyperglycaemic 
microenvironment (Torres-Castro et al., 2016). Furthermore, high CD11c expression on macrophages could 
be correlated with higher BMI, insulin resistance and excess triglycerides in hyperglycaemic patients, 
highlighting the close correlation between obesity, hyperglycaemia and inflammatory processes (Torres-
Castro et al., 2016). This is in line with previous findings that the adipose tissue of lean individuals 
predominantly comprises M2-macrophages, whereas there is a shift towards M1-macrophages with weight 
onset (Johnson et al., 2012; Castoldi et al., 2016). Within the adipose of obese, a complex crosstalk between 
adipocytes and macrophages with abundant secretion of chemokines and cytokines adopts a self-enhancing 
character recruiting further macrophages and adipocytes and promotes inflammation and insulin resistance 
(Xu et al., 2003; Weisberg et al., 2003) (Figure 5). 
Additionally, hypoxia is a common feature of adipose tissue and an initiator of M1-polarisation. Besides 
leading to increased Glut-1 expression, levels of pro-inflammatory cytokines are enhanced upon exposure 
to hypoxic conditions (Fujisaka et al., 2013). 
There is evidence that the reciprocal influence between hyperglycaemia, obesity and macrophages adopts a 
crucial role within diseases and inflammatory processes. As the incidence of metabolic disorders such as 
T2DM and obesity rise in an alarming pace, an integral grasp of the intertwined signalling cascades is of 
great importance for potential therapeutic targeting. One such possible target is the intervention into 
metabolic pathways of macrophages thereby disabling their repolarisation and acquaintance of a pro-
inflammatory character. 
Figure 5: Schematic illustration of macrophage polarisation in healthy state (lean) and metabolic disorder 
(obesity/T2DM). In lean state (left), M2-polarised macrophages form the predominant immune cell population in 
fat tissue. They rely on STAT6- and PPARγ,b,d-dependent oxidative phosphorylation to meet their energetical needs. 
This is facilitated by PGC-1ß and CARKL. M2-macrophages secrete anti-inflammatory cytokines and growth factors 
such as IL-10 and TGF-b1. In the state of metabolic disorder (e.g. Obesity or T2DM), macrophages adopt a pro-
inflammatory M1-related phenotype with secretion of TNF-a, IL-1b, IL-6 and others (right). They primarily 
metabolise glucose via hypoxia-inducible factor-1a (HIF-1a)-dependent glycolysis. For this, further intracellular 
molecules such as TLR2/4, STAT1, Glut-1, mTORC1 need to be activated. Downstream targets of TLRs such as 
JNK, ERK, IkB, IKKβ, and Pi3Kγ are intertwined in the signalling cascade promoting insulin resistance. 






























1.2.3 Macrophages in PDAC 
As described in section 1.1.5, the composition of the tumour micromilieu does not only have an important 
role in regard to PDAC progression but is also of prognostic value. As TAM are one of the main immune 
cell populations within the desmoplastic stroma and macrophage accumulation is also described for other 
tumour entities besides PDAC, their role in tumour promotion has been analysed in various studies in the 
recent years (Noy and Pollard, 2014). Zhu et al. recently showed that TAM derive from tissue resident 
macrophages (embryonic origin) as well as from circulating monocytes (Zhu et al., 2017). Despite slightly 
differing functionalities and key points of attack, all TAM promote tumour growth by enhanced cytokine 
secretion and angiogenesis, immune evasion mechanisms and cytotoxic activities (Sica et al., 2015). 
The majority of TAM in PDAC are positive for both cell surface markers CD163 and CD204, which 
classifies them as M2-polarised macrophages according to the dichotomic model (Nielsen et al., 2016). 
Several studies have shown that the number of M2-macrophages present within the pancreatic stroma is 
closely correlated to the prognosis of PDAC patients (Ino et al., 2013; Protti and De Monte, 2013). Kurahara 
et al. were able to link poorer survival of PDAC patients with abundant M2-polarised macrophages to 
enhanced lymph node metastasis. One possible explanation for this is that the increased VEGF production 
of M2-macrophages leads to enhanced formation of peritumoural lymph vessels (Kurahara et al., 2011, 
2013). Further pro-tumourigenic factors excreted by TAM are IL-6, IL-10, TNF-a and VEGF (Mantovani 
et al., 2006; Hermano et al., 2014). As described in section 1.1.5, IL-6 promotes tumour progression via 
STAT3 signalling (Lesina et al., 2011). In low concentrations corresponding to those of TAM secretion, 
TNF-a predominantly promotes cancer cell growth and angiogenesis similar to VEGF (Sica et al., 2015). 
Moreover, macrophages in PDAC tissue are characterised by higher CCL18 levels than in healthy pancreatic 
tissue. Meng et al. stated a CCL18-dependent upregulation of the transcriptional factor Snail in PDEC, 
indicating progression via Epithelial Mesenchymal Transition (EMT) (Meng et al., 2015). Macrophages’ 
contribution to PDAC progression was further corroborated through the finding, that CCL18 promotes an 
NF-kB-dependent increase of Vascular Cell Adhesion Molecule-1 (VCAM-1), which encourages 
proliferation, colony formation and mobility of PDEC. Additionally, VCAM-1 promotes a metabolic shift 
in PDEC towards enhanced glycolysis leading to lactate accumulation, which activates and polarises TAM 
towards M2-macrophages in a positive feedback loop (Meng et al., 2015; Ye et al., 2018). 
There are several other pathways also associating macrophages to PDAC progression. The macrophage 
kinase PI3Kg has been shown to initiate crucial signalling cascades for the promotion of an 
immunosuppressive micromilieu allowing immune evasion and tumour cell growth (Kaneda et al., 2016a; 
Kaneda et al., 2016b). Its signalling cascades via AKT/mTOR diminish NF-kB-dependent transcription of 
pro-inflammatory cytokines and simultaneously promotes the transcription of immunosuppressive factors 
such as Arg-1 (Kaneda et al., 2016a). 
However, TAM do not exclusively exhibit characteristics concomitant with anti-inflammatory M2-
macrophages but also M1-attributed ones. Pro-inflammatory features such as an ample secretion of IL-1b, 
IL-6, TNF-a, CCL2 and expression of HLA-DR, among others, are also detectable in TAM and contribute 
to their PDAC promoting effect (Helm et al., 2014b; Hermano et al., 2014). Likewise, isolated TAM and in 
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vitro generated M1- and M2-macrophages were shown to promote EMT in benign and malignant PDEC, 
independently of their phenotype (Helm et al., 2014a). 
1.3 Malignant progression 
The capacity of local invasion and metastasis of tumour cells are comprised among the hallmarks of cancer 
by Hanahan and Weinberg (Hanahan and Weinberg, 2011). Over 90% of all cancer patients die as a 
consequence of advanced metastatic disease and not of the primary tumour itself, underlining the 
significance of malignant progression (Gupta and Massagué, 2006). 
The invasion-metastasis cascade is a well described phenomenon composed of a complex course of events. 
These include local invasion into the surrounding tissue, intravasation into the nearby blood-vessels, 
adherence in distant organ tissue with successive extravasation, formation of micrometastasis and 
proliferation (Gupta and Massagué, 2006). 
In PDAC, metastatic spreading is a common and early event in tumourigenesis (Rhim et al., 2012; Gaianigo 
et al., 2017). Therefore, the understanding of the mechanisms orchestrating malignant progression is of 
great importance towards improved therapeutic targeting. It is possible that primary and secondary tumour 
lesions possess differing resistance mechanisms towards chemotherapy and call for an adapted therapeutic 
approach for effective targeting (Gaianigo et al., 2017). 
1.3.1 Epithelial-Mesenchymal-Transition 
A prerequisite for malignant progression is the ability of cells to overcome the intrinsic epithelial barrier in 
order to leave the primary context (Thiery et al., 2009). For this, changes in cell morphology and 
functionality are necessary and underlie a complex program summarised as EMT (Kalluri and Weinberg, 
2009). It comprises the loss of epithelial markers and subsequent dissolution of cell-cell-contacts, the loss 
of cellular polarisation and the gain in mesenchymal characteristics including enhanced motility (Valastyan 
and Weinberg, 2011). Physiological forms of EMT are undergone during embryonic development: 
implantation, gastrulation and neural crest development in all vertebrates rely on this process (Thiery et al., 
2009). Similarly, wound healing and tissue regeneration are dependent on EMT (Thiery et al., 2009). 
Pathological forms of EMT are associated with organ fibrosis and cancer progression (Kalluri and Weinberg, 
2009; Thiery et al., 2009). 
A key-step in the process of EMT is the reduction of E-Cadherin, an adhesion molecule contributing to the 
maintenance of stable cell-cell-contacts via adherens- and tight-junctions (Peri et al., 1998). Its expression 
levels have been shown to be inversely correlated with patient survival in various cancer entities (Yang et 
al., 2014; Li et al., 2017; Radulović and Krušlin, 2018). The downregulation of the epithelial marker is closely 
linked to the upregulation and enhanced activity of EMT-inducing transcription factors such as Slug, Snail 
and Zeb1, which repress E-Cadherin expression through binding to its promotor (Peinado et al., 2007; 
Weinberg, 2008). Simultaneously, the transcription of other epithelial markers such as Occludin and Claudin 
is also repressed, whereas it is induced in the case of mesenchymal markers such as Vimentin and alpha-
Smooth Muscle Actin (a-SMA) (Peinado et al., 2007). There are several other known points of interaction 
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for EMT regulation. For example, Snail can induce Zeb1 expression, thereby intensifying and prolonging 
its repressive effect on epithelial genes (Guaita et al., 2002). Additionally, an interplay of microRNA 
(miRNA) and EMT-inducing transcriptional factors has been identified. Members of the miRNA-200 family 
which are promotors of epithelial differentiation are repressed by Zeb1 (Korpal et al., 2008; Wellner et al., 
2009). 
Furthermore, the tumour microenvironment plays a crucial role in malignant progression. TAM, cancer 
myofibroblasts and other cells of the desmoplastic stroma produce pro-inflammatory cytokines and growth 
factors such as IL-1b, IL-6, TNF-a and TGF-b1, which are strong EMT inducers (Xu et al., 2009; Jing et 
al., 2011; Leibovich-Rivkin et al., 2013). Their effect is predominantly exerted via ROS- and NF-kB-
dependent signalling (Rhyu et al., 2005; Karin, 2006). Among these pro-inflammatory factors, TGF-b1 is 
referred to as one of the most potent EMT inducers (Jing et al., 2011). Through both SMAD-dependent 
and -independent (e.g. p38/JNK/MAPK or PI3k/AKT/mTOR) signalling pathways, it influences the 
transcription factors Snail, Slug and Zeb1 (Xu et al., 2009). Additionally, its impact on the EMT program 
can be amplified by autocrine TGF-b1 production (Kalluri and Weinberg, 2009). Moreover, TGF-b1 is 
intertwined with the induction of the adhesion molecule L1CAM. Upon exposure to myofibroblasts, 
L1CAM expression in PDEC is upregulated in a TGF-b- and Slug-dependent manner, leading to a more 
mesenchymal and motile phenotype (Geismann et al., 2009). 
Several other stress associated factors are known to play a pivotal role in the acquisition of metastatic 
potential. T2DM-related hyperglycaemic conditions were shown to foster EMT progression in PDAC 
(Zhou et al., 2010; Rahn et al., 2018) and other tumour entities such as breast cancer (Samuel et al., 2018) 
and colorectal cancer (Wu et al., 2018). The underlying mechanisms are multifold but are all closely linked 
to inflammatory signalling cascades (Wang et al., 2016; Li et al., 2016). Similarly, hypoxia induces EMT 
through HIF-1a and ROS accumulation and increases in TGF-b1-levels (Jing et al., 2011). 
1.4 Cancer stemness 
1.4.1 Stem cells  
Stem cells are a small cell population within the tissue of mammals and can be divided into two groups 
according to their origin (Herreros-Villanueva et al., 2014). Embryonic stem cells derive from the inner cell 
mass of a blastocyst and are pluripotent, which implies that they can differentiate into all cell types (Donovan 
and Gearhart, 2001). Multipotent adult stem cells can be found in various tissues throughout the body and 
are of great importance for the maintenance of homeostasis and in the context of wound healing (Alison et 
al., 2002). 
Adult stem cells are characterised by their ability to undergo both symmetric and asymmetric cell division, 
giving them the unique capacity of self-renewal (Figure 6). Symmetric cell division implies that one stem 
cell gives rise to two identical daughter stem cells, allowing the maintenance and regulation of their cell 
number. By asymmetric cell division, one stem cell gives rise to one daughter stem cell and one progenitor 
cell which can subsequently differentiate into a functional tissue cell. Controlled asymmetric cell division is 
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essential for growth, tissue remodelling and wound healing (Fulawka et al., 2014; Batlle and Clevers, 2017). 
Whereas stem cells are long-living and possess an intermittent division rate with a slow cell cycle, their 
progenies are short-living but highly proliferative (Morrison and Kimble, 2006; Fulawka et al., 2014). 
Figure 6: Schematic overview of stem cell division. Stem cells can divide in a symmetric manner giving rise to two 
identical daughter stem cells or in an asymmetric manner giving rise to one daughter stem cell and one progenitor cell 
capable of differentiation to various specialised tissue cells. An equilibrium of both forms of cell division is of 
importance for the maintenance of tissue homeostasis. Figure modified from (Fulawka et al., 2014). 
As tumour growth is a continuous process showing an astonishing resistance towards multiple external 
factors such as low oxygen and nutrient levels or chemotherapeutics, it has assumed that the tumour tissue 
comprises some cells with similar characteristics to adult stem cells (Batlle and Clevers, 2017). Leukaemia 
was the first cancer entity in which a small subset of distinct cancer cells with enhanced stemness properties 
was detected and proven to be of significance for tumour initiation and growth (Bonnet and Dick, 1997). 
Since then, cancer stem cells (CSC) have also been identified in a multitude of solid tumour entities, such as 
breast, brain and colorectal cancer and PDAC (Al-Hajj et al., 2003; Singh et al., 2004; Li et al., 2007; Ricci-
Vitiani et al., 2007) and are linked to tumour heterogeneity, malignant progression and chemoresistance 
besides tumour initiation and growth (Valle et al., 2018). 
1.4.2 Cancer stem cells  
CSC are attributed the capacity of self-renewal and the ability to give rise to differentiated tumour cells. 
They represent a very small proportion (less than 5%) of the tumour mass but are crucial contributors to 
tumour development (Reya et al., 2001; Li et al., 2007). Whereas the bulk of differentiated tumour cells 
shows very limited proliferation, CSC have a dominant proliferative potential. These observations led to a 
new model of cancer initiation. 
The concept of clonal evaluation assuming that all cells within a tumour mass have malignant potential with 
high proliferative rates had been the prevailing notion for a long time (Nowell, 1976; Sugihara and Saya, 
2013). It postulates that genomic instability and subsequent clonal selection results in a heterogeneous 
tumour tissue (Figure 7 A). With the increased awareness of CSC, the cancer stemness model was proposed 
(Shackleton et al., 2009; Sugihara and Saya, 2013). It attributes tumour heterogeneity to the presence of CSC 
in multiple stages of differentiation (stem cells, progenitor, mature cells) (Figure 7 B). The current 
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interpretation suggests a combined model which considers that CSC are also subject to genomic instability, 
giving rise to clonal variants of stem cells and subsequently leading to clonal variants of progenitor cells 
(Figure 7 C) (Fulawka et al., 2014). It has been reported that CSC-properties can be lost and gained in a 
context dependent manner, which additionally contributes to the vast heterogenicity and plasticity attributed 
to CSC (Fulawka et al., 2014). 
Figure 7: Overview of tumour progression models. A) The clonal evolution model assumes that heterogeneity in 
tumour tissue is caused by genomic and epigenetic instability and subsequent clonal selection. B) the CSC model 
defines a small subset of cells within the tumour - CSC - as sole cancer initiators. Tumour heterogeneity is attributed 
to cells in differing stages of maturation. C) In the combined model, CSC undergo clonal evolution and hence give rise 
to clonal variance of progenitor and mature cells. Modified after (Fulawka et al., 2014). 
Many studies have been dedicated to the identification of CSC markers. Due to the heterogeneity of CSC, 
markers can not only vary between differing tumour entities but also within one entity. Still, a wide panel of 
markers has been established. In PDAC, cell surface markers such as CXCR4, CD44, CD24, CD133, ATP-
Binding Cassette super-family G member 2 (ABCG2), cytoplasmic proteins such as Nestin and aldehyde 
dehydrogenase (ALDH) and the transcriptional factors Oct-4, Sox2 and Nanog serve as CSC markers (Silva 
et al., 2009; Matsuda et al., 2011; Fulawka et al., 2014; Herreros-Villanueva et al., 2014; Xia, 2014). 
A functional assessment of stemness features in vitro is the performance of colony formation assays (CFA). 
These assays are based on the self-renewal capacity of CSC to generate colonies from single cells (Franken 
et al., 2006; Han et al., 2014). Based on the morphological differences, colonies are categorised as holo-, 
mero- and paraclones: holoclones are characterised by small, densely packed cells with very distinct borders 
and comprise the highest amount of CSC of all colony types. Paraclones are characterised by widely spread 
cells with fragmented borders and consist of differentiated cells. Meroclones are an intermediate type, best 
to distinguish from holoclones through smaller number of CSC (Tan et al., 2011). Contrary to the other two 
colony forms, holoclones were shown to possess the capacity of long-term self-renewal in vitro and to express 
higher amounts of CSC-related cell surface markers (Tan et al., 2011). Furthermore, holoclones were the 
only clones able to initiate tumour growth in a mouse model (Tan et al., 2011; Beaver et al., 2014). Therefore, 




Besides being strongly associated with tumour initiation and progression, CSC are of crucial importance in 
tumour metastasis and responsiveness to chemotherapeutic treatment (Batlle and Clevers, 2017; Valle et al., 
2018). A pronounced resistance towards multiple chemotherapeutics of CSC compared to non-CSC has 
been observed in PDAC (Hermann et al., 2007; Pozza et al., 2015), explaining the frequent recurrence of 
cancer after chemotherapeutic treatment. Classic chemotherapeutics may target the main (proliferating) 
tumour cell population in an effective manner but miss out on (quiescent, rarely dividing) CSC which can 
subsequently re-establish tumour growth (Fulawka et al., 2014; Aponte and Caicedo, 2017; Batlle and 
Clevers, 2017; Valle et al., 2018). 
Furthermore, Hermann et al. could detect a distinct subpopulation of CSC at the invasive front of PDAC 
which were characterised by high CD133 and CXCR4 expression levels (Hermann et al., 2007). Depletion 
of these proteins led to reduced metastasis by sustained tumourigenic potential in a mouse model. Similar 
results were obtained in PDAC patients: high CXCR4 expression levels were correlated with high migratory 
potential of tumour cells and advanced metastatic disease in (Wehler et al., 2006; Krieg et al., 2015; Zhang 
et al., 2018). 
Several other studies aimed to elucidate the contribution of the microenvironment to the acquisition of 
CSC-related properties. Just like somatic stem cells, CSC reside in cellular niches where they are subject to 
abundant signals (Plaks et al., 2015; Batlle and Clevers, 2017). A complex crosstalk between tumour 
microenvironment and CSC establishes a favourable milieu for maintenance and enhancement of features 
linked to stemness with subsequent tumour promotion (Ye et al., 2014; Plaks et al., 2015). Especially, 
inflammatory cells within the niche have been reported to be of great importance. In hepatocellular 
carcinoma, TAM-derived IL-6 was linked to CSC expansion in vitro and in vivo (Wan et al., 2015). In PDAC, 
blocking TAM infiltration decreases the number of CSC, enables metastasis and ameliorates the 
responsiveness towards chemotherapeutics (Mitchem et al., 2014), underlining the direct contribution of 
TAM to the promotion of CSC features. Additionally, CSC are able to recruit TAM towards the tumour site 
and to modulate their phenotype, establishing a positive feedback loop resulting in reinforced tumour 
progression and stemness-associated characteristics (Sainz et al., 2014). 
Besides an inflammatory microenvironment, a hyperglycaemic one has also been revealed as potential 
modulator of CSC-properties. In lung adenocarcinoma cells, high glucose levels increase the fraction of cells 
exhibiting stem cell features (Liu et al., 2014). Moreover, the facilitative glucose transporter Glut-1 plays a 
crucial role for the maintenance of CSC in PDAC and other tumour entities. Inhibition of the transporter 
abolished self-renewal capacity and tumour initiation (Shibuya et al., 2014). PDEC exposed to 
hyperglycaemia were altered in a TGF-b1-signalling dependent manner. Besides amplified stemness features 
a mesenchymal phenotype could also be demonstrated (Rahn et al., 2018). Similarly, Zhao et al. attributed 
enhanced glycolysis and ROS accumulation to the maintenance of both EMT- and stemness-associated 
properties in PDEC (Zhao et al., 2017). These findings support a link between acquisition of CSC features 
and EMT, which has been first describes by Mani et al. (Mani et al., 2009). 
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1.4.3 EMT and plasticity of CSC 
As stemness is correlated to cell heterogeneity, plasticity and the capacity of metastatic spreading very much 
alike to EMT and both are regulated by similar pathways, it was hypothesised that these two phenomena 
might be closely linked. Indeed, Mani et al. were the first to show that breast cancer cells that undergo the 
process of EMT simultaneously acquire CSC features. And also conversely, cultured CSC and CSC extracted 
from breast cancer were proven to exhibit a mesenchymal phenotype (Mani et al., 2009). Similarly, IL-6-
induced EMT amplified CSC-characteristics in breast cancer cells (Xie et al., 2012). In the meantime, a 
connection between EMT and CSC has also been established in PDAC. Su et al. demonstrated a 
TGF-b1/SMAD-pathway dependent link between expression levels of the stemness marker Nestin and 
EMT. Whereas overexpression of Nestin results in a more mesenchymal phenotype, Nestin knockdown 
leads to amplified epithelial characteristics with reduced tumour growth and migratory capacity (Su et al., 
2013). Furthermore, it has been revealed that the EMT-inducer Zeb1 silences stemness-inhibiting members 
of the miRNA-200 thereby fostering mesenchymal, migratory CSC (Burk et al., 2008; Wellner et al., 2009). 
The above-mentioned findings provide evidence of the close interconnection between the acquisition of 
stemness-associated features and EMT. However, the underlying molecular mechanisms have not been fully 
elucidated and require further research. 
1.5 Aim of  the study 
A link between PDAC and metabolic disorders is long established. Whereas it is acknowledged that 
metabolic disorders such as obesity and T2DM are associated with hyperglycaemia and chronic low-grade 
inflammation in the surrounding tissue, the underlying molecular mechanisms by which this might promote 
PDAC initiation and progression largely remain obscure. 
Within the inflammatory stroma of PDAC, macrophages are attributed great importance as they already 
accumulate in early lesions and present the main immune cell population of the tumour stroma. They were 
shown to possess the ability of EMT induction, thus facilitating the malignant progression of PDEC (Helm 
et al., 2014a). Moreover, hyperglycaemia was identified as an additional promotor of EMT- and CSC-
associated characteristics in PDEC (Rahn et al., 2018). Previous studies could show that hyperglycaemia 
also influences the phenotype of macrophages, imposing the question whether an interplay of high glucose 
concentrations and macrophages further promotes malignancy-associated alterations in PDEC. 
As short-term exposure to high glucose levels and macrophages predominantly led to EMT-associated 
alterations in PDEC (Plundrich, 2017), it was hypothesised that a prolonged subjection to these T2DM-
related surroundings might intensify the effects and also impact on their CSC-associated characteristics. 
Therefore, the aim of the current study was to analyse the long-term impact of hyperglycaemia itself and in 
interplay with macrophages on PDEC in regard to EMT and the acquisition of stemness features. 
Furthermore, macrophages were to be characterised in regard to their inflammatory cytokine profile after 
coculture with PDEC under normo- and hyperglycaemic conditions to gain a more explicit insight into their 






Device             Manufacturer 
Centrifuges 
AvantiTM J-20 XP Centrifuge        Beckmann Coulter GmbH, Krefeld, DE 
Heraus Biofuge pico          Thermo Scientific, Schwerte, DE 
Heraeus Fresco 17          Thermo Scientific, Schwerte, DE 
Heraeus Multifufe X1         Thermo Scientific, Schwerte, DE 
Heraeus Pico 17           Thermo Scientific, Schwerte, DE 
JE-5.0 Elutriator          Beckmann Coulter GmbH, Krefeld, DE 
Rotina 420 R           Hettrich, Tuttlingen, DE 
Sprout mini-centrifuge         Heathrow Scientific, Vermion Hills, US 
Incubators 
BBD 6220 CO2 Incubator        Thermo Scientific, Schwerte, DE 
Gyro Twister 3D shaker         Labnet, Woodbridge, US 
QBA1 Table Incubator         Grant, Cambridge, UK 
Stuart SRT9 Roll mixer         Bibby Scientific Ltd., Stone, UK 
WNB 7-45 Water bath         Memmert, Schwabach, DE 
WTC ED-53 Incubator         Bindner, Tuttlingen, DE 
Measuring devices 
Fusion SL Detection System        Vilber Lourmat, Eberhardzell, DE 
FACScaliburTM Flow Cytometer      Beckton Dickinson, Heidelberg, DE  
Infinite® 200 PRO, Microplate- Reader      Tecan, Crailsheim, DE 
Light Cycler 480 II          Roche, Basel, CH 
NanoQuant Plate          Tecan, Crailsheim, DE  
Neubauer counting chamber        Marienfeld, Lauda-Koenigshofen, DE  
pH 7110 pH-Meter           ionLab, Weilheim, DE  
Microscopes 
AE2000            Motic, Wetzlar, DE 
Evos XL Core Cell Imaging System       AMG, Bothell, US 
Lionheart FX           Biotec, Bad Friedrichshall, DE 
Other devices 
ARPEGE 110 nitrogen tank        AirLiquide, Paris, FR 
CS-300V Powersupply         Cleaver Scientific, West Sussex, UK 
Freezer (-20 °C)           Liebherr, Ochsenhausen, DE 
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HERAFreeze Basic Freezer (-80 °C)       Thermo Scientific, Schwerte, DE  
Laboport vacuum pump         KNF Neuberger GmbH, Freiburg, DE 
MACS Multistand           Milteny Biotec GmbH,  
              Bergisch Gladbach, DE 
MACS Quatro Magnet          Milteny Biotec GmbH, 
              Bergisch Gladbach, DE 
MILLI-Q Reafent Water System       Merck Millipore, Billerica, US  
MR Hei-Mix S Magnetic Stirrer       Heidoph Instruments, Schwabach, DE   
OmniPAGE VS10D Gel chamber      Cleaver scientific, West Sussex, UK  
Refrigerator (4 °C)          Liebherr, Ochsenhausen, DE  
SD20 Semi Dry Maxi Transfer Chamber     Cleaver scientific, West Sussex, UK  
Sonicator Sonoplus          Bandelin, Berlin, DE  
Vortex Genius 3          IKA-Werke, Staufen, DE  
Sterile benches 
HERA Safe            Thermo Scientific, Schwerte, DE  
HERA Safe KS            Thermo Scientific, Schwerte, DE  
Scales 
Precisa BJ 2100D           Precisa Gravimetrics AG, Dietikon, CH  
Precisa XB120A           Precisa Gravimetrics AG, Dietikon, CH  
Pipettes 
Finnpipette F1 0.2 – 2 μl         Thermo Scientific, Schwerte, DE 
Finnpipette F1 1 – 10 μl         Thermo Scientific, Schwerte, DE  
Finnpipette F1 2 – 20 μl         Thermo Scientific, Schwerte, DE 
Finnpipette F1 20 – 200 μl         Thermo Scientific, Schwerte, DE  
Finnpipette F1 100 – 1000 μl        Thermo Scientific, Schwerte, DE  
Finnpipette F2 30 – 300 μl,        Thermo Scientific, Schwerte, DE 
multichannel pipette  
Macro Pipette Controlle          Thermo Scientific, Schwerte, DE  
Pipetboy-acu           Integra-Biosciences, Fernwald, DE 
2.2 Consumables 
 
Consumables           Manufacturer 
0.1–10 μl, 10–200 μl, 100-1000 μl       Sarstedt, Nümbrecht, DE  
pipette tips  
1.25 ml, 5.0 ml Ritips         Ritter, Schwabmuenchen, DE  
0.5 ml, 1.5 ml, 2 ml Safe Seal tubes      Sarstedt, Nümbrecht, DE 
15 ml, 50 ml tubes          Sarstedt, Nümbrecht, DE 
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5 ml, 10 ml, 25 ml serological pipettes     Sarstedt, Nümbrecht, DE 
6-/ 12-/ 96-Well flat-bottom plates       Sarstedt, Nümbrecht, DE 
25 cm2 cell culture flasks         Sarstedt, Nümbrecht, DE  
75 cm2 cell culture flasks         Sarstedt, Nümbrecht, DE 
96-well PCR plate, white         Roche, Basel, CH 
Cell Scraper 25 cm          Sarstedt, Nümbrecht, DE  
Coverslips Thermanox Plastic, 15 mm     Nunc Brand Products, Rochester, 
New York, US 
CryoPure tube 1.0 ml white        Sarstedt, Nümbrecht, D  
FACS-tube           Sterilin, Lodon, UK 
Feather Disposable scalpel         PFM medical, Cologne, DE 
MACS-LD columns  Milteny Biotec GmbH,  
Bergisch Gladbach, DE 
Micro-Touch Nitril gloves        Ansell GmbH, München, DE 
Parafilm M            Brand, Wertheim, DE 
Pasteur pipettes ISO 7712, 230 mm     Glaswarenfabrik Karl Hecht    
     GmbH&CoKG, Sondheim/Röhn, DE 
 Pre-Separation filter, 30 μm         Milteny Biotec GmbH, 
Bergisch Gladbach, DE 
Syringe, 20 ml           Becton Dickinson, Heidelberg, DE 
Sterile filter Minisart          Sartorius Stedin Biotech, Göttingen, DE  
Transfer pipettes 3.5 ml         Sarstedt, Nümbrecht, DE  
Whatman-3MM filter paper        FE Healthcare, Buckinghamshire, UK  
Westran Polyvinylidenfluorid (PVDF)     Th. Geyer GmbH, Renningen, DE  
membrane 0.45 μm    
2.3 Chemicals and Reagents 
 
Chemicals            Manufacturer 
2-Mercaptoethanol          Sigma-Aldrich, München, DE 
6-Aminocaproic acid         Sigma-Aldrich, München, DE 
Accutase solution          EMD Millipore Corporation, Temecula, 
California, US 
Acetic acid 10 %          Carl Roth GmbH, Karlsruhe, DE 
AEC substrate-Chromogen        Dako Diagnostika, Hamburg, DE 
Ammonium persulfat (APS)        Merck Millipore, Darmstadt, DE 
Bovine serum albumin (BSA), FractionV     Biomol, Hamburg, DE 
Bromphenol blue          Merck Millipore, Darmstadt, DE 
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CD11b-Microbeads  Milteny Biotec GmbH, 
Bergisch Gladbach, DE 
Citric acid            Carl Roth GmbH, Karlsruhe, DE 
Dimethyl sulfoxide (DMSO)        Chemsolute, Th. Geyer, Renningen, DE 
Sodium phosphate dibasic dihydrate      Carl Roth GmbH, Karlsruhe, DE 
(Na2HPO4 x 2 H2O) 
Dithiothreitol (DTT)          Sigma-Aldrich, München, DE 
EGF, human recombinant        Life Technologies, Darmstadt, DE 
EpCam-Microbeads          Milteny Biotec GmbH, 
Bergisch Gladbach, DE 
Ethanol 99 %, denaturated        Chemsolute, Th. Geyer, Renningen, DE 
Ethanol absolute, puriss.         Chemsolute, Th. Geyer, Renningen, DE 
GM-CSF, human recombinant       BioLegend, Fell, DE 
Grams Crystal Violet Solution       Merck Millipore, Darmstadt, DE 
HiPerFect Transfection reagent        Qiagen, Hilden, DE 
Hoechst 33258           Sigma-Aldrich, München, DE 
Hydrochloride acid 1.0 M        Chemosolute, Th. Geyer, Renningen, DE 
Hydrogen peroxide 30 %        Th. Geyer GmbH, Renningen, DE 
LightCycler® 480 SYBR Green I Master     Roche Diagnostics, Mannheim, DE 
Mayer’s hemalaun solution        Applichem, Darmstadt, DE 
Methanol            Chemsolute, Th. Geyer, Renningen, DE 
Milk powder           Carl Roth GmbH, Karlsruhe, DE 
Mounting Medium          Thermo Fischer Scientific, Schwerte, DE 
Monopotassium phosphate (KH2PO4)      Carl Roth GmbH, Karlsruhe, DE 
Opti-MEMTM, reduced serum medium     Thermofisher Scientific, Darmstadt, DE  
PageRuler Prestained Protein Ladder      Thermo Fischer Scientific, Schwerte, DE 
Pancoll human           PAN Biotech,  Aidenbach, DE  
Paraformaldehyde (PFA) 4.5 % (w/v)  BUEFA Chemilkalien GmbH Co. KG, Hude, 
DE 
Penicillin-Streptomycin (Pen/Strep)      PAA, Pasching, AT 
Phosphate-buffered Saline (PBS)       Biochrom GmbH, Berlin, DE 
Potassium chloride (KCl)        Chemsolute, Th. Geyer, Renningen, DE 
Preserving agent for water baths       Carl Roth GmbH, Karlsruhe, DE 
Rotiphorese gel 40 (37.5:1)        Carl Roth GmbH, Karlsruhe, DE 
 Acrylamide/Bisacrylamide 40 % Solution 
(PAA) 
Sodium chloride (NaCl)         Carl Roth GmbH, Karlsruhe, DE 
Sodium dodecyl sulfate (SDS) ultra-pur     Carl Roth GmbH, Karlsruhe, DE 
Tetramethylethylendiamine (TEMED)     Carl Roth GmbH, Karlsruhe, DE 
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Tri-Sodium Citrate Dihydrate       Carl Roth GmbH, Karlsruhe, DE 
Tris-Base            Carl Roth GmbH, Karlsruhe, DE 
Triton X-100           Sigma-Aldrich, München, DE 
Trypan blue Solution Fluka 0.4 %      Sigma-Aldrich, München, DE 
Trypsin-Ethylenediaminetetraacetic (EDTA)    PAA, Pasching, AT 
Tween 20            Serva, Heidelberg, DE 
Westernbright ECL substrate       Advansta, San Jose, US 
 
2.4 Buffers und Gels 
 
Buffer             Formulation 
Blotto             5 % (w/v) Milk powder in TBS-T (1x) 
Laemmli-Buffer (2x)  128 mM Tris-Base 
4.6 % (w/v) SDS 
10 % (v/v) Glycerol 
1 mM Natriumorthovanadat 
pH 7.6 
 
MACS-Buffer  0.5 % (w/v) BSA in PBS 
 
PBS (10x)            1.37 M NaCl 
26.8 mM KCl 
97.8 mM Na2HPO4 x 2 H2O  
17.6 mM KH2PO4 
pH 7.4 
  
PBS-Tween (PBS-T)          10 % (v/v) PBS (10x) 
              0.05 % (v/v) Tween 20 
 
Tris-buffered Saline (TBS; 10x)       29 mM Tris-Base 
140 mM NaCl 
pH 7.6 
TBS-Tween (TBS-T)         10 % (v/v) TBS (10x) 







Elutriation buffer          PBS, 1 % FCS 
              10 mM EDTA 
              pH 7.4 
 
Magnetic Activated Cell Sorting 
MACS-Sorting-Buffer         2 mM EDTA in MACS - Buffer 
              pH 7.2 
Western Blotting 
Blot buffer A           300 mM Tris-Base  
20 % (v/v) Methanol 
pH 11  
 
Blot buffer B           25 mM Tris-Base  
20 % (v/v) methanol  
pH 10.6 
 
Blot buffer C  25 mM Tris-Base 
20 % (v/v) ethanol 
40 mM 6-Aminocaproic acid  
pH 10.6  
 
Loading dye (4x)          2.5 % (v/v) b-mercaptoethanol 
0.005 % (w/v) Bromphenol blue 
              in 2xLaemmli buffer 
 
Running buffer           25 mM Tris-Base 
192 mM Glycerol 
0.1 % (w/v) SDS 
              in ddH20 
 
Separating gel buffer          1.5 M Tris-Base 
              0.4 % (w/v) SDS 
              pH 8.8 
 
Stacking gel buffer          0.5 mM tris-Base 
              0.4 % (w/v) SDS 
              pH 6.8 
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2.5 Cell biological Materials  
2.5.1 Cell lines  
Cell line           Information 
H6c7-pBp, benign       Human pancreatic ductal epithelial cell line  
      immortalised via HPV-16 E6/E7 oncogenes 
       and transduced with the empty retroviral 
       pBabepuro vector (Furukawa et al., 1996) 
 
H6c7-kras, premalignant       Human pancreatic ductal epithelial cell line  
       immortalised via HPV-16 E6/E7 oncogenes  
       and transduced with the retroviral pBabepuro- 
Kras4BG12Vvector (Furukawa et al., 1996; Qian et al., 
2005).   
 
2.5.2 Cell culture additives 
Cell culture additives        Manufacturer 
D-Glucose           Sigma-Aldrich, München, DE 
Bovine pituitary extract (BPE)      Life Technologies, Darmstadt, DE 
EGF            BioLegend, Fell, DE 
Fetal Calf Serum (FCS)        BioLegend, Fell, DE 
GM-CSF           BioLegend, Fell, DE 
Keratinocyte serum-free medium       Life Technologies, Darmstadt, DE 
L-glutamine           PAA, Pasching, AT 
Pen/Strep           PAA, Pasching. AT 
PBS            Biochrom, Berlin, DE 
Puromycin           InvivoGen, Toulouse, FR 
Roswell Park Memorial Institute (RPMI)    Biochrom, Berlin, DE 
1640 Medium, 
11 mM glucose, no L-glutamine  
Roswell Park Memorial Institute (RPMI)    Lonza, Basel, CH 
1640 Medium, 





2.5.3 Cell culture media  
Cell line           Formulation 
Routine cell culture medium 
 H6c7-kras / H6c7-pBp        50 % (v/v) Keratinocyte serum-free medium 
50 % (v/v) RPMI 1640  
5 % (v/v) FCS 
0.5 % (v/v) L-glutamine 
50 μg/ml BPE 
5 ng/ml EGF 
4 μg/ml Puromycin 
Differentiation medium  
GM-CSF- stimulated monocytes  RPMI 1640 
supplemented with 1 % (v/v) FCS,  
1 % (v/v) L-glutamine, 1 % (v/v) Pen/Strep 
  50 ng/ml GM-CSF (240 U/ml) 
Coculture medium 
M1-Macrophage Monoculture      RPMI (no Glucose, with 1 % L-glutamine), 
H6c7-kras - / H6c7-pBp- Monoculture    supplemented with 10 % (v/v) FCS, 
H6c7-kras / M1-Coculture       5 mM or 25 mM D-Glucose 
H6c7-pBp / M1-Coculture 
CFA-medium 
H6c7-kras / H6c7-pBp        routine cell culture medium 
2.5.4 Small interfering RNA (siRNA) 
siRNA            Manufacturer 
Control siRNA          Santa Cruz Biotechnology, Heidelberg, DE 
TGF-b1 - Receptor II siRNA      Santa Cruz Biotechnology, Heidelberg, DE 
 
2.6 Primer for qPCR-Analysis 
2.6.1 Primer from Eurofins (Ebersberg, DE) 
Primer     5`-3`-Sequence                Annealing-Temperature (°C) 
GAPDH   forward   TCCATGACAACTTTGGTATCGTGG     58 
     reverse   GACGCCTGCTTCACCACCTTCT  
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IL-1b    forward  AGTGCTCCTTCCAGGACCTGGA      58 
     reverse   CACTCTCCAGCTGT AGAGTGG  
Nestin  forward  GAAACAGCCATAGAGGGCAAA      58 
reverse   TGGTTTTCCAGAGTCTTCAGTGA  
Sox-2    forward TCCCATCACCCACAGCAAATGA     58 
     reverse   TTTCTTGTCGGCATCGCGGTTT 
TGF-b1   forward  CGTGGAGCTGTACCAGAAATA      58 
     reverse  TCCGGTGACATCAAAAGATAA  
TNF-a    forward  TCCTTCAGACACCCTCAACC      58 
     reverse  AGGCCCCAGTTTGAATTCTT  
Zeb1    forward  TCCATGCTTAAGAGCGCTAGCT     61 
     reverse  ACCGTAGTTGAGTAGGTGTATGCCA  
2.6.2 Primer from RealTimePrimers (via Biomol, Hamburg, DE) 
Primer    5`-3`-Sequence                  Annealing-Temperature (°C) 
E-Cadherin   forward  TGCTCTTGCTGTTTCTTCGG       55 
     reverse  TGCCCCATTCGTTCAAGTAG   
IL-6    forward  ATGCAATAACCACCCCTGAC      58 
     reverse  GAGGTGCCCATGCTACATTT  
IL-8    forward  GTGTGAAGGTGCAGTTTTGCC      55 
     reverse  AACTTCTCCACAACCCTCTGC 
IL-10    forward  AAGCCTGACCACGCTTTCTA       58 
     reverse  ATGAAGTGGTTGGGGAATGA  
L1CAM   forward  GAACTGGATGTGGTGGAGAG       58 
     reverse  GAGGGTGGTAGAGGTCTGGT  
Nanog    forward  ACCTACCTACCCCAGCCTTT       58 
     reverse  CATGCAGGACTGCAGAGATT   
TGF-bRII   forward  TTGAGTCCTTCAAGCAGACC      58 
     reverse  TCAACGTCTCACACACCATC 
Vimentin   forward  TCCAAGTTTGCTGACCTCTC       58 
     reverse  TCAACGGCAAAGTTCTCTTC 
VEGF    forward  CGCTTACTCTCACCTGCTTC      58 




2.6.3 Primer from Biometra (Göttingen, DE) 
Primer    5`-3`-Sequence                    Annealing-Temperature (°C) 
Snail    forward  CTGCTCCACAAGCACCAAGAGTC     58 
     reverse  CCAGCTGCCCTCCCTCCAC  
Slug    forward  ATATTCGGACCCACACATTACCT     58 
     reverse  GCAAATGCTCTGTTGCAGTGA 
2.7 Antibodies 
2.7.1 Antibodies for Western Blotting 
Specifity (Clone)  Host (Isotype)    Stock concentration   Dilution  Manufacturer 
Primary antibodies 
E-Cadherin (32A8)  mouse (IgG1)   -     1:1000   Cell Signalling,  
                 (in BSA)  Frankfurt, DE 
 
Hsp90 (F-8)    mouse (IgG2A)  200 μg/ml    1:2000   Santa Cruz 
                     Biotechnology,  
                     Heidelberg, DE 
 
L1CAM (9.3)   mouse (IgG3)  2.46 mg/ml    1:1000   Santa Cruz 
                     Biotechnology,  
                     Heidelberg, DE 
 
NF-kB p-p65   mouse (IgG3)   1 mg/ml    1:500   Merck  
(12H11)                  Darmstadt, DE 
 
NF-kB t-p65   mouse    200 µg/ml    1:500   Santa Cruz 
(F-6)                   Biotechnology, 
                     Heidelberg, DE 
 
Vimentin (V9)   mouse (IgG1)  200 µg/ml    1:200   Santa Cruz 
Biotechnology, 
 Heidelberg, DE 
 
Secondary antibodies  Host          Dilution  Manufacturer 
Mouse-IgG-HPR  horse          1:2000   Cell Signalling 
                     Frankfurt, DE 
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2.7.2 Blocking antibodies  
Antibody    Target    Stock    Final     Manufacturer 
           concentration  concentration 
Primary antibodies 
Tocilizumab   h IL-6R	   2 µg/ml   1 µg/ml   kindly provided  
by Prof. Stefan  
 Rose-John,   
Kiel, DE 
 
sgp130Fc    IL-6/IL-6R   0.99 mg/ml   10 µg/ml   kindly provided 
      complex             by Prof. Stefan  
Rose-John,   
Kiel, DE  
 
Control antibodies 
Rituximab    for Tocilizumab  10 mg/ml   1 µg/ml   kindly provided 
                     by Prof.   
                     Matthias Peipp 
                     Kiel, DE 
 
Fc control    for sgp130Fc  4.443 mg/ml  10 µg/ml   kindly provided 
                     by Prof.   
                     Matthias Peipp 
                     Kiel, DE 
2.8 Kits 
 
Kit               Manufacturer 
CellTraceTM CFSE Kit          Thermo Scientific, Schwerte, DE  
CellTraceTM Violet Kit          Thermo Scientific, Schwerte, DE  
DCTM Protein Assay           Bio-Rad Laboratories, München, DE  
peqGOLD Total RNA Kit         PeqLab, Erlangen, DE  







Software             Manufacturer 
FUSION-CAPT 16.06           Vilber Lourmat, Eberhardzell, DE  
FACScalibur CellQuest           BD Bioscience, San Jose, US  
Gen5 Data Analysis Software         BioTek, Bad Friedrichshall, DE 
GraphPadPRISM 7.0          GraphPad Software Inc., La Jolla, US  
i-controlTMMicroplate Reader Software       Tecan, Crailsheim, DE  
LightCycler480 Software (Version 1.5)      Roche, Basel, CH  




3.1 Cell biological methods 
3.1.1 Cell lines 
The two human cell lines H6c7-pBp and H6c7-kras were used as a model for benign and premalignant 
pancreatic ductal epithelial cells. Both of them originate from human pancreatic duct cells which are 
immortalized by retroviral transduction with the oncogenes E6 and E7 of the human papilloma virus 16 
(Furukawa et al., 1996). Whereas H6c7-pBp cells represent pancreatic duct epithelium without any of the 
common mutations of PDAC and were retrovirally transduced with the empty pBapepuro vector, H6c7-
kras cells were transduced with the KrasG12V-containing vector (Qian et al., 2005). As the mutational 
activation of the oncogene KrasG12V is already to be found in early PanIN, H6c7-kras cells mimic precursor 
lesions of PDAC. 
Both the pBapepuro vector and the KrasG12V-containing vector encode a puromycin resistance, which allows 
to ensure stable expression of the respective phenotype by addition of puromycin during cell culture as 
described in 3.1.2.  
3.1.2 Cell cultivation 
All cell culture work was performed at a sterile bench and only sterile material was used. All media were 
prewarmed in a water bath for 10 to 15 minutes prior to usage if not specified otherwise. 
The cells were cultured in 75 cm2 cell culture flasks in 10 ml of routine cell culture media and cultivated in 
an incubator (37 °C, 5 % CO2, humidity of 85 %). For maintenance and expansion, cells were split twice a 
week or when their confluency was at approximately 80 %. For this, the supernatant was aspirated and the 
cells incubated with 5 ml of Trypsin-ETDA for 10 minutes at 37 °C. In order to stop the enzymatic reaction, 
the cells were transferred into a 50 ml tube containing an equivalent amount of prewarmed cell culture 
media. After centrifugation (300 x g, 5 min), the supernatant was aspirated and the cell pellet resuspended 
in 10 ml of routine cell culture media. Depending on further planning, the cells were either counted and 
seeded for consecutive experiments, or split in a ratio of 1:3 or 1:4 into two new 75 cm2 flasks. 4 µg/ml of 
puromycin were added per flask to ensure the selection of positively transduced clones. 
The cells were kept in cultivation for approximately 15 to 20 passages, before being exchanged for new 
ones. Cells were regularly checked for mycoplasma contamination (MycoAlert® Mycoplasma Detection 
Kit); controls were negative throughout all experiments. 
3.1.3 Freezing and thawing of cells 
In order to prepare cells for long-term storage, they were first detached by using Trypsin-EDTA and 
centrifuged as described in 3.1.2. Cells were then washed with PBS and centrifugated once again. Afterwards, 
the cells were resuspended in 1 ml 10 % DMSO in FCS and quickly transferred into a cryo vial. This was 
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placed in a cryo box at -80 °C to allow a controlled cooling before it was placed in a liquid nitrogen tank for 
longterm storage two days later. 
For the thawing of cells, these were removed from the liquid nitrogen tank and the lid of the cryo vial was 
slightly opened to allow pressure equalization before being incubated at 37 °C, 5 % CO2 and 85 % humidity 
until completely thawed. It is important to work quickly to minimize the stress the cells are exposed to and 
to guarantee high survival rates. The cells were transferred into a 50 ml tube containing 5 ml of prewarmed 
routine cell culture media and were gently resuspended. After centrifugation (300 x g, 5 min), the 
supernatant was aspirated, the cell pellet resuspended in 10 ml of cell culture media and seeded into a 75 cm2 
cell culture flask. Puromycin was added for the first time the following day and then at each passaging 
timepoint as described in 3.1.2. 
3.1.4 Determination of cell numbers 
For the determination of the cell number, a Neubauer chamber was used. The cells were detached and 
centrifuged as described in 3.1.2, resuspended in 10 ml of cell culture media and then 10 µl of the cell 
suspension were pipetted into the chamber. The vital cells were counted in at least two quadrants of the 







3.1.5 Isolation of human monocytes 
Monocytes were extracted from the blood of healthy donors who had given their informed consent. An 
approval of the ethics committee at the Faculty of Medicine and the University Hospital Schleswig-Holstein 
Campus Kiel is also on hand (ethics committee votum number D429/09 and A110/99). 
In the context of platelet donations leukoreduction system chambers (LRS) arise as by-products. They 
contain highly concentrated leukocytes which include peripheral blood mononuclear cells (PBMC). 
Normally these chambers are discarded; the UKSH Blood Donor Centre Kiel kindly provided them for 
research use, allowing us to isolate monocytes for the in vitro generation of polarised macrophages. This is a 
two-step procedure: primarily, the PBMC are enriched through density gradient centrifugation and 
afterwards, monocytes are purified via counterflow centrifugation elutriation. 
First of all, 20 ml of sterile PBS were filled into a 75 cm2 cell culture flask. The blood of the LRS was added 
into the flask and diluted with PBS until a total volume of 140 ml was reached. Four 50 ml tubes were 
prepared with 15 ml of Pancoll solution each and 35 ml of the thoroughly mixed, diluted blood sample were 
carefully layered on top, avoiding a mixture of blood and Pancoll solution. The tubes were cautiously 
transferred into a centrifuge and centrifuged for 25 min with slow acceleration to a maximum speed of 
800 x g and following deceleration without any mechanical brake at all. 
During this density gradient centrifugation, cellular blood components such as erythrocytes and 
granulocytes are separated from the PBMCs. The former aggregate with a polysaccharide contained in the 
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Pancoll solution and thus accumulate at the bottom of the tube due to their high sedimentation rate. The 
latter, however, do not aggregate but form a so-called buffy coat at the boundary of the Pancoll and blood 
solution which is visible as a white ring (Figure 8). 
 
Figure 8: Schematic view of PBMC isolation out of a blood donor sample. The separation medium Pancoll and 
density centrifugation makes it possible to separate the PBMC based on their differing sedimentation properties. 
Enriched PBMC form a buffy coat at the interface of the two phases and can be separated from other blood 
components for further usage. 
The plasma above the buffy coats was aspirated. Two of the buffy coats were then transferred into one new 
50 ml tube together. The tubes were filled with cold elutriation buffer up to a total volume of 50 ml. After 
centrifugation (300 x g, 10 min, 4 °C), the cells were washed in 20 ml of cold elutriation buffer and 
centrifuged once again (300 x g, 7 min, 4 °C). In the following step the two cell pellets were united in 50 ml 
of elutriation buffer and the cell number was determined as described in 3.1.4. A maximum cell number of 
1x109 in 100 ml of elutriation buffer was used for counterflow elutriation. 
Before the elutriation was started, the elutriator was rinsed with 200 ml of 70% ethanol, 300 ml of 
autoclaved ddH2O and 200 ml of cold elutriation buffer at a flow rate of 65 ml/min. During this procedure, 
the system was freed of air bubbles by empty centrifugation at 1000 rpm (Rotor JE5, AvantiTM J-20 XP 
Centrifuge) and cooled to 4 °C. PBMC were then loaded at 3500 rpm and a flowrate of 26 ml/min. Once 
all cells had entered the system and approximately 100 ml of elutriation buffer had followed, the flowrate 
was augmented in 2 ml/min steps per 50 ml up to a flowrate of 32 ml/min. The flow increased steps were 
then reduced to 1 ml/min per 50 ml. All fractions up to a flowrate of 35 ml/min were discarded whereas 
the following fractions of 36 to 41 were collected in prepared 50 ml tubes. The centrifuge was then switched 


















Figure 9: Schematic illustration of the elutriation procedure. (A) Elutriator construction: cells are pumped into 
the chamber, separated and released for subsequent collection. (B) Separation process in detail: the cells reaching the 
elutriator chamber are exposed to centrifugal forces and counterflow. By increasing pump pressure, counterflow slowly 
overcomes centrifugational forces and allows cell separation based on their size and sedimentation properties. Modified 
according to (Benz et al., 2017) and (Z.-J. Zhu et al., 2015). 
 
100 µl of each fraction were transferred into flow cytometry tubes and the monocyte purity determined via 
forward- and sideward-scatter properties (Figure 10), using FACScaliburTM Flow Cytometer. Only 















Figure 10: Representative dot plot showing cells after elutriation procedure according to their forward- and 
sideward-scatter. (A) Gating (R1) allows to exclude cell debris from (B) purity analysis of lymphocyte (R2) and 
monocyte (R3) population. 
The elutriator was first rinsed with 300 ml of autoclaved ddH20, then twice with 200 ml of Solution 555 
with a 15-minute pause in between, followed by 200 ml of ddH20 and 200 ml of 70 % ethanol. The system 
stayed loaded with ethanol until the next use. 
3.1.6 In vitro generation of macrophages 
For the in vitro generation of M1-polarized macrophages, isolated monocytes were cultivated in the presence 
of GM-CSF. 
The chosen fractions of monocytes (see 3.1.5) were centrifuged at 300 x g and 4 °C for 10 min, the cell 
pellets pooled in 10 ml of differentiation media, and the cell number was determined. 
Between 15 x 106 and 20 x 106 cells were resuspended in 27 ml of differentiation media. The cell suspension 
was carefully pipetted into VueLife cell culture bags avoiding the formation of air bubbles. Cells were then 
incubated at 37 °C, 5 % CO2 and humidity of 85 % for 7 days. 
3.1.7 Harvest of in vitro generated macrophages 
Macrophages were harvested after one week of differentiation. For this, the cell bags were removed from 
the incubator and left on ice for an hour before being vigorously tapped onto the working surface for 
additional mechanical detachment. The cell suspension was poured into a 50 ml tube, the bag rinsed with 
20 ml of PBS and controlled for the efficiency of detachment by microscopic inspection. Subsequently, the 
cells were centrifugated at 300 x g and room temperature (RT) for 10 min. The supernatant was aspirated, 
the cell pellet resuspended in 10 ml of macrophage medium and the cell number determined (see 3.1.4). The 
macrophages were now ready for coculture experiments. 
3.1.8 Direct coculture of epithelial cells and macrophages  
To study the interaction of pro-inflammatory macrophages and PDEC and the impact of hyperglycaemia 
on both cell populations, a direct coculture model was chosen. 
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Depending on which cell type was supposed to be analysed after 5 days of cocultivation, i.e. epithelial cells 
or macrophages, the respective monoculture and cocultures of H6c7-pBp/H6c7-kras and M1-macrophages 
(M1-MF) were seeded under normo- and hyperglycaemic conditions, leading to the following two possible 
experimental setups: 
 
1) Experimental setup for the analysis of epithelial cells 
H6c7-pBp           H6c7-kras 
H6c7- pBp monoculture 5 mM      H6c7-kras monoculture 5 mM  
H6c7 -pBp monoculture 25 mM      H6c7-kras monoculture 25 mM 
H6c7-pBp / M1-MF coculture 5 mM     H6c7-kras / M1-MF coculture 5 mM 
H6c7-pBp / M1-MF coculture 25 mM    H6c7-kras / M1-MF coculture 25 mM 
 
2) Experimental setup for the analysis of macrophages 
M1- Macrophages 
M1-MF monoculture 5 mM 
M1-MF monoculture 25 mM 
M1-MF / H6c7-pBp coculture 5 mM 
M1-MF / H6c7-pBp coculture 25 mM 
M1-MF / H6c7-kras coculture 5 mM 
M1-MF / H6c7-kras coculture 25 mM 
 
For each setting at least 6 wells of a 12-well plate were used. 
One day prior to the harvest of the macrophages from the culture bags (see 3.1.5), the epithelial cells were 
seeded in a 12-well plate in their routine cell culture medium allowing them to adhere properly overnight 
(Figure 11). To obtain a comparable ratio of PDEC and macrophages, a cell number of 2 x104 per well was 
chosen for the benign H6c7-pBp cells, whereas 3 x104 premalignant H6c7-kras cells were seeded per well. 
The well plates were stored in an incubator (37 °C, 5 % CO2, humidity of 85 %). 
The macrophages were harvested as described in 3.1.7. and resuspended in the respective coculture medium 
supplemented with either 5 or 25 mM of D(+)-glucose. The epithelial cells seeded a day earlier were 
controlled under the microscope, the supernatant of those wells designated for coculture aspirated and 
2.5 x105 macrophages carefully added per well. 
The supernatant of those wells intended for epithelial monoculture was also withdrawn and replaced by 
1 ml of the respective cocultivation medium. All of the cells were then placed back in the incubator for a 
total of 5 days. On day 2, the cells were washed with 1 ml of PBS per well and then 1.5 ml of the equivalent 





Figure 11: Schematic illustration of the experimental coculture setup. Cocultures of H6c7-pBp or H6c7-kras cells 
with M1-polarised macrophages were cultivated in medium supplemented with either 5 or 25 mM of glucose for 5 
days. Dependent on the experiment, monocultures of PDEC or M1-macrophages were also cultivated under the same 
conditions serving as a control. Figure modified according to (Plundrich, 2017). 
3.1.9 Magnetic Activated Cell Sorting 
To investigate the effects of coculture and hyperglycaemia on macrophages and epithelial cells respectively, 
the two cell types needed to be separated from one another. For this, magnetic activated cell sorting (MACS) 
was used, a procedure allowing separation of different cell types in suspension by making use of distinct 
surface molecule expression. Magnetic microbeads that are conjugated to an antibody directed to a surface 
molecule which only one of the cell populations expresses, are added to the cell suspension. The suspension 
is then transferred to a column placed in a strong magnetic field. The labelled cells are held back in the 
column, whereas the non-labelled cell population passes through unrestrictedly.  
MACS allows both positive and negative cell separation. Positive selection means that the cells of interest 
are labelled by microbeads and are consequently held back in the column, whereas the other cells are in the 
flow-through. By removing the column from the magnetic field, the labelled cells can be obtained for further 
usage. 
For negative selection or depletion, on the other hand, microbeads are conjugated to an antibody directed 
to a surface molecule not present on the cell line of interest, allowing to obtain unlabelled cells; while all 
other cells are retained in the column. 
 
In this study, negative selection was performed. If the epithelial cells H6c7-pBp/-kras were of interest for 
further analysis, microbeads linked to an antibody targeting CD11b were used; if the M1-polarized 
macrophages were to be investigated, microbeads attached to an anti-EpCam-antibody were utilised.  
After 5 days of cocultivation, the supernatant was aspirated and the cells incubated at 37 °C with 1 ml of 
Trypsin-EDTA per well for 10 minutes. All cells from one experimental setup (see 3.1.8) were transferred 













coculture medium. After centrifugation (300 x g, 4 °C, 5 min), the cells were carefully resuspended in 3 ml 
of ice-cold MACS-buffer. To singularise the cells, they were pipetted onto a pre-separation filter which was 
placed on a 15 ml tube and had been moistened with 500 µl of MACS-buffer beforehand. The filter was 
then washed three times with 500 µl of MACS buffer each before it was discarded and the cell suspension 
was centrifuged at 300 x g, 4 °C for 5 min. Once the supernatant was withdrawn, the cell pellet was 
resuspended in 80 µl of MACS-buffer and 20 µl of the respective microbeads and incubated at 4 °C for 
15 min. Thereafter, 2 ml of MACS-buffer were added and the cells centrifuged once again (300 x g, 4 °C, 
5 min). 
In the meantime, the LD-columns were placed in the magnetic field and moistened with 2 ml of buffer. To 
collect the flow-through, 50 ml tubes were positioned underneath the columns. The cell pellets were 
resuspended in 500 µl of MACS buffer and pipetted onto the columns. To obtain as many non-labelled cells 
as possible, the columns were washed trice with 1 ml of buffer each. The collected cells were then 
centrifuged (300 x g, 4 °C, 5 min), resuspended in PBS, counted and divided for further experimental 
approach. 
3.1.10 Colony Formation Assay 
In this study, colony formation assays (CFAs) of mono- and cocultured H6c7-pBp and H6c7-kras cells of 
both normo- and hyperglycaemic conditions were carried out to analyse the self-renewal capacity of PDEC 
after the different culture conditions. Monocultured cells were detached with Trypsin-EDTA as described 
in 3.1.1 and washed with PBS. Cocultured cells needed to be separated from the macrophages first, which 
was done via MACS as described in 3.1.9. In either case, cells were then brought into solution in their 
routine cell culture medium and counted. Precisely 800 singularised cells were seeded in a well of a 6-well 
plate in duplicates or triplicates in 2 ml of cell culture media. The cells were then cultivated in an incubator 
(37 °C, 5 % CO2, humidity of 85 %) for 8 to 14 days, depending on the cell line and on the treatment they 
had been exposed to prior to the CFA. To stop colony formation, the supernatant was discarded, the cells 
thoroughly washed with PBS and then fixed with 4.5 % PFA for 10 min at RT. The PFA was withdrawn 
and the wells rinsed twice with ddH2O. Subsequently, the cells were incubated in 1 ml of 0.1 % crystal violet 
per well for 1h at RT for staining. After this, they were washed with ddH2O at least five times or until no 
further crystal violet came off. The 6-well plates were left to dry overnight. For evaluation, the total number 
of colonies formed and the type of clone (holo-, para- or meroclone) were determined under microscopic 
view (Figure 12). For this, Evos XL Core Cell Imaging Systems was used. Only colonies containing more 




Figure 12: Representative pictures from Colony formation assay. Example of a (A) holoclone, (B) meroclone and 
(C) paraclone formed by H6c7-pBp cells are shown at 56-fold magnification. The scale bar represents 100 µm. 
 
3.1.11 siRNA-mediated knockdown of TGF-b receptor II 
Silencing of gene expression can be achieved by the introduction of small interfering RNAs (siRNA) 
targeting the respective messenger RNA (mRNA) and thus stopping translation into amino acids and 
proteins. Cells treated in that manner show reduced but not completely abolished expression levels of the 
respective gene. 
In this study, a knockdown of the TGF-b receptor II (TGF-bRII) was chosen to analyse the contribution 
of TGF-b1 to the progression of EMT and the acquisition of cancer stemness related properties of H6c7-
pBp and H6c7-kras cells under exposure to macrophages and/or hyperglycaemic stress. As TGF-bRII is 
indispensable for the successful initiation of the TGFb-1-signalling pathway, its reduced expression levels 
inhibit the potential effect of the ligand TGF-b1 on the epithelial cells.  
For the siRNA mediated knockdown, epithelial cells were seeded two days prior to addition of the 
macrophages and the cell number adapted to 1.5 x104 per well for the H6c7-pBp cells and to 2 x104 per well 
for the H6c7-kras cells, taking into account the prolonged cultivation time. The experimental setup using 
either control siRNA (ctrl siRNA) or TGF-bRII siRNA was extended to the following: 
 
Experimental setup for TGFbRII knockdown 
H6c7-pBp           H6c7-kras 
                                                     Treatment with crtl siRNA 
H6c7-pBp / M1-MF coculture 5 mM     H6c7-kras / M1-MF coculture 5 mM 
H6c7-pBp / M1-MF coculture 25 mM    H6c7-kras / M1-MF coculture 25 mM 
Treatment with TGFbRII siRNA 
H6c7-pBp / M1-MF coculture 5 mM     H6c7-kras / M1-MF coculture 5 mM 







For each approach, 6 wells of a 12-well plate were used.  
One day after the seeding of the epithelial cells, the transfection reagent was prepared as listed below and 
left to incubate for 10 min at RT.  
 
Transfection reagent (per well) 
100 µl OptiMEM 
6 µl HiPerfect 
2 µl TGF-bRII siRNA or ctrl siRNA 
 
In the meantime, the medium of the epithelial cells was withdrawn and replaced by 1 ml of fresh routine 
cell culture medium. After 10 minutes, the transfection reagent was given into the respective wells, the well 
plates were carefully swirled and put back into the incubator. From this point onwards, the experimental 
procedure was identical to the one described in 3.1.8 – 3.1.10. 
The efficiency and stability of the knockdown was validated by qRT-PCR analysis. TGF-bRII levels of 
PDEC were analysed two, four and six days post transfection showing a stable gene suppression (data not 
shown). This affirmed that the established transfection protocol was convenient for subsequent coculture 
experiments of 5 days. 
3.1.12 IL-6 blockade 
To investigate the potential effect of IL-6 on the progression of EMT and the acquisition of cancer stemness 
related properties of H6c7-pBp and H6c7-kras cells under coculture with macrophages and/or under 
hyperglycaemic stress, a blockade of the IL-6 signalling pathway was performed. To consider classic and 
trans-signalling of lL-6 separately, two experimental setups were chosen: First of all, a blockade of IL-6 
receptor via Tocilizumab was performed, blocking both signalling cascades of IL-6. Secondly, a blockade 
via sgp130Fc was performed, allowing the distinct analysis of the effects of IL-6 via trans-signalling. 
Coculture was set up as described in 3.1.8. On day two of coculture, the wells were washed with 1 ml of 
PBS each and 1.5 ml of coculture medium supplemented with the equivalent blocking reagent was given to 
each well. Tocilizumab and its control antibody Rituximab were added at a concentration of 1 µg/ml, 
whereas gp130Fc and its control-Fc were used at a concentration of 10 µg/ml. Coculture was continued for 
four further days before separating the epithelial cells from the macrophages as described in 3.1.9 and using 
them for qPCR and CFA analysis. 
Successful blocking of the downstream signalling pathways was verified by western blot analysis of 
phosphorylated STAT3 in PDEC two and five days after the addition of the respective blocking reagents. 
As the phosphorylation of the IL-6 downstream target was still visibly reduced five days post Tocilizumab 





3.1.13 Scratch Assay 
For further analysis of the impact of TGF-bRII knockdown and blockade of IL-6 signalling on EMT 
progression, scratch assays were performed allowing to evaluate potential changes in the cells’ mobility 
capacity upon the different treatments. For this, the experimental setup was as described in chapter 3.1.11 
(TGF-bRII knockdown) or 3.1.12 (blockade of IL-6 signalling), however, only one well per treatment was 
seeded. After 5 days of coculture with M1-polarised macrophages under normo- or hyperglycaemic 
conditions, a scratch was applied in each well with a 100 μl pipette tip. The cells were then immediately 
photographed with the Lionheart FX Automated Microscope, designating this as timepoint zero (t=0). 
Further pictures were taken 9 and 24 hours after the scratch had been applied. For analysis of the cellular 
confluence, the wound surfaces at these timepoints were compared to the equivalent surface at t=0 using 
the Gen5 Data Analysis Software. 
3.2 Molecular biological methods 
3.2.1 RNA isolation 
For the analysis of gene expression of PDEC and macrophages after mono- or coculture and after 
exposition to normo- or hyperglycaemia, RNA was isolated. For this, cells were harvested, separated via 
MACS where applicable (see chapter 3.1.9), washed with PBS and then centrifuged (300 x g, RT, 5 min). 
The cell pellet was resuspended in 300 µl of lysis buffer T from the peqGOLD Total RNA Kit (PeqLab, 
Erlangen, DE). All the following steps of RNA isolation were performed according to the manufacturer’s 
instruction. First of all, the lysate was pipetted onto the DNA removing column and centrifugated at 
12.000 x g and RT for 1 min. The column holding back DNA and other debris was discarded, the flow-
through containing the RNA was washed with 300 µl of 70 % ethanol and pipetted onto the PerfectBind 
RNA column. Centrifugation at 10.000 x g and RT for 1 min followed. The RNA was now bound to the 
column, which was washed twice, once with 500 µl of Wash buffer I and, after repeated centrifugation 
(10.000 x g, RT, 1 min), with 600 µl of Wash buffer II. A further centrifugation step followed to eliminate 
any remaining fluid from the column (10.000 x g, RT, 2 min). Finally, the PerfectBind RNA column was 
placed into a 1.5 ml reaction tube, 40 µl of nuclease-free ddH2O were pipetted directly onto the matrix and 
left to rest for 3 min. The isolated RNA was then eluted from the column by centrifugation for 1 min at 
5.000 x g and RT. 
Nucleic acid concentration was measured by using an Infinite 200 PRO Microplate Reader. To assure a high 
purity degree of the RNA samples, the ratio of absorbances at the wavelengths 260 nm and 280 nm, 
representing the absorbance maxima of nucleid acids and proteins, respectively, was controlled and made 
sure to be close to 2. RNA samples were then stored at -80 °C until further usage. 
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3.2.2 cDNA synthesis 
Complementary DNA (cDNA) was generated from isolated RNA (see chapter 3.2.1) by using the RevertAid 
Strand cDNA Synthesis Kit (Thermo Scientific, Schwerte, DE) according to the manufacturer’s instruction. 
For this, 100 to 500 ng of RNA were diluted with nuclease-free ddH2O up to a total volume of 11.5 µl. 
One µl of oligo (dT)18 primer was added to each sample, the solution thoroughly mixed and incubated at 
65 °C for 5 min. Subsequently, the samples were cooled on ice, mixed and briefly centrifugated before 
following components were added: 
 
Reaction mixture per RNA sample 
4.0 µl 5x reaction buffer 
0.5 µl RiboLock RNase Inhibitor 
2.0 µl 10 mM dNTP mix 
1.0 µl RevertAid 
 
The solution was mixed and incubated at 42 °C for 1 h. To stop the reaction, a final incubation step followed 
at 70 °C for 5 min. The cDNA was then diluted with nuclease-free water in a ratio of 1:4 and stored at -20 °C 
until further usage. 
3.2.3 Quantitative Realtime-Polymerase Chain Reaction 
To evaluate specific gene expression of macrophages or H6c7-pBp /-kras cells under specific cultivation 
conditions, quantitative Realtime-Polymerase Chain Reaction (qRT-PCR) was performed. All the following 
steps were carried out on ice. First of all, 2.5 µl of cDNA were pipetted into one well of a LightCycler 
96-well microtiter plate in duplicates and supplemented by 7.5 µl of a reaction mixture. The reaction mixture 
was prepared as specified below, depending on the provider of the primer.  
 
Reaction mixture for Eurofins Primers   Reaction mixture for RealTimePrimers 
(per cDNA sample)        (per cDNA sample) 
5 µl SYBR Green I Mastermix(2x)     5 µl SYBR Green I Mastermix(2x) 
1 µl Forward Primer         1 µl Primer Mastermix 
1 µl Reverse Primer         1.5 µl nuclease-free ddH20 





Reaction mixture for Biometra Primers 
(per cDNA sample) 
5 µl SYBR Green I Mastermix(2x) 
0.0375 µl Forward Primer 
0.0375 µl Reverse Primer 
1.425 µl nuclease-free ddH20 
 
Then, the microtiter plate was sealed with a translucent adhesive film and centrifuged at 300 x g and 4 °C 
for 2 min. The qRT-PCR was carried out using a LightCycler 480 II with a maximum of 50 cycles and a 
subsequent analysis of the melting curve for PCR quality control. 
A detailed qPCR protocol is listed below; the corresponding annealing temperature for the different gene 
specific primers can be found in 2.6.1-2.6.3. 
 
qPCR protocol 
1) Initial Denaturation   5 min   95 °C 
2) Denaturation    10 sec   95 °C  
3) Annealing     20 sec  58-61 °C (see 2.6.1-2.6.3)  40-50 cycles of step 2-4 
4) Elongation     30 sec   72 °C 
5) Final Extension    10 min  
6) Melting Curve       72 °C 
7) Cooling         4 °C 
 
The duration of the annealing phase was prolonged to 45 sec for analysation of L1CAM, Nanog and 
TGF-bRII.  
Subsequent evaluation was performed using the LightCycler 480 software and Microsoft Excel. The relative 
expression level of the evaluated genes was calculated using the 2∆∆- method and the expression of the 
housekeeper gene GAPDH as a normalisation reference. 
 
3.3 Biochemical methods 
3.3.1 Generation of whole cell lysates 
For the isolation of whole cell lysates of H6c7-pBp and H6c7-kras cells after mono- or coculture and 
exposition to normo- or hyperglycaemia, cells were harvested and, where applicable, separated from 
macrophages via MACS as described in 3.1.9. The cells were centrifuged at 300 x g and RT for 5 min, and 
then resuspended in 80-100 µl of 2xLaemmli buffer. The lysates were briefly sonicated three times, ensuring 
complete disruption of the cell membrane. The samples were stored at -20 °C until further usage. 
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3.3.2 Determination of protein concentration 
To determine the concentration of proteins within whole cell lysates, the DC Protein Assay (Bio-Rad 
Laboratories, München, DE) was used according to the manufacturer’s instructions.  
First of all, all reagents were prewarmed to RT to avoid precipitation and thus to allow precise calorimetric 
reaction. Five µl of each sample and of a standard row with concentrations ranging from 0.193 g/ml to 
1.55 mg/ml were pipetted into the wells of a translucent 96-well flat bottom plate in duplicates. Then, 25 µl 
of reagent A` (1:50 dilution of reagent S in reagent A) and subsequently 200 µl of reagent B were added into 
each well and the plate left to incubate in the dark for 15 min at RT. After this time, the protein 
concentration was measured by using the Tecan Infinite M200PRO spectrophotometer with a wavelength 
of 680 nm.  
3.3.3 Western Blotting 
3.3.3.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) enables the separation of proteins 
according to their molecular weight. For this, 10 µg of protein were diluted with 2xLaemmli buffer ensuring 
that all samples were brought up to the same final volume. Loading dye (4x) was added to each sample at a 
ratio of 1:4 before samples were heated to 95 °C for 5 min. Samples were then cooled on ice and spun 
down. 
In the meantime, a separation gel was prepared as shown in the list below and topped with isopropanol. 
Once it was polymerised, the isopropanol was withdrawn, a stacking gel layered above (see components 
below) and a suitable sample comb carefully inserted avoiding formation of air bubbles.  
 
Separation gel (10 %)     Stacking gel 
4.0 ml ddH20       2000 µl ddH20 
2.0 ml separation gel buffer    765 µl stacking gel buffer 
2.0 ml PAA        31 µl PAA 
30 µl 10 % APS       20 µl 10 % APS 
6.0 µl TEMED       3.0 µl TEMED 
 
After complete polymerisation, the gel was placed into a running chamber, covered with running buffer and 
the comb cautiously pulled out. The samples and at least one PageRulerTM Plus Prestained Protein Ladder 
per gel were loaded into the pockets. Electrophoretic separation was carried out at a voltage of 90 mV until 
the samples had reached the separation gel, then the voltage was increased to 130 mV.  
3.3.3.2 Protein transfer 
After completed segregation of the proteins, gels were transferred onto a polyvinylidene fluoride (PVDF) 
membrane in a semidry blotting chamber. First of all, the PVDF membrane was activated by incubation in 




withdrawn from the running chamber and placed onto the PVDF membrane. Both membrane and gel were 
then enclosed in between Whatman paper soaked in Blotting buffer as shown in Figure 13. 
Figure 13: Schematic depiction of semidry blotting technique. Six sheets of Whatmanpapers were soaked in blot 
buffer A and placed onto the anode of the blotting system. Three Whatmanpapers trenched in blot buffer B and the 
activated PVDF membrane followed. Next, the SDS-gel was carefully stacked on top and 6 Whatmanpapers soaked 
in blot buffer C. Once the cathode was placed on top, the system was ready for protein transfer. Figure according to 
(Lenk, 2017). 
The blotting chamber was closed, and the proteins transferred onto the membrane by application of an 
electric current of 70 mA per gel for 1 h.  
3.3.3.3 Immunodetection of proteins 
Once the protein transfer onto the PVDF-membrane was terminated, the blotting chamber was 
disassembled and the membrane washed in TBS-T for 10 min on a shaker. 
To decrease unspecific binding of proteins, the PVDF membrane was blocked with Blotto for at least 1 h 
at RT. Subsequently, the membrane was transferred into a 50 ml tube containing the respective primary 
antibody diluted in Blotto if not specified otherwise (see chapter 2.7.1) and was left to incubate on a roll 
mixer at 4 °C overnight. The following day, the membrane was washed in TBS-T three times before being 
transferred into the according secondary antibody (see chapter 2.7.1). Secondary antibodies are linked to 
horseradish peroxidase allowing luminescent detection. After 1 h of incubation at RT on a roll mixer, the 
membrane was once again washed in TBS-T three times for 10 min each before being incubated in 
WesternBright ECL substrate for 3 min in the dark. The emerging chemiluminescent signal was detected 
using the Fusion SL Detection System. The PageRulerTM Plus Prestained Protein Ladder allowed control 







3.4 Statistical Analysis 
Statistical analysis was performed using GraphPadPRISM Version 7.0a. Normal distribution was tested via 
the Shapiro-Wilk-Test. Parametric data were either analysed by unpaired t-test or one-way analysis of 
variance (one-way ANOVA) if comparing the impact of multiple factors. Data are represented by their 
mean and their standard error of mean (SEM). Non-parametric data were analysed by Kruskal-Wallis one-
way ANOVA on ranks and their median and interquartile range are represented. Results were considered 
as statistically significant for p-values < 0,05. Significance of results is indicated as follows:  




4.1 The impact of  hyperglycaemia and PDEC on macrophages 
Previous experiments revealed that high glucose levels increase the pro-inflammatory character of M1-
polarised macrophages. It could also be shown that PDEC which are simultaneously exposed to M1-
macrophages and hyperglycaemia are influenced in their EMT-properties. First findings suggested that this 
gain of tumourigenesis-associated characteristics may be attributed to elevated TNF-a levels expressed by 
macrophages (Plundrich, 2017). However, so far only little is known about the impact of the mentioned 
interplay between pro-inflammatory M1-macrophages and PDEC in T2DM-associated hyperglycaemic 
conditions on macrophages themselves. To elucidate this and to gain further insights on macrophages’ 
potential contribution to the findings of Plundrich et al., a direct coculture system of PDEC and 
macrophages was conducted and the gene expression level of several pro- and anti-inflammatory cytokines 
and growth factors in macrophages was analysed. 
4.1.1 The presence of PDEC and high glucose levels alters the cytokine profile of 
macrophages 
In a first step, the combined impact of hyperglycaemia and coculture with PDEC on macrophages was 
analysed. For this, macrophages were cultivated with H6c7-pBp or H6c7-kras cells in coculture medium 
supplemented with either 5 or 25 mM glucose for 5 days. As a control, macrophages were monocultured in 
normo- or hyperglycaemic settings. After 5 days, macrophages were separated from coculture via EpCam 
MACS-depletion of PDEC or harvested from monoculture and their relative gene expression levels of pro- 
and anti-inflammatory cytokines and growth factors were evaluated. Indeed, macrophages that had been 
cocultured with PDEC were influenced in their expression level of the analysed EMT- and CSC-inducing 
mediators. Here, IL-6 levels were altered most impressively: normoglycaemic coculture with H6c7-pBp cells 
led to a 263-fold, and hyperglycaemic coculture to a 229-fold increase compared to monocultured 
macrophages under similar glycaemic conditions (Figure 14 A). In macrophages cocultured with H6c7-kras 
cells, elevated glucose levels had a synergistic effect causing a 297-fold increase in hyperglycaemic while a 
231-fold increase in normoglycaemic settings could be observed compared to respectively monocultured 




Figure 14: The presence of benign and premalignant PDEC and high glucose levels alters the gene 
expression level of pro- and anti-inflammatory cytokines and growth factors in macrophages (MF). M1-
polarised macrophages were cultivated in mono- or coculture with H6c7-pBp or H6c7-kras cells for 5 days under 
normo- or hyperglycaemic conditions (5 or 25 mM glucose). MF were separated from direct coculture with epithelial 
cells via EpCam-MACS depletion of PDEC or harvested from monoculture and used for qRT-PCR analysis. The 
relative gene expression levels of IL-6 (A), IL-8 (B), TNF-a (C), VEGF (D), TGF-b1 (E) and IL-10 (F) are depicted, 
normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the normoglycaemic 
monocultured MF sample. Data are presented as mean and standard error of mean; one-way ANOVA was performed 









































































































































































































































The mRNA levels of the pro-inflammatory cytokines IL-8 and TNF-a were very similarly impacted by 
coculture with PDEC and high glucose levels. Both mediators were elevated in a coculture-dependent 
manner and hyperglycaemia further aggravated this upregulation (Figure 14 B and C). In general, the effect 
induced through coculture with the premalignant H6c7-kras cells was slightly more pronounced than the 
one evoked through coculture with the benign H6c7-pBp cells (IL-8 levels: 5.0- and 5.7-fold increase through 
normo- and hyperglycaemic coculture with H6c7-pBp; 6.2- and 6.5-fold increase through normo- and 
hyperglycaemic coculture with H6c7-kras cells. TNF-a levels: 6.1- and 7.1-fold increase through normo- 
and hyperglycaemic coculture with H6c7-pBp; 6.2- and 7.3-fold increase normo- and hyperglycaemic 
coculture with H6c7-kras cells). 
VEGF, which is known to be an important factor in the context of vasculogenesis and angiogenesis (Luo 
et al., 2001) as well as in the stimulation of monocyte and macrophage migration (Wheeler et al., 2018), was 
also clearly upregulated through coculture with both PDEC lines, irrespective of the glucose level 
(Figure 14 D). 
The mRNA level of TGF-b1 in macrophages was less impacted by coculture than had been the case for the 
other cytokines analysed (Figure 14 E). Whereas normoglycaemic coculture with the benign PDEC line did 
not influence the gene expression level at all, hyperglycaemic coculture led to a 1.5-fold increase compared 
to normoglycaemic monoculture. A similar increase of nearly 50 % was evoked through normoglycaemic 
coculture with the premalignant PDEC line, whereas hyperglycaemic coculture intriguingly led to a 
reduction of 62 % compared to macrophages from normoglycaemic coculture. 
Remarkably, IL-10 showed significantly increased mRNA levels in macrophages cocultured with H6c7-pBp 
cells irrespective of the glucose level, whereas macrophages cocultured with the premalignant H6c7-kras 
cells showed diminished mRNA levels of this factor (Figure 14 F). The diminution was slightly more 
pronounced under normoglycaemic than under hyperglycaemic coculture conditions. 
Altogether, these data show that the gene expression level of pro- and anti-inflammatory cytokines of 
macrophages are clearly impacted by the presence of PDEC and hyperglycaemia. Especially the presence of 
the premalignant H6c7-kras cells and high glucose levels promote a pro-inflammatory phenotype of 
macrophages with high expression levels of IL-6, IL-8, TNF-a  and VEGF and simultaneously low 










4.1.2 High glucose levels faintly promote the pro-inflammatory phenotype of 
macrophages cocultured with PDEC 
In order to better discriminate whether elevated glucose levels or the presence of PDEC account for the 
aggravation of a pro-inflammatory phenotype in macrophages, the alone effect of glucose on macrophages 
that had either been monocultured or cocultured with H6c7-pBp or H6c7-kras cells was analysed in a second 
step. For this, the experimental setup was identical to the one mentioned in section 4.1.1, but for analysis 
the relative gene expression level of the pro- and anti-inflammatory cytokines and growth factors of the 
cells cultivated under hyperglycaemic conditions were compared to the equivalent cells from 
normoglycaemic cultivation conditions. Interestingly, monocultured macrophages showed a significant 
decrease in the gene expression level of IL-6 (Figure 15 A) through high glucose and tendencies of decrease 
for IL-8, TNF-a, VEGF and IL-10 (Figure 15 B, C, D, F). TGF-b1 expression, on the other hand, was 
slightly upregulated through hyperglycaemia in monocultured macrophages (Figure 15 E). 
In contrast, macrophages that had been cocultured with either epithelial cell line showed tendencies of 
increase in the mRNA levels of all pro-inflammatory cytokines and growth factors through elevated glucose 
levels (Figure 15 A-C). Hyperglycaemia induced a 2.7-fold elevation in the expression level of VEGF in 
macrophages from coculture with the premalignant cells, whereas it did not alter the expression in 
macrophages from coculture with the benign PDEC. The immunosuppressive cytokines and growth factors 
did not show uniform effects: TGF-b1 expression was increased through high glucose levels in macrophages 
from coculture with H6c7-pBp cells but decreased in those from coculture with H6c7-kras cells. The gene 
expression level of IL-10 was only affected in macrophages arising from coculture with the premalignant 
PDEC showing a slight glucose-dependent increase (Figure 15 E and F). 
Thus, overall, glucose alone only faintly impacted on the gene expression level of the analysed potential 
EMT- and CSC- inducers. This leads to the assumption that the effects seen in section 4.1.1 are mainly 
caused by the interaction between macrophages and PDEC. Therefore, the effect of coculture with PDEC 




Figure 15: High glucose levels faintly amplify the pro-inflammatory phenotype of macrophages (MF) 
cocultured with PDEC. M1-polarised MF were cultivated under normo- or hyperglycaemic conditions (5 or 25 mM 
of glucose) for 5 days in mono- or coculture with H6c7-pBp or H6c7-kras cells. MF were separated from direct 
coculture with epithelial cells via EpCam-MACS depletion or harvested from monoculture and used for qRT-PCR 
analysis. The relative gene expression levels of IL-6 (A), IL-8 (B), TNF-a (C), VEGF (D), TGF-b1 (E) and IL-10 (F) 
are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the 
equivalent sample arising from the normoglycaemic setting. Normally distributed data are presented as mean and 
standard error of mean, unpaired t-test was performed for statistical analysis. Not normally distributed data (indicated 
via (#)) are shown as median and interquartile range. Wilcoxon Signed Rank Test was used for statistical analysis.           





































































































































































































































































4.1.3 The presence of PDEC strengthens the pro-inflammatory phenotype of 
macrophages 
After having analysed the combined effect of glucose and coculture with PDEC on macrophages and the 
one of glucose alone, the effect of coculture on its own was now to be investigated. For this, the 
experimental setup was the same as described in section 4.1.1, but the monocultured macrophages of the 
equivalent glucose condition served as a control for comparative analysis. 
The gene expression level of IL-6 was markedly elevated through coculture with both pancreatic epithelial 
cell lines, irrespective of the glucose level. Interestingly, the statistically most significant increase was evoked 
through coculture with H6c7-pBp cells under normoglycaemic conditions (263-fold increase compared to 
normoglycaemic monoculture). But also normoglycaemic H6c7-kras cell coculture and hyperglycaemic 
H6c7-pBp cell coculture led to a significant elevation of the pro-inflammatory cytokine (231-fold increase, 
and 838-fold increase, respectively) (Figure 16 A). 
Similar effects were also detected for all other analysed pro-inflammatory cytokines and growth factors. 
Even though the effects were not as pronounced as for IL-6, a clear coculture-induced amplification on 
mRNA level could be observed (Figure 16 B-D). Under normoglycaemic conditions IL-8 mRNA levels 
showed significant 5.06-fold and 6.19-fold increases upon coculture with the benign and premalignant 
PDEC, respectively (Figure 16 B). Hyperglycaemic coculture further intensified these increases (6.64-fold 
and 8.36-fold for coculture with benign and premalignant PDEC, respectively, compared to monoculture). 
TNF-a expression showed a significant 9.17-fold increase through coculture with H6c7-pBp cells under 
high glucose levels (Figure 16 C).Macrophages’ VEGF levels were elevated by the factor 2.73 or 3.06 upon 
exposure to normo- or hyperglycaemic coculture with H6c7-pBp cells, respectively, and also coculture with 
H6c7-kras cells led to 2.47- and 3.75-fold increases (Figure 16 D). TGF-b1 levels of macrophages were not 
influenced by coculture with the benign H6c7-pBp cells, suggesting that hyperglycaemia was the main 
mediator of the effects seen upon exposure to coculture and high glucose levels in section 4.1.1. Coculture 
with the premalignant H6c7-kras cells, however, did impact on the TGF-b1 levels of macrophages: 
normoglycaemic coculture led to a 1.4-fold increase on mRNA level, whereas hyperglycaemic coculture 
evoked a significant decrease of 60 % compared to monocultured macrophages (Figure 16 E). 
As for IL-10, coculture with benign H6c7-pBp cells evoked a significant increase in gene expression 
irrespective of the glucose level the cells were subjected to (2.62-fold increase for normoglycaemic and 2.79-
fold for hyperglycaemic coculture) (Figure 16 F). Contrary to this, coculture with H6c7-kras cells decreased 
the mRNA level of IL-10, reaching statistical significance under normoglycaemic settings with a reduction 




Figure 16: The presence of PDEC amplifies the pro-inflammatory phenotype of macrophages (MF). M1-
polarised MF were cultivated in mono- or coculture with H6c7-pBp or H6c7-kras cells for 5 days under normo- or 
hyperglycaemic conditions (5 or 25 mM of glucose). MF were separated from direct coculture with epithelial cells via 
EpCam-MACS depletion of PDEC or harvested from monoculture and used for qRT-PCR analysis. The relative gene 
expression levels of IL-6 (A), IL-8 (B), TNF-a (C), VEGF (D), TGF-b1 (E) and IL-10 (F) are depicted, normalised to 
the housekeeping gene GAPDH and presented as n-fold expression compared to the equivalent monocultured sample. 
Normally distributed data are presented as mean and standard error of mean, unpaired t-test was performed for 
statistical analysis. Not normally distributed data (indicated via (#)) are shown as median and interquartile range. 
Wilcoxon Signed Rank Test was used for statistical analysis.                          









































































































































































































































































Altogether, these findings suggest that the shift towards a more pro-inflammatory phenotype in the presence 
of high glucose levels and - especially premalignant - PDEC seen on the mRNA level of macrophages in 
Figure 14 was mainly triggered by coculture with PDEC. Hyperglycaemia alone led to similar tendencies, 
but these were rather minor, thereby excluding high glucose levels as the sole mediator of the observed 
effects. Exposure to hyperglycaemia, however, further amplified several of the coculture-dependent 
increases in gene expression. Only mRNA levels of the important EMT-inducer TGF-b1 seemed to be 
more impacted by high glucose levels than by coculture. Remarkably, IL-10 gene expression levels showed 




4.2 The impact of  hyperglycaemia and macrophages on PDEC 
Previous studies investigated the impact of a two-day exposure to hyperglycaemia and M1-polarised 
macrophages on both benign and premalignant PDEC. On gene expression level, EMT induction was 
asserted identifying TNF-a as a potential mediator of these effects (Plundrich, 2017). Promotion of CSC-
properties was detected to a lesser extent, raising the question whether a longer subjection to a 
hyperglycaemic and inflammatory microenvironment may also promote stemness characteristics in PDEC. 
Furthermore, it was suggested that a prolonged exposure of PDEC to hyperglycaemia and macrophages 
might corroborate the previous findings by also showing EMT- and CSC-associated changes on protein 
level. In preliminary experiments EMT- and CSC-associated characteristics in PDEC were analysed upon 
short- (2 days) and long-term (5 days) exposure to a hyperglycaemic and inflammatory environment. These 
experiments revealed that some EMT-associated alterations in gene expression were initiated upon short-
term exposure to hyperglycaemia and macrophages but amplified over time (especially in the premalignant 
H6c7-kras cells) (data not shown). This indicates a time-dependence in the acquisition of malignancy-
associated characteristics upon exposure to glucose and macrophages. Therefore, further coculture 
experiments were performed for 5 days and alterations in EMT- and CSC-associated characteristics of 
PDEC upon exposure to a hyperglycaemic inflammatory microenvironment were analysed on gene level 
(chapter 4.2.1), protein level (chapter 4.2.2) and through colony formation assays (chapter 4.2.3).  
4.2.1 Impact of hyperglycaemia and macrophages on the gene expression levels of EMT- 
and CSC-associated genes in PDEC 
To elucidate the impact of a T2DM-associated microenvironment on the gene expression level of PDEC, 
H6c7-pBp and H6c7-kras cells were cultivated in mono- or coculture with M1-polarised macrophages under 
normo- or hyperglycaemic conditions for five days. The epithelial cells were then separated from the direct 
coculture via CD11b-MACS depletion or harvested from monoculture and used for qRT-PCR analysis.  
As in previous studies (Plundrich, 2017), IL-6, IL-8, TNF-a and TGF-b1 were analysed as potential EMT-
inducing cytokines and growth factors. Slug, Snail and Zeb1 mRNA level were analysed as EMT- and CSC-
inducing transcriptional factors. E-Cadherin, Vimentin and L1CAM were chosen as EMT markers and 
finally Nestin and Nanog were analysed representing typical CSC markers. 
In a first step, analysis focused on the combined effect of glucose and macrophages on the gene expression 
level of PDEC (4.2.1.1). In a second step, the sole effect of glucose on PDEC was analysed (4.2.1.2) and 
finally the effect of coculture alone on the gene expression level of PDEC was evaluated (4.2.1.3). 
4.2.1.1 Combined impact of glucose and coculture on PDEC 
To analyse the impact of a T2DM-associated microenvironment – that is the combined impact of glucose 
and coculture with M1-polarised macrophages – on PDEC, the experimental setup was as described in 4.2.1. 
For analysis, the relative gene expression levels of EMT- and CSC-associated mediators and transcription 




4.2.1.1.1 Hyperglycaemia and the presence of macrophages reduce the expression of pro-
inflammatory mediators in benign and elevates them in premalignant PDEC 
Compared to monocultured benign H6c7-pBp cells, those that had been exposed to macrophages showed a 
decrease in their relative gene expression level of the pro-inflammatory cytokines IL-6, IL-8 and TNF-a 
(Figure 17A, C, E). This effect was highly significant for IL-8 irrespective of the glucose level: a reduction 
of 70% in normoglycaemic and of 68% in hyperglycaemic coculture compared to the equivalent 
monoculture was to be observed. As for the gene expression level of TNF-a, only hyperglycaemic coculture 
settings evoked a statistically significant decrease of roughly 56% compared to the equivalent monoculture 
setting. 
Remarkably, the coculture-induced effects seen on the gene expression level of the benign PDEC for IL-6 
and TNF-a were contrary to those in the premalignant cells. Both factors were upregulated on the mRNA 
level in H6c7-kras cells that had been exposed to macrophages (Figure 17 B and F). The effects were more 
explicit for TNF-a, reaching statistical significance irrespective of the glucose level (3.1-fold elevation in 
normoglycaemic coculture and 2.4-fold elevation in hyperglycaemic coculture compared to normoglycaemic 
monoculture). The expression level of IL-8, on the other hand, was not affected at all through 
hyperglycaemia and macrophage coculture in H6c7-kras cells (Figure 17 D). 
 
Figure17: Combined impact of glucose and coculture on the gene expression level of EMT- and CSC- 









































































































































































































































































































Figure 17: Combined impact of glucose and coculture on the gene expression level of EMT- and CSC- 
inducing IL-6, IL-8, TNF-a and TGF-b1 in H6c7-pBp and H6c7-kras cells. (continued) H6c7-pBp or H6c7-kras 
cells were mono- or cocultured with M1-polarised macrophages (MF) for 5 days in normo-or hyperglycaemic settings 
(5 or 25 mM of glucose). The epithelial cells were separated from direct coculture via CD11b-MACS depletion of M1- 
MF or harvested from monoculture and used for qRT-PCR analysis. The relative gene expression levels of IL-6 (A 
and B), IL-8 (C and D), TNF-a (E and F) and TGF-b1 (G and H) of both cell lines are depicted, normalised to the 
housekeeping gene GAPDH and presented as n-fold expression compared to the monocultured sample from 
normoglycaemic settings. Normally distributed data are presented as mean and standard error of mean and one-way 
ANOVA was performed for statistical analysis.                
*: 0,05>p>0,0332 **: =0,0331>p>0,0021 ***=: 0,002>p>0,0001 ****: p<0,0001; n=7 
 
The impact of a T2DM-associated microenvironment on the gene expression level of the anti-inflammatory 
TGF-b1 was similar in both cell lines. Exposure to macrophages led to tendencies of elevation and 
hyperglycaemia evoked a slight increase in monocultured cells (Figure 17 G and H). 
 
4.2.1.1.2 The EMT- and CSC-associated transcription factor Zeb1 is elevated through 
hyperglycaemia and the presence of macrophages in PDEC 
Next, the gene expression levels of the EMT- and CSC-associated transcription factors Snail, Slug and Zeb1 
were analysed. 
Whereas hyperglycaemia and coculture did not influence the gene expression level of Snail in H6c7-pBp cells 
(Figure 18 A), they did lead to an elevated level in H6c7-kras cells (Figure 18 B). The most explicit increase 
was to be seen under hyperglycaemic coculture conditions (1.75-fold elevation compared to 









































































































































































































































































































Figure 18: Combined impact of glucose and coculture on the gene expression level of EMT- and CSC-
associated transcription factors. H6c7-pBp or H6c7-kras cells were monocultured or cocultured with M1-polarised 
macrophages (MF) for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose). The epithelial cells were 
separated from direct coculture via CD11b-MACS depletion of M1-MF  or harvested from monoculture and used for 
qRT-PCR analysis. The relative gene expression levels of Snail (A and B), Slug (C and D) and Zeb1 (E and F) of both 
cell lines are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression compared 
to the monocultured sample from normoglycaemic settings. Normally distributed data are presented as mean and 
standard error of mean and one-way ANOVA was performed for statistical analysis. Not normally distributed data 
(indicated via #) are shown as median and interquartile range. Kruskal-Wallis one-way ANOVA on ranks was used for 
statistical analysis. *: 0,05>p>0,0332; n=7 
The impact on the mRNA level of Slug was similar in both cell lines: a coculture-dependent elevation, 
slightly more pronounced under normoglycaemic conditions in the benign PDEC and under hyperglycaemic 
conditions in the premalignant PDEC (Figure 18 C and D). Interestingly, H6c7-pBp cells showed an 
upregulation of Zeb1 on mRNA level throughout all samples (Figure 18 E). Normoglycaemic coculture led 






































































































































































































































monoculture, respectively.  Hyperglycaemic coculture conditions even led to statistically significant changes 
compared to the monocultured normoglycaemic cells (3.79-fold upregulation). In H6c7-kras cells, only 
coculture under normoglycaemic conditions led to elevated Zeb1 levels (2.48-fold compared to 
normoglycaemic monoculture); cells mono- or cocultured in hyperglycaemia did not show any changes 
(Figure 18 F). 
4.2.1.1.3 Hyperglycaemia and macrophages promote changes in the expression of EMT markers 
in PDEC 
The epithelial marker E-Cadherin and the two mesenchymal markers Vimentin and L1CAM were chosen 
as indicators for potential EMT-associated alteration in PDEC. Both cell lines were characterised by a loss 
of epithelial and a gain of mesenchymal markers through the impact of hyperglycaemia and macrophages. 
However, the reduction of E-Cadherin was more pronounced in H6c7-kras than in H6c7-pBp cells, with a 
maximum reduction of 50 % provoked by hyperglycaemic coculture (Figure 19 A and B).  
The increase of the mesenchymal marker Vimentin, on the other hand, was more pronounced in the benign 
PDEC. Here, normoglycaemic coculture led to a 15.2-fold, and hyperglycaemic coculture to a 13.6-fold 
increase in H6c7-pBp cells compared to cells of the normoglycaemic monoculture (Figure 19 C). In the 




Figure 19: Combined impact of glucose and coculture on the gene expression level of EMT markers in 


































































































































































































































Figure 19: Combined impact of glucose and coculture on the gene expression level of EMT markers in 
PDEC. (continued) H6c7-pBp or H6c7-kras cells were mono- or cocultured with M1-polarised macrophages (MF) for 
5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose). The epithelial cells were separated from direct 
coculture via CD11b-MACS depletion of M1-MF or harvested from monoculture and used for qRT-PCR analysis. 
The relative gene expression levels of E-Cadherin (A and B), Vimentin (C and D), and L1CAM (E and F) of both cell 
lines are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the 
monocultured sample from normoglycaemic settings. Normally distributed data are presented as mean and standard 
error of mean and one-way ANOVA was performed for statistical analysis. Not normally distributed data (indicated 
via #) are shown as median and interquartile range. Kruskal-Wallis one-way ANOVA on ranks was used for statistical 
analysis. *: 0,05>p>0,0332  **: =0,0331>p>0,0021; n=7 
The effects on the gene expression level of mesenchymal L1CAM were similar in both cell lines, but slightly 
more pronounced in the premalignant PDEC. A coculture-dependent upregulation under normoglycaemic 
settings could be observed. High glucose levels, however, rather decreased the mRNA level of L1CAM in 
monocultured cells and neutralised the coculture-dependent increase (Figure 19 E and F). 
4.2.1.1.4 Stemness markers Nestin and Nanog in PDEC are heterogeneously impacted by a 
T2DM-associated microenvironment 
As indicators for stemness, Nestin and Nanog expression levels were evaluated. Interestingly, Nestin 
showed a coculture-dependent decrease in its expression level in the benign PDEC (Figure 20 A). In 
contrast, the mRNA level of Nestin in the premalignant PDEC was increased through both glucose and 
coculture, the strongest effect to be seen in those cells cultivated in hyperglycaemic coculture (3.5-fold 
increase compared to normoglycaemic monoculture) (Figure 20 B). 
Monocultured H6c7-pBp cells exposed to high glucose levels showed a 1.53-fold increase in Nanog level 
compared to the normoglycaemic monoculture (Figure 20 C). A less explicit increase was evoked through 
normoglycaemic coculture. Remarkably, hyperglycaemic coculture with M1-polarised macrophages had the 
opposite effect on the benign epithelial cells so that the mRNA level was reduced by 40 %. 
A similar reduction of Nanog was also observed on the mRNA level of the premalignant H6c7-kras cells 
arising from hyperglycaemic coculture (Figure 20 D). Gene expression levels were reduced by 55 % 
compared to the normoglycaemic monoculture. Contrary to the effects seen in H6c7-pBp cells, however, 
hyperglycaemic monoculture led to slight tendencies of decrease in the expression level of Nanog compared 



































































































































































































































Figure 20: Combined impact of glucose and coculture on the gene expression level of stemness markers in 
PDEC. H6c7-pBp or H6c7-kras cells were mono- or cocultured with M1-polarised macrophages (MF) for 5 days in 
normo- or hyperglycaemic settings (5 or 25 mM of glucose). The epithelial cells were separated from direct coculture 
via CD11b-MACS depletion of M1-MF or harvested from monoculture and used for qRT-PCR analysis. The relative 
gene expression levels of Nestin (A and B) and Nanog (C and D) of both cell lines are depicted, normalised to the 
housekeeping gene GAPDH and presented as n-fold expression compared to the monocultured sample from 
normoglycaemic settings. Normally distributed data are presented as mean and standard error of mean and one-way 
ANOVA was performed for statistical analysis. n=7 
Altogether, these data demonstrate that an inflammatory and hyperglycaemic microenvironment impacts 
on the expression level of both EMT- and CSC-associated genes in PDEC. Especially a loss of epithelial 
markers and a gain of mesenchymal ones was to be observed, indicating a glucose and coculture-dependent 
promotion of EMT. Furthermore, it is to note that the combined effect of glucose and M1-polarised 
macrophages was not always uniform in both cell lines. The effect on EMT markers was more pronounced 
in H6c7-pBp cells, whereas the one on the EMT- and CSC-associated transcription factors was stronger in 
H6c7-kras cells. The gene expression levels of the pro-inflammatory cytokines IL-6, IL-8 and TNF-a were 
even contrarily affected in H6c7-pBp and H6c7-kras cells. Elevated gene expression level of Nestin, 
suggesting a gain of CSC-properties, was seen in both cell lines. This effect, however, was exclusively 
glucose-dependent in the benign but coculture- and glucose-dependent in the premalignant PDEC. 
These findings suggest that some CSC- and EMT-associated alterations in PDEC are rather glucose-
dependent than coculture-dependent and vice versa. The genetic constitution might influence this 
behaviour, as differences were seen between the benign H6c7-pBp cells and the premalignant H6c7-kras 




















































































































































4.2.1.2 Impact of glucose alone on PDEC 
The qRT-PCR analysis revealed an impact of a pro-inflammatory and hyperglycaemic microenvironment 
on EMT induction in PDEC, a gain of CSC-related properties and an induction of pro-inflammatory factors 
especially in the premalignant PDEC. However, some gene expression levels seemed to be rather affected 
through coculture with M1-polarised macrophages, mimicking the inflammatory surrounding, whereas 
other genes were more influenced by the differing glucose conditions. Therefore, the effect of glucose alone 
on the gene expression level in PDEC was to be analysed in a next step. For this, the experimental setup 
was identical to the one mentioned in 4.2.1, but cells arising from normoglycaemic settings now served as a 
control for those exposed to hyperglycaemia under each culture condition. 
4.2.1.2.1 Hyperglycaemia increases TGFß-1 levels in PDEC 
In accordance with the findings in 4.2.1.1, high glucose levels only slightly increased the gene expression of 
the pro-inflammatory cytokine IL-6 in H6c7-pBp cells (in mono-and coculture equally) but did not alter it 
in H6c7-kras cells ( Figure 21 A and B).  





Figure 21: Impact of hyperglycaemia on the expression level of EMT- and CSC-inducing mediators in mono- 











































































































































































































































































































Figure 21: Impact of hyperglycaemia on the expression level of EMT- and CSC-inducing mediators in mono- 
and cocultured PDEC. (continued) H6c7-pBp or H6c7-kras cells were cultivated in normo- or hyperglycaemic 
conditions (5 or 25 mM of glucose) in mono- or coculture with M1-polarised macrophages (MF). The epithelial cells 
were separated from direct coculture with macrophages via CD11b-MACS depletion of M1-MF or harvested from 
monoculture and used for qRT-PCR analysis. The relative gene expression levels of IL-6 (A and B), IL-8 (C and D), 
TNF-a (E and F) and TGF-b1 (G and H) for both cell lines are depicted, normalised to the housekeeping gene 
GAPDH and presented as n-fold expression compared to the equivalent sample arising from normoglycaemic setting. 
Normally distributed data are presented as mean and standard error of mean, unpaired t-test was performed for 
statistical analysis. Not normally distributed data (indicated via #) are shown as median and interquartile range. 
Wilcoxon Signed Rank Test was used for statistical analysis.              
*: 0,05>p>0,0332 **: =0,0331>p>0,0021 ***=: 0,002>p>0,0001; n=7 
 
There were also no visible changes for TNF-a levels in the benign PDEC nor in cocultured premalignant 
H6c7-kras cells. However, exposure to hyperglycaemia resulted in a significant decrease in TNF-a levels in 
monocultured H6c7-kras cells (roughly 50%) (Figure 21 E and F). The important EMT-inducer TGF-b1 
was expressed at a slightly higher level in cells subjected to high glucose levels, the effect being slightly 
stronger in the benign (1.6-fold increase in hyperglycaemic compared to normoglycaemic monoculture) than 
in the premalignant cell line (1.3-fold increase in monoculture upon exposure to hyperglycaemia) 
(Figure 21 G and H). 
4.2.1.2.2 High glucose levels increase Zeb1 expression in benign and Snail in premalignant 
PCEC  
The gene expression level of Snail in H6c7-pBp cells was not affected by exposure to hyperglycaemia 
(Figure 22 A), whereas it was weakly increased in H6c7-kras cells from hyperglycaemic conditions 










































































































































































































































































































monocultured ones (1.40 and 1.30-fold increase compared to normoglycaemic conditions, respectively). 
Expression levels of Slug were slightly increased in monocultured H6c7-pBp cells upon exposure to high 
glucose levels (1.32-fold increase compared to normoglycaemic monoculture), whereas cocultured H6c7-
pBp cells showed diminished expression levels of Slug (0.75-fold) in hyperglycaemic settings (Figure 22 C). 
In H6c7-kras cells, on the other hand, expression levels of Slug showed a glucose-dependent decrease of 
similar strength in mono- and cocultured cells (Figure 22 D). As for Zeb1, expression levels were increased 
in a glucose-dependent manner in the benign PDEC, reaching statistical significance in H6c7-pBp cells 
cocultured with M1-macrophages (2.21-fold elevation in cocultured; 1.81-fold elevation in monocultured 
cells compared to the equivalent normoglycaemic sample) (Figure 22 E). In the premalignant cells, 
however, no glucose-dependent influence was visible on expression levels of Zeb1(Figure 22 F) 
 
Figure 22: Impact of hyperglycaemia on the expression level of EMT- and CSC-associated transcription 
factors of mono- and cocultured PDEC. H6c7-pBp or H6c7-kras cells were cultivated in normo- or hyperglycaemic 
conditions (5 or 25 mM of glucose) in mono- or coculture with M1-polarised macrophages (MF). The epithelial cells 
were separated from direct coculture with macrophages via CD11b-MACS depletion of M1-MF or harvested from 
monoculture and used for qRT-PCR analysis. The relative gene expression levels of Snail (A and B), Slug (C and D) 
and Zeb1(E and F) for both cell lines are depicted, normalised to the housekeeping gene GAPDH and presented as 
n-fold expression compared to the equivalent sample arising from normoglycaemic setting. Normally distributed data 
are presented as mean and standard error of mean, unpaired t-test was performed for statistical analysis.          
































































































































































































































4.2.1.2.3 High glucose levels alter the expression of EMT markers in PDEC 
The impact of glucose on the gene expression levels of the EMT markers E-Cadherin, Vimentin and 
L1CAM was more pronounced in the premalignant than in the benign PDEC.  
With the exception of monocultured H6c7-pBp cells, PDEC from all other culture conditions were 
characterised by a significant loss of the epithelial marker E-Cadherin when subjected to hyperglycaemia 
(Figure 23 A and B).  
 
Figure 23: Impact of hyperglycaemia on the expression level of EMT markers of mono- and cocultured 
PDEC. H6c7-pBp or H6c7-kras cells were cultivated in normo- or hyperglycaemic conditions (5 or 25 mM of glucose) 
in mono- or coculture with M1-polarised macrophages (MF). The epithelial cells were separated from direct coculture 
with macrophages via CD11b-MACS depletion of M1-MF or harvested from monoculture and used for qRT-PCR 
analysis. The relative gene expression levels of E-Cadherin (A and B), Vimentin (C and D) and L1CAM (E and F) for 
both cell lines are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression 
compared to the equivalent sample arising from normoglycaemic setting. Normally distributed data are presented as 
mean and standard error of mean, unpaired t-test was performed for statistical analysis. Not normally distributed data 
(indicated via #) are shown as median and interquartile range. Wilcoxon Signed Rank Test was used for statistical 
































































































































































































































Exposure to high glucose levels also resulted in an upregulation of Vimentin expression levels (Figure 23 C 
and D). This effect was most impressive in cocultured H6c7-kras cells which showed an 8.0-fold increase 
compared to the equivalent normoglycaemic sample. 
Surprisingly, the mesenchymal marker L1CAM was significantly downregulated by hyperglycaemia in 
cocultured H6c7-pBp cells and in both mono- and cocultured H6c7-kras cells (Figure 23 E and F). This 
decrease was slightly more pronounced in the cocultured than in the monocultured premalignant cells. 
4.2.1.2.4 Hyperglycaemia increases Nestin levels but decreases Nanog expression in PDEC 
The PDAC-associated stem cell marker Nestin showed upregulated expression levels upon exposure to 
hyperglycaemia in both cell lines (Figure 24 A and B). This effect was most pronounced in the cocultured 
premalignant H6c7-kras cells with a 1.9-fold elevation compared to the equivalent normoglycaemic sample 
(1.3-fold glucose-dependent elevation in monocultured H6c7-kras cells, 1.6-fold in cocultured and 1.4-fold 
in monocultured H6c7-pBp cells). 
 
 
Figure 24: Impact of hyperglycaemia on the expression level of CSC markers of mono- and cocultured H6c7-
pBp and H6c7-kras cells. H6c7-pBp or H6c7-kras cells were cultivated in normo-or hyperglycaemic conditions (5 or 
25 mM of glucose) in mono- or coculture with M1-polarised MF. The epithelial cells were separated from direct 
coculture with macrophages via CD11b-MACS depletion of M1-MF or harvested from monoculture and used for 
qRT-PCR analysis. The relative gene expression levels of Nestin (A and B) and Nanog (C and D) for both cell lines 
are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the 
equivalent sample arising from normoglycaemic setting. Normally distributed data are presented as mean and standard 
error of mean, unpaired t-test was performed for statistical analysis. Not normally distributed data (indicated via #) are 
shown as median and interquartile range. Wilcoxon Signed Rank Test was used for statistical analysis.          
























































































































































Nanog, on the other hand, was not impacted that uniformly. Whereas its expression rate was slightly 
increased in monocultured benign PDEC upon exposure to high glucose levels (1.53-fold compared to 
normoglycaemic conditions), it was significantly decreased by roughly 40% in cocultured H6c7-pBp cells 
when subjected to high glucose (Figure 24 C). Hyperglycaemia also decreased the mRNA level of Nanog 
in H6c7-kras cells. This effect was more pronounced in co- than in monocultured premalignant PDEC, 
glucose leading to a significant loss of 51% compared to normoglycaemic coculture (Figure 24 D). 
 
Collectively, these experiments showed that hyperglycaemia predominantly influences EMT- and only 
slightly CSC-associated marker genes in PDEC. A glucose-mediated EMT induction was observed in both 
H6c7-pBp and H6c7-kras cells. This effect was more pronounced in the premalignant than in the benign 
PDEC. Hyperglycaemia also led to slightly increased TGF-b1 levels in both cell lines, whereas no distinctive 
glucose-dependent effect was observed on the gene expression level of IL-6, IL-8 or TNF-a. Finally, an 
elevation of the stem cell marker Nestin was seen in both H6c7-pBp and H6c7-kras cells when exposed to 
high glucose levels. Again, this impact was more pronounced in the premalignant H6c7-kras cells than in 




4.2.1.3 Impact of coculture alone on PDEC 
In a final step, the exclusive impact of exposure to M1-polarised macrophages in PDEC was investigated. 
The aim was to elucidate the macrophages’ contribution to the effects observed above on EMT and CSC 
marker gene expression of PDEC upon exposition to T2DM-associated microenvironment. The 
experimental setup was the same as the one in section 4.2.1, but the monocultured epithelial cells of each 
glucose condition served as a reference compared to cocultured ones. 
4.2.1.3.1 The presence of macrophages reduces pro-inflammatory cytokine expression in benign 
PDEC and increases them in premalignant cells 
H6c7-pBp cells and H6c7-kras cells showed rather different reactions upon exposure to M1-macrophages 
in their gene expression level of IL-6, IL-8, TNF-a and TGF-b1. 
The benign PDEC did not show relevant changes on mRNA level for IL-6, but a statistically highly 
significant decrease in gene expression level of IL-8 upon exposure to macrophages (Figure 25 A and C). 
Interestingly, this effect was slightly more pronounced under hyperglycaemic cultivation conditions (0.27-
fold in 25 mM of glucose, 0.31-fold in 5 mM of glucose), even though no glucose-dependent effect had 
been seen in 4.2.1.2.1. Similar results were obtained for TNF-a in H6c7-pBp cells: coculture with 
macrophages significantly diminished gene expression level of this pro-inflammatory cytokine (Figure 25 
E). The effect was also slightly more marked under high glucose levels (reduction of 46% and 43%, 
respectively, compared to the equivalent monocultured cells). Gene expression levels of TGF-b1, on the 
other hand, were slightly elevated in the presence of macrophages in normoglycemia, but not in 
hyperglycaemia (Figure 25 G).  
In the premalignant H6c7-kras cells, IL-6 levels were slightly increased, whereas IL-8 was not affected at all 
by exposure to macrophages (Figure 25 B and D). Surprisingly, coculture showed contrary effects on the 
gene expression level of TNF-a in H6c7-kras cells compared to their benign counterpart. Here, TNF-a was 
significantly increased in cocultured cells and the effect more distinct under hyperglycaemia than 
normoglycaemia (3.9-fold and 3.1-fold elevation respectively compared to the equivalent monocultured 
cells) (Figure 25 F). Coculture with pro-inflammatory macrophages also led to a weak increase in the gene 
expression level of TGF-b1, irrespective of the glucose level (Figure 25 H). 
Figure 25: Coculture with macrophages (MF) impacts on the expression level of pro- and anti-inflammatory 























































































































































































































































































































Figure 25: Coculture with macrophages (MF) impacts on the expression level of pro- and anti-inflammatory 
cytokines and growth factors of PDEC. (continued) H6c7-pBp or H6c7-kras cells were mono- or cocultured with 
M1-polarised MF for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose). The epithelial cells were 
separated from direct coculture via CD11b-MACS depletion pf M1-MF  or harvested from monoculture and used for 
qRT-PCR analysis. The relative gene expression levels of IL-6 (A and B), IL-8 (C and D), TNF-a (E and F) and TGF-
b1 (G and H) are depicted for both cell lines, normalised to the housekeeping gene GAPDH and presented as n-fold 
expression compared to the equivalent monocultured sample. Normally distributed data are presented as mean and 
standard error of mean, unpaired t-test was performed for statistical analysis. Not normally distributed data (indicated 
via #) are shown as median and interquartile range. Wilcoxon Signed Rank Test was used for statistical analysis.  
*: 0,05>p>0,0332 **: =0,0331>p>0,0021 ***=: 0,002>p>0,0001 ****: p<0,0001; n=7 
4.2.1.3.2 Macrophages lead to enhanced Zeb1 and Slug expression in PDEC 
qRT-PCR analysis of EMT- and CSC-associated transcription factors upon exposure to macrophages 
showed analogous results in both cell lines, albeit all effects were slightly more dominant in H6c7-kras cells.  
The gene expression level of Snail did not show clear coculture impacts, only faint tendencies of increase in 
























































































































































































































































































































mRNA levels of Slug, on the other hand, were upregulated, reaching statistical significance in 
normoglycaemic coculture conditions for H6c7-pBp cells and in both normo- and hyperglycaemic coculture 
conditions for H6c7-kras cells (Figure 26 C and D). Similar results were obtained for Zeb1: gene expression 
was increased in cocultured PDEC and this effect was slightly more pronounced under additional exposure 
to high glucose levels (Figure 26 E and F). 
 
Figure 26: Coculture with macrophages (MF) enhances the expression level of EMT- and CSC-associated 
transcription factors in PDEC. H6c7-pBp or H6c7-kras cells were mono- or cocultured with M1-polarised MF for 
5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose). The epithelial cells were separated from direct 
coculture via CD11b-MACS depletion of M1-MF or harvested from monoculture and used for qRT-PCR analysis. 
The relative gene expression levels of Snail (A and B), Slug (C and D) and Zeb1 (E and F) of both cell lines are 
depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the 
equivalent monocultured sample. Normally distributed data are presented as mean and standard error of mean, 
unpaired t-test was performed for statistical analysis. Not normally distributed data (indicated via #) are shown as 
median and interquartile range. Wilcoxon Signed Rank Test was used for statistical analysis.            
















































































































































































































































4.2.1.3.3 Macrophages alter the expression level of EMT markers in PDEC 
Coculture with M1-polarised macrophages clearly led to a downregulation of epithelial markers and an 
upregulation of genes linked to a more motile phenotype in PDEC. The EMT-inducing effect, which had 
been seen in 4.2.1.1.3 upon exposition to a pro-inflammatory and hyperglycaemic microenvironment, thus 
seems to be a predominately coculture-induced one being reinforced by hyperglycaemia in some cases. 
 
 
Figure 27: Coculture with macrophages (MF) leads to loss of epithelial and gain of mesenchymal marker 
expression in PDEC. H6c7-pBp or H6c7-kras cells were mono- or cocultured with M1-polarised MF for 5 days in 
normo- or hyperglycaemic settings (5 or 25 mM of glucose). The epithelial cells were separated from direct coculture 
via CD11b-MACS depletion of M1-MF or harvested from monoculture and used for qRT-PCR analysis. The relative 
gene expression levels of E-Cadherin (A and B), Vimentin (C and D) and L1CAM (E and F) of both cell lines are 
depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the 
equivalent monocultured sample. Normally distributed data are presented as mean and standard error of mean, 
unpaired t-test was performed for statistical analysis. Not normally distributed data (indicated via #) are shown as 
median and interquartile range. Wilcoxon Signed Rank Test was used for statistical analysis.              










































































































































































































































A coculture-dependent decrease in the gene expression level of E-Cadherin was seen in both cell lines but 
was even more explicit in the premalignant H6c7-kras cells (Figure 27 A and B). In accordance with the 
findings in 4.2.1.2.3, the downregulation was stronger under hyperglycaemic conditions in both cell lines. 
The mesenchymal marker Vimentin was significantly increased in both H6c7-pBp and H6c7-kras cells upon 
exposure to macrophages (Figure 27 C and D). Interestingly, this increase was more manifest under 
hyperglycaemia in the benign cells (5.39-fold versus 3.56-fold increase), but of similar strength in both 
glucose conditions in the premalignant cells (3.4-fold). It is also important to note that the coculture-
dependent changes for Vimentin were more distinct in H6c7-pBp cells, which are characterised by a 
significantly lower basal expression than their premalignant counterpart (data not shown). 
mRNA levels of L1CAM were not impacted by coculture in H6c7-pBp cells. In H6c7-kras cells, on the other 
hand, a clear coculture-related induction of the gene expression level of L1CAM was to be noted in both 
glucose conditions (Figure 27 E and F). 
 
To sum up, the results obtained are all in favour of the view that the induction of the EMT-program on 
mRNA level is predominantly coculture-dependent in PDEC. The coculture-induced effect in gene 
expression levels of Vimentin was more pronounced in H6c7-pBp cells, the effect on gene expression levels 
of E-Cadherin and L1CAM, however, more implicit in H6c7-kras cells. 
 
 
4.2.1.3.4 Macrophages impact heterogeneously on the expression levels of CSC markers in 
benign and premalignant PDEC 
Contrary to the glucose-dependent upregulation that had been seen in 4.2.1.2.4 on the gene expression level 
of Nestin, coculture decreased the mRNA level of this CSC-associated gene in H6c7-pBp cells (Figure 28 
A). In H6c7-kras cells, a coculture-induced increase on the mRNA level of Nestin was to be observed, in 
line with the glucose-dependent findings (Figure 28 B). 
As for expression levels of Nanog, hyperglycaemic coculture resulted in a significant decrease in both cell 
lines. Normoglycaemic coculture, on the other hand, slightly increased the mRNA level in H6c7-pBp cells, 




Figure 28: Impact of coculture on the expression level of CSC marker of PDEC. H6c7-pBp or H6c7-kras cells 
were mono- or cocultured with M1-polarised macrophages (MF) for 5 days in normo- or hyperglycaemic settings (5 
or 25 mM of glucose). The epithelial cells were separated from direct coculture via CD11b-MACS depletion of M1-
MF or harvested from monoculture and used for qRT-PCR analysis. The relative gene expression levels of Nestin (A 
and B) and Nanog (C and D) of both cell lines are depicted, normalised to the housekeeping gene GAPDH and 
presented as n-fold expression compared to the equivalent monocultured sample. Normally distributed data are 
presented as mean and standard error of mean, unpaired t-test was performed for statistical analysis. Not normally 
distributed data (indicated via #)) are shown as median and interquartile range. Wilcoxon Signed Rank Test was used 
for statistical analysis. *: 0,05>p>0,0332  **: =0,0331>p>0,0021 ***=: 0,002>p>0,0001; n=7 
Altogether, these findings demonstrate the promotion of malignancy-associated features in both PDEC 
lines through exposure to a hyperglycaemic und inflammatory microenvironment. However, glucose- and 
coculture-dependent effects have to be taken into account and considered separately as they seem of varying 
importance for the different markers and also for the two cell lines. 
Whereas the important EMT-inducer TGF-b1 was elevated in a glucose-dependent manner in both cell 
lines, the other cytokines analysed where influenced in a coculture-dependent manner. However, the effects 
were inverse in the benign and premalignant PDEC, showing decreased levels in H6c7-pBp but increased 
levels in H6c7-kras cells. 
The transcriptional factors Zeb1 and Slug were influenced in a coculture- rather than a glucose-dependent 
manner. 
Increases in the expression level of Nestin also indicate enhanced acquisition of properties associated with 
cancer stemness in PDEC. In the benign cells, the elevation was glucose-dependent, whereas in the 
premalignant cells, glucose and macrophages showed synergistic effects, evoking the most pronounced 


































































































































































4.2.2 Exposure to macrophages and hyperglycaemia induces mesenchymal phenotype 
in PDEC on protein level 
To obtain further insights into the kinetics of EMT induction in PDEC upon exposure to hyperglycaemia 
and/or macrophages, several EMT markers were also investigated on protein level. Additionally, protein 
levels of phosphorylated-p65 (p-p65) and total-p65 (t-p65) were analysed to explore the contribution of 
activation of NF-kB, the central inflammatory signalling pathway, to EMT induction. Upon binding of e.g. 
TNF-a to its receptor, inhibitor of kappa B (IkB) is phosphorylated and ubiquitinated by the activated IkB 
kinase. This leads to IkBs degradation with subsequent release of the NF-kB subunit p65 which can then 
translocate into the nucleus and initiate signalling cascades involved in the regulation of apoptosis, 
proliferation and invasiveness (Hayden and Ghosh, 2004; Maier et al., 2010). 
In the benign cells, a coculture- and glucose-dependent loss of E-Cadherin was clearly to be seen (Figure 29 
A). The strongest diminution of E-Cadherin was to be observed in cells arising from hyperglycaemic 
coculture, in which E-Cadherin could not be detected any more. 
The protein levels of the mesenchymal markers L1CAM and Vimentin were elevated in a coculture-
dependent manner. Whereas this coculture-dependent upregulation was further amplified by high glucose 
levels in L1CAM, no such additive glucose-dependent effect was to be observed in Vimentin levels. 
Phosphorylated p65 displayed clear coculture-dependent increases on protein level. Total-p65, on the other 
hand, was decreased in cocultured H6c7-pBp cells and high glucose levels further strengthened this effect. 
Figure 29: Exposure to hyperglycaemia and macrophages (MF ) promotes EMT-associated changes on 
protein levels in PDEC. H6c7-pBp or H6c7-kras cells were cultivated in mono- or coculture with M1-polarised MF 
under normo- or hyperglycaemic conditions (5 or 25 mM of glucose). Epithelial cells were separated from direct 
coculture with macrophages via CD11b-MACS depletion of M1-MF or harvested from monoculture and used as 
whole cell lysates for Western Blot analysis. The protein levels of L1CAM, E-Cadherin, Vimentin, p-p65 and t-p65 in 
H6c7-pBp (A) and H6c7-kras cells (B) were analysed. Hsp90 was used as loading control. A representative of three 













































































In the premalignant cells, the protein level of E-Cadherin was also clearly decreased upon exposure to high 
glucose levels and/or macrophages (Figure 29 B). In line with the findings for H6c7-pBp cells, this effect 
was most pronounced upon exposure to a hyperglycaemic and inflammatory micromilieu. 
Coculture with macrophages also led to clearly elevated protein levels of Vimentin in H6c7-kras cells. 
However, this increase did not reach the intensity of the one observed in the benign PDEC upon exposure 
to macrophages (Figure 29 A). This finding is in line with the coculture-dependent increase of Vimentin 
observed on mRNA level which was also more pronounced in the benign than in the premalignant cells 
(Figure 27 C and D). 
Exposure to glucose also promoted protein levels of Vimentin in monocultured premalignant PDEC. 
Remarkably, L1CAM was decreased in a coculture-dependent manner on protein level, which stands in 
contrast to the effects observed on mRNA level. Also differing from the qRT-PCR results, hyperglycaemia 
promoted L1CAM expression in monocultured H6c7-kras cells. 
Very similar to their benign counterpart, premalignant PDEC showed a coculture-dependent increase in 
protein levels of p-p65. However, even monocultured H6c7-kras cells showed clear expression levels of 
p-p65 whereas no signal could be detected in monocultured H6c7-pBp cells. For t-p65, protein levels were 
decreased in a coculture-dependent manner, and no glucose-induced effect was to be observed.  
 
Overall, the findings favour the view of EMT induction in PDEC through exposure to a hyperglycaemic 
and inflammatory surrounding. The key step of EMT induction is the loss of E-Cadherin, which was 
predominantly coculture-dependent in both PDEC lines and amplified by glucose. Furthermore, elevated 
levels of p-p65 indicate promoted inflammatory signalling especially in PDEC arising from coculture with 
macrophages. 
4.2.3 Exposure to macrophages and high glucose levels leads to an increased colony 
formation capacity of PDEC and promotion of colonies with high CSC-potential 
For the analysis of the acquisition of CSC-properties on a functional level, colony formation assays were 
performed. The cells’ ability to form clones upon exposure to macrophages and/or hyperglycaemia was 
investigated. In detail, the total number of clones formed per well and the quality of clones (para-, mero- or 
holoclones) were evaluated. To get an insight on the impact of glucose environment on the colony formation 
abilities of PDEC, results were normalised to the equivalent sample arising from cultivation under 
normoglycaemic conditions. It was decided not to compare cells from mono- and coculture settings, as first 
experiments showed that MACS-separation affected the colony formation. Cells that had been exposed to 
the stress of a magnetic cell separation procedure, showed a shift in quality of clones formed towards more 
holoclones, thus, counterfeiting an increased gain in CSC-associated properties (data not shown). Therefore, 
cells arising from coculture were only compared among themselves for analysis of the impact of glucose. 
The total number of colonies formed was slightly decreased by the factor 0.92 upon exposure to high 
glucose levels in monocultured benign PDEC. In cocultured benign PDEC, on the other hand, exposure 




Figure 30: Hyperglycaemia promotes the formation of colonies with high CSC-potential in mono- and 
cocultured PDEC. H6c7-pBp and H6c7-kras cells were cultivated in normo- or hyperglycaemic conditions (5 or 25 
mM of glucose) in mono- or coculture with M1-polarised macrophages (MF). The epithelial cells were separated from 
direct coculture with macrophages via CD11b-MACS depletion of M1-MF or harvested from monoculture and used 
for colony formation assays. For this, 800 cells/well were seeded in duplicates and cultivated for 8 to 14 days. After 
fixation and staining, colonies of more than 50 cells were analysed. The total number of colonies per well (A and B) 
and the quality of colonies (C and D) formed under the differing glycaemic conditions are shown. Data are depicted 
as n-fold to the equivalent sample arising from normoglycaemic settings. Normally distributed data are presented as 
mean and standard error of mean, unpaired t-test was performed for statistical analysis.             
*: 0,05>p>0,0332; n=6 
In monocultured H6c7-kras cells, exposure to high glucose levels led to an 0.77-fold reduction in the number 
of colonies formed compared to normoglycaemic conditions. H6c7-kras cells cocultured with M1-polarised 
macrophages, however, were not impacted in their ability of colony formation through hyperglycaemia 
(Figure 30 B). 
Even though the total number of colonies formed was reduced, a significant 2.98-fold increase in holoclones 
was observed after exposure to high glucose levels in monocultured benign PDEC (Figure 30 C). In 
cocultured H6c7-pBp cells, glucose also led to a slight shift towards mero- and holoclone (1.23-fold and 
1.25-fold increase, respectively, compared to the equivalent normoglycaemic cells) at the expense of 
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The impact of glucose on the type of colonies was similar in mono- and cocultured premalignant PDEC. 
Both showed a greater proportion of mero- and holoclones after subjection to high glucose levels and thus 
fewer paraclones (Figure 30 D). This effect was slightly more pronounced in H6c7-kras cells arising from 
coculture settings (1.50-fold increase in meroclones and 1.30-fold increase in holoclones compared to the 
normoglycaemic coculture) than in cells from monoculture (1.40-fold increase in mero- and 1.1-fold in 
holoclones compared to normoglycaemic monoculture). 
 
Together, these findings suggest that hyperglycaemia promotes cancer stemness characteristics in both 
H6c7-pBp and H6c7-kras cells. Whereas the glucose-induced acquisition of CSC-associated properties was 





4.3 TGF-bIIR Knockdown 
TGF-b1 is regarded as a potent inducer of EMT- and CSC-properties and is attributed an important role in 
the process of metastatic spreading (J. Xu et al., 2009; Jing et al., 2011). We could show that gene expression 
levels of TGF-b1 were increased in PDEC exposed to a hyperglycaemic and inflammatory 
microenvironment (Figure 17). To analyse whether enhanced TGF-b1-signalling is responsible for the 
glucose- and coculture-dependent alterations in malignancy-associated properties of PDEC, TGF-bRII 
expression was supressed by transfection with siRNA. TGF-b-signalling depends on the association of 
TGF-bRI and TGF-bRII upon the activation by the TGF-b ligand. TGF-bRII then phosphorylates TGF-
bRI and permits subsequent downstream action of TGF-b (Feng and Derynck, 2005; Jakowlew, 2006). 
Therefore, suppression of TGF-bRII disables functional TGF-b1-signalling. 
The knockdown of TGF-bRII was performed in H6c7-pBp and H6c7-kras cells one day prior to coculture 
in normo- and hyperglycaemic conditions.  
Prior to these experiments, the stability of the knockdown was analysed to ensure that TGF-bRII signalling 
was suppressed throughout the whole experimental time span, this is up to 6 days post-transfection. To this 
end, TGF-bRII mRNA levels were clearly reduced on day 2, 4 and 6 after transfection with TGF-bRII 
siRNA (data not shown). 
4.3.1 Impact of TGF-bRII knockdown on gene expression levels of EMT- and CSC-
associated genes in cocultured PDEC 
To evaluate whether the knockdown of TGF-bRII impacts on the gene expression level of EMT- and 
stemness-associated genes in PDEC, H6c7-pBp and H6c7-kras cells were transfected with either TGF-bRII 
siRNA or control (ctrl) siRNA and cocultured with M1-polarised macrophages in normo- or hyperglycaemic 
conditions for 5 days. The epithelial cells were then separated from the direct coculture via CD11b-MACS 
depletion of macrophages and used for qRT-PCR analysis. Cells arising from the equivalent coculture setting 
but transfected with ctrl siRNA served as a control. 
4.3.1.1 TGF-bRII knockdown reduces gene expression levels of IL-6, TNF-a and TGF-b1 in 
PDEC 
In a first step, it was evaluated whether the knockdown of TGF-bRII impacts the gene expression level of 
EMT- and stemness-inducing factors in PDEC arising from normo- or hyperglycaemic coculture with M1-
polarised macrophages. 
Knockdown of TGF-bRII reduced the gene expression level of IL-6 by 53% in benign PDEC arising from 
normoglycaemic coculture. This effect was less explicit under hyperglycaemic coculture conditions, showing 
a reduction of 26% (Figure 31 A). In the premalignant PDEC, the knockdown also led to a reduction of 
roughly 32% in both coculture settings (Figure 31 B). Gene expression levels of IL-8, on the other hand, 
were not affected at all through knockdown of TGF-bRII, neither in H6c7-pBp nor in H6c7-kras cells under 
either condition (Figure 31 C and D). Transfection with TGF-bRII siRNA led to a reduction in gene 
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expression of TNF-a levels in H6c7-pBp cells, which was strengthened by high glucose levels (0.53-fold 
decrease) compared to low glucose levels (0.81-fold decrease) (Figure 31 E). In H6c7-kras cells, on the 
other hand, TGF-bRII knockdown led to elevated levels of TNF-a in cells from normoglycaemic coculture, 
whereas cells arising from coculture with high glucose levels did not show any alteration in their gene 
expression level of TNF-a (Figure 31 F). Finally, TGF-b1 expression was significantly reduced in H6c7-
pBp cells from normoglycaemic coculture upon knockdown of TGF-bRII (0.76-fold compared to the 
equivalent sample transfected with ctrl siRNA); tendencies of increase were observed in the gene expression 
level of TGF-b1 after knockdown of TGF-bRII under hyperglycaemic conditions (Figure 31 G). H6c7-
kras cells showed a weak decrease of TGF-b1 expression upon transfection with TGF-bRII siRNA under 
either condition (Figure 31 H). 
 
Figure 31: TGF-bRII knockdown reduces the expression of EMT- and CSC-inducing factors in cocultured 














































































































































































































































Figure 31: TGF-bRII knockdown reduces the expression of EMT- and CSC-inducing factors in cocultured 
PDEC. (continued) H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised macrophages (MF) for 5 days in 
normo- or hyperglycaemic settings (5 or 25 mM of glucose) and transfected with TGF-bRII-siRNA or ctrl siRNA. 
The epithelial cells were separated from direct coculture via CD11b-MACS depletion of M1-MF and used for qRT-
PCR analysis. The relative gene expression levels of IL-6 (A and B), IL-8 (C and D), TNF-a (E and F) and TGF-b1 
(G and H) of both cell lines are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold 
expression compared to the equivalent ctrl siRNA sample. Normally distributed data are presented as mean and 
standard error of mean, unpaired t-test was performed for statistical analysis. ***=: 0,002>p>0,0001; n=3 
4.3.1.2 TGF-bRII knockdown heterogeneously impacts on EMT- and CSC-associated 
transcription factors 
Next, the gene expression levels of the EMT- and CSC-associated transcription factors Snail, Slug and Zeb1 
were analysed in PDEC which had been transfected with TGF-bRII siRNA or ctrl siRNA and cocultured 
with M1-polarised macrophages under normo- or hyperglycaemic conditions. 
TGF-bRII knockdown hardly affected the gene expression level of Snail in both PDEC lines, irrespective 
of the glucose level at which the cells had been cocultured (Figure 32 A and B). mRNA levels of the 
transcription factor Slug were not affected in H6c7-pBp cells transfected with TGF-bRII siRNA under 
normoglycaemic conditions. However, H6c7-pBp cells transfected with TGF-bRII siRNA cells and arising 
from hyperglycaemic coculture showed 1.82-fold elevated mRNA levels of Slug compared to the equivalent 
cells transfected with ctrl siRNA (Figure 32 C). In H6c7-kras cells, Slug levels were elevated in all samples 
after TGF-bRII knockdown; with a more pronounced effect in cells from normoglycaemic than from 
hyperglycaemic coculture (2.26- and 1.49-fold increase respectively) (Figure 32 D). 
Finally, the knockdown did not impact on gene expression level of Zeb1 in the benign cells, nor in the 
premalignant cells arising from normoglycaemic coculture (Figure 32 E and F). However, benign PDEC 
transfected with TGF-bRII siRNA and exposed to high glucose levels showed significantly reduced 
expression levels of Zeb1 (0.54-fold compared to the equivalent cells transfected with ctrl siRNA) 














































































































































































































































Figure 32: Impact of TGF-bRII knockdown on the gene expression levels of EMT- and CSC-associated 
transcription factors in PDEC. H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised macrophages (MF) 
for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and transfected with TGF-bRII-siRNA or 
ctrl siRNA. The epithelial cells were separated from direct coculture via CD11b-MACS depletion of M1-MF and used 
for qRT-PCR analysis. The relative gene expression levels of Snail (A and B), Slug (C and D) and Zeb1 (E and F) of 
both cell lines are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression 
compared to the equivalent ctrl sample. Normally distributed data are presented as mean and standard error of mean, 
unpaired t-test was performed for statistical analysis. *: 0,05>p>0,0332; n=4 
4.3.1.3 TGF-bRII knockdown promotes gene expression level of the epithelial marker E-
Cadherin in PDEC 
In a next step, the impact of TGF-b1-signalling suppression on the gene expression level of EMT-markers 





















































































































































































Knockdown of TGF-bRII led to clearly elevated expression levels of the epithelial marker E-Cadherin in 
both cell lines arising from normoglycaemic conditions. While an increase was also observed in H6c7-pBp 
cells under hyperglycaemic coculture (1.6-fold compared to equivalent cells transfected with ctrl siRNA), 
TGF-bRII suppression did not impact E-Cadherin expression in H6c7-kras cells under comparable 
conditions (Figure 33 A and B). 
 
Figure 33: TGF-bRII knockdown promotes the expression of the epithelial marker E-Cadherin in PDEC. 
H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised macrophages (MF) for 5 days in normo- or 
hyperglycaemic settings (5 or 25 mM of glucose) and transfected with TGF-bRII-siRNA or ctrl siRNA. The epithelial 
cells were separated from direct coculture via CD11b-MACS depletion of M1-MF and used for qRT-PCR analysis. 
The relative gene expression levels of E-Cadherin (A and B), Vimentin (C and D) and L1CAM (E and F) of both cell 
lines are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the 
equivalent ctrl sample. Normally distributed data are presented as mean and standard error of mean, unpaired t-test 
was performed for statistical analysis. *: 0,05>p>0,0332 ****: p<0,0001; n=4 
Intriguingly, the gene expression level of the mesenchymal marker Vimentin was slightly reduced through 


























































































































































































premalignant cells under both glucose conditions. This effect was even more pronounced in 
normoglycaemic coculture (5.30-fold elevation compared to equivalent cells transfected with ctrl siRNA) 
than in hyperglycaemic coculture (1.25-fold increase compared to equivalent cells transfected with ctrl 
siRNA) (Figure 33 D). 
Finally, L1CAM gene expression levels were hardly affected by the knockdown of TGF-bRII, but showed 
a slight increase in all samples except in H6c7-kras cells arising from normoglycaemic coculture (Figure 33 
E and F). 
4.3.1.4 TGF-bRII knockdown impacts on the expression of CSC markers in PDEC 
Finally, the impact of TGF-bRII knockdown on the expression level of the stemness indicators Nestin and 




Figure 34: Impact of TGF-bRII knockdown on the expression of CSC markers in PDEC. H6c7-pBp or H6c7-
kras cells were cocultured with M1-polarised macrophages (MF) for 5 days in normo- or hyperglycaemic settings (5 
or 25 mM of glucose) and transfected with TGF-bRII-siRNA or ctrl siRNA. The epithelial cells were separated from 
direct coculture via CD11b-MACS depletion of M1-MF and used for qRT-PCR analysis. The relative gene expression 
levels of Nestin (A and B) and Nanog (C and D) of both cell lines are depicted, normalised to the housekeeping gene 
GAPDH and presented as n-fold expression compared to the equivalent ctrl sample. Normally distributed data are 
presented as mean and standard error of mean, unpaired t-test was performed for statistical analysis.  
n=4 
Whereas only H6c7-pBp cells from normoglycaemic coculture showed slightly elevated gene expression 


























































































































elevated in H6c7-kras transfected with TGF-bRII siRNA irrespective of the glucose level (1.78- and 1.67- 
increase for normo-and hyperglycaemic coculture settings compared to the equivalent cells transfected with 
ctrl siRNA) (Figure 34 B). 
mRNA levels of Nanog were elevated in H6c7-pBp cells arising from normo- and hyperglycaemic 
knockdown samples (1.94- and 2.24-fold increase, respectively, compared to the equivalent cells transfected 
with ctrl siRNA) (Figure 34 C). In H6c7-kras cells, however, TGF-bRII knockdown also led to increased 
Nanog expression in hyperglycaemic coculture settings (1.42-fold compared to cells from hyperglycaemic 
coculture transfected with ctrl siRNA), but to slightly decreased Nanog levels in normoglycaemic conditions 
(0.79-fold compared to the equivalent cells transfected with ctrl siRNA) (Figure 34 D). 
 
4.3.2 TGF-bRII knockdown reduces the fraction of holoclones formed by PDEC arising 
from coculture with M1-polarised macrophages under hyperglycaemic conditions 
In a next step, colony formation assays were performed to analyse the effect of the TGF-bRII knockdown 
on the acquisition of CSC-properties in PDEC on a functional level. For this, the ability of PDEC cocultured 
with M1-polarised macrophages under normo- or hyperglycaemic conditions and transfected with either 
TGF-bRII siRNA or ctrl siRNA to form clones of more than 50 cells was compared and the type of clones 
formed was evaluated.  
Whereas the total number of colonies formed was hardly affected by the knockdown of TGF-bRII in both 
PDEC lines (Figure 35 A and B), the type of colonies was altered. 
In detail, H6c7-pBp cells arising from the hyperglycaemic coculture and transfected with TGF-bRII siRNA 
formed significantly fewer holoclones (0.37-fold reduction compared to the control sample), but more 
paraclones, whereas the fraction of meroclones was constant. H6c7-pBp cells arising from the 
normoglycaemic coculture, on the other hand, formed more holoclones upon transfection with TGF-bRII 
siRNA (1.38-fold elevation compared to the equivalent control), whereas the fraction of para-and 
meroclones were hardly impacted (Figure 35 C). 
H6c7-kras cells arising from the hyperglycaemic coculture and transfected with TGF-bRII siRNA also 
showed a proportional reduction of holoclones (0.49-fold decrease compared to the equivalent cells 
transfected with ctrl siRNA), while H6c7-kras cells arising from normoglycaemic coculture formed slightly 




Figure 35: TGF-bRII knockdown reduces the fraction of holoclones formed by H6c7-pBp and H6c7-kras 
cells arising from hyperglycaemic coculture with M1-polarised macrophages (MF). H6c7-pBp and H6c7-kras 
cells were cocultured with M1-polarised MF for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) 
transfected with TGF-bRII-siRNA or ctrl siRNA. The epithelial cells were separated from direct coculture with 
macrophages via CD11b-MACS depletion of M1-MF and used for colony formation assays. For this, 800 cells/well 
were seeded in duplicates and cultivated for 8 to 14 days. After fixation and staining, colonies of more than 50 cells 
were analysed. The total number of colonies per well (A and B) and the quality of colonies (C and D) formed under 
the differing treatments are shown. Data are depicted as n-fold compared to the equivalent ctrl sample. Normally 
distributed data are presented as mean and standard error of mean, unpaired t-test was performed for statistical analysis. 
*: 0,05>p>0,0332; n=4 
4.3.3 Knockdown of TGF-bRII reduces the migratory potential of PDEC arising from 
normoglycaemic coculture with M1-polarised macrophages 
To analyse possible changes in the migratory potential of PDEC through the knockdown of TGF-bRII, a 
scratch assay was performed with PDEC transfected with either TGF-bRII siRNA or ctrl siRNA and 
cocultured with M1-polarised macrophages under normoglycaemic conditions. 
At the early timepoint of evaluation (t=9h), benign PDEC transfected with TGF-bRII siRNA showed a 
slightly pronounced gap closure compared to the equivalent control (22.38% and 17.65% compared to t=0, 
respectively) (Figure 36 A). After 24 hours, however, this effect was reversed. TGF-bRII knockdown led 
to a reduced closure of the scratch in H6c7-pBp cells cocultured with M1-polarised macrophages, indicating 
































































































































































Figure 36: Knockdown of TGF-bRII reduces the migratory potential of PDEC arising from normo- or 
hyperglycaemic coculture with M1-polarised macrophages (MF). H6c7-pBp and H6c7-kras cells were cocultured 
with M1-polarised MF for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and transfected with 
TGF-bRII siRNA or ctrl siRNA. The migratory potential of PDEC was evaluated via scratch assay using Lionheart 
FX Automated Microscope. Scratch closure was assessed at t=0, t=9h and t=24h for H6c7-pBp CoM1 (A) and H6c7-
kras CoM1 cells (B). The percentage of closure was evaluated with the Gen5 Data Analysis Software. Normally 
distributed data are presented as mean and standard error of mean, unpaired t-test was performed for statistical analysis. 
n=4 
Similarly, cellular migration was also reduced in premalignant PDEC upon knockdown of TGF-bRII. 
However, contrary to the benign PDEC, this reduction in migratory potential was already visible after 9 
hours: H6c7-kras transfected with TGF-bRII siRNA showed a closure of 19.77% and 27,52% after 9 and 
24 hours, respectively (compared to t=0) compared to cells from the equivalent control (30.57% and 39.48% 
after 9 and 12 hours) (Figure 36 B). 
 
In summary, the knockdown of TGF-bRII revealed that TGF-b1 signalling is involved in the glucose- and 
M1-MF-dependent alterations of malignancy-associated properties of PDEC. 
The knockdown of TGF-bRII led to reduced mRNA levels of the EMT- and CSC- inducing factors IL-6, 
TNF-a and TGF-b1 in both PDEC lines. Furthermore, the important epithelial marker E-Cadherin showed 
elevated expression levels upon transfection with TGF-bRII siRNA, indicating a role of TGF-b-signalling 
in glucose- and inflammation-mediated EMT in these cells. The reduced cellular motility of PDEC after 
knockdown of TGF-bRII underlines these findings. However, gene expression levels of the mesenchymal 
marker Vimentin were also elevated, indicating that EMT induction is not completely reversed by the 
knockdown. 
Finally, the decrease in the number of holoclones formed by PDEC transfected with TGF-bRII siRNA 
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4.4 Blockade of  IL-6 signalling pathway 
IL-6-dependent signalling pathways are closely linked to inflammatory processes (Mauer et al., 2014; Scheller 
et al., 2014). Extremely high levels of IL-6 have been reported within inflammatory tissues (Robak et al., 
1998; Rose-John et al., 2006), which is in accordance with the impressive gene expression levels of IL-6 we 
observed in macrophages upon exposure to PDEC and/or glucose (section 4.1). To elucidate whether this 
pro-inflammatory cytokine is involved in the EMT- and CSC-associated alterations in PDEC upon exposure 
to a T2DM-associated inflammatory microenvironment, IL-6 signalling was blocked in coculture 
experiments. 
IL-6 is characterised by a complex signalling pathway. A classic-signalling pathway is distinguished from a 
trans-signalling one. For the initiation of the classic-signalling cascade, IL-6 needs to bind to a membrane-
bound IL-6 receptor (IL-6R). This receptor is only expressed on a few cells, e.g., on monocytes and 
macrophages as well as on hepatocytes. Once the IL-6-IL-6R-complex is formed, various pathways, such 
as Ras/Raf/MAPK, PI3K are activated (Rose-John, 2012). 
Trans-signalling, on the other hand, is not reliant on the membrane bound IL-6R but on a soluble IL-6 
receptor (sIL-6R). Once IL-6 binds to the sIL-6R, the complex can initiate downstream signalling (Rose-
John, 2012). 
Several studies assume that classic-signalling initiates anti-inflammatory activities of IL-6, whereas trans-
signalling promotes pro-inflammatory reactions (Atreya et al., 2000; Barkhausen et al., 2011; Rose-John, 
2012). 
In a first step, both pathways of IL-6-signalling were blocked by the antibody Tocilizumab which binds to 
IL-6R (chapter 4.4.1). Rituximab was used as a control antibody. In a second step, just trans-signalling was 
disabled via sgp130Fc (chapter 4.4.2). Sgp130Fc only binds to IL-6 that is bound to the sIL-6R and does 
not interfere with the classic-signalling via the membrane bound IL-6R. Ctrl-Fc was used as a control in 
these experiments. 
4.4.1 Complete blockade of IL-6-signalling via Tocilizumab 
4.4.1.1 Impact of IL-6 blockade via Tocilizumab on the gene expression levels of EMT-and 
CSC-associated genes in cocultured PDEC  
To evaluate whether the blockade of IL-6 signalling impacts the gene expression level of EMT- and 
stemness-associated mediators in PDEC, H6c7-pBp and H6c7-kras cells were treated with either 
Tocilizumab or Rituximab and cocultured with M1-polarised macrophages in normo- or hyperglycaemic 
conditions for 5 days. The epithelial cells were then separated from direct coculture via CD11b-MACS 
depletion of macrophages and used for qRT-PCR analysis. Cells arising from the equivalent coculture setting 
treated with Rituximab served as a control. 
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4.4.1.1.1 Tocilizumab increases expression levels of EMT- and CSC- inducing mediators in 
hyperglycaemic cocultured H6c7-kras cells 
In a first step, it was evaluated whether the blockade of both IL-6 trans- and IL-6 classic-signalling via 
Tocilizumab impacts the gene expression level of EMT- and stemness inducing factors in PDEC arising 
from normo- or hyperglycaemic coculture with M1-polarised macrophages. 
The benign PDEC were not impacted in their gene expression of IL-6, IL-8 or TGF-b1 through blockade 
via Tocilizumab (Figure 37 A, C and G). Only the pro-inflammatory cytokine TNF-a showed a 1.5-fold 
increase upon IL-6 blockade in normoglycaemic coculture conditions compared to the control sample. 
Under hyperglycaemic conditions, however, no Tocilizumab-induced effect was to be seen (Figure 37 E). 
H6c7-kras cells from normoglycaemic coculture with macrophages were also not affected in their expression 
level of these mediators by Tocilizumab. However, cells arising from hyperglycaemic coculture showed 
increased levels for IL-6 (1.8-fold (Figure 37 B)), IL-8 (1.78-fold (Figure 37 D)), TNF-a (1.66-fold 




Figure 37: Blockade of IL-6 signalling via Tocilizumab leads to an elevation of EMT- and CSC-associated 




























































































































































































































































































































Figure 37: Blockade of IL-6 signalling via Tocilizumab leads to an elevation of EMT- and CSC-associated 
mediators in cocultured hyperglycaemic H6c7-kras cells. (continued) H6c7-pBp or H6c7-kras cells were 
cocultured with M1-polarised macrophages (MF) for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of 
glucose) and treated with 1 μg/ml of Tocilizumab or Rituximab (ctrl). The epithelial cells were separated from direct 
coculture via CD11b-MACS depletion of M1-MF and used for qPCR analysis. The relative gene expression levels of 
IL-6 (A and B), IL-8 (C and D), TNF-a (E and F) and TGF-ß1 (G and H) of both cell lines are depicted, normalised 
to the housekeeping gene GAPDH and presented as n-fold expression compared to the equivalent ctrl sample. 
Normally distributed data are presented as mean and standard error of mean, unpaired t-test was performed for 
statistical analysis. Not normally distributed data (indicated via #) are shown as median and interquartile range. 
Wilcoxon Signed Rank Test was used for statistical analysis. *: 0,05>p>0,0332; n=4 
4.4.1.1.2 Tocilizumab treatment promotes Zeb1 expression in hyperglycaemic cocultured H6c7-
kras cells  
Next, the gene expression levels of the EMT- and CSC-associated transcription factors Snail, Slug and Zeb1 
were analysed in PDEC treated with Tocilizumab or Rituximab and cocultured with M1-polarised 
macrophages under normo- or hyperglycaemic conditions. 
Tocilizumab hardly influenced the benign PDEC in their gene expression level of the EMT- and CSC-
associated transcription factors irrespective of the coculture condition (Figure 38 A, C, E). 
In contrast, slight increases were observed in the premalignant PDEC line from hyperglycaemic coculture 
treated with Tocilizumab for Snail and Slug (1.32-fold increase for both transcription factors compared to 
the equivalent control samples) (Figure 38 B and D), and a significant 1.87-fold increase was observed for 




























































































































































































































































































































Figure 38: Blockade of IL-6 signalling via Tocilizumab increases Snail, Slug and Zeb1 expression in 
cocultured hyperglycaemic H6c7-kras cells. H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised 
macrophages (MF) for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and treated with 1 μg/ml 
of Tocilizumab or Rituximab (ctrl). The epithelial cells were separated from direct coculture via CD11b-MACS 
depletion of M1-MF and used for qPCR analysis. The relative gene expression levels of Snail (A and B), Slug (C and 
D) and Zeb1 (E and F) of both cell lines are depicted, normalised to the housekeeping gene GAPDH and presented 
as n-fold expression compared to the equivalent ctrl sample. Normally distributed data are presented as mean and 
standard error of mean, unpaired t-test was performed for statistical analysis. **: =0,0331>p>0,0021; n=4 
4.4.1.1.3 Tocilizumab increases expression of epithelial and mesenchymal markers in H6c7-kras 
cells from hyperglycaemic coculture 
In a next step, the impact of the blockade of IL-6-signalling on the gene expression level of EMT markers 












































































































































































































































Figure 39: Blockade of IL-6 signalling via Tocilizumab increases epithelial and mesenchymal markers in 
cocultured hyperglycaemic H6c7-kras cells. H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised 
macrophages (MF) for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and treated with 1 μg/ml 
of Tocilizumab or Rituximab (ctrl). The epithelial cells were separated from direct coculture via CD11b-MACS 
depletion of M1-MF and used for qPCR analysis. The relative gene expression levels of E-Cadherin (A and B), 
Vimentin (C and D) and L1CAM (E and F) of both cell lines are depicted, normalised to the housekeeping gene 
GAPDH and presented as n-fold expression compared to the equivalent ctrl sample. Normally distributed data are 
presented as mean and standard error of mean, unpaired t-test was performed for statistical analysis. n=4 
Similar to the effects of Tocilizumab treatment on the expression of EMT-associated mediators and 
transcription factors of H6c7-pBp cells, gene expression levels of the EMT markers E-Cadherin and 
Vimentin were also not influenced by blockade of IL-6 signalling (Figure 39 A and C). Only L1CAM levels 
were slightly diminished in H6c7-pBp cells arising from hyperglycaemic coculture treated with Tocilizumab 








































































































































































































































Interestingly, Tocilizumab treatment evoked an increase in both epithelial and mesenchymal markers in 
premalignant H6c7-kras cells under hyperglycaemic coculture. E-Cadherin levels showed a 1.96 -fold 
elevation compared to the control (Figure 39 B); Vimentin a 1.5-fold (Figure 39 D) and L1CAM a 1.86-
fold elevation (Figure 39 F). 
4.4.1.1.4 Tocilizumab slightly increases the expression of stemness markers in PDEC 
Finally, the impact of Tocilizumab treatment on the expression level of the stemness indicators Nestin and 
Nanog were evaluated in PDEC arising from normo- or hyperglycaemic coculture with M1-polarised 
macrophages. 
 
Figure 40: Blockade of IL-6 signalling via Tocilizumab slightly increases the expression of CSC-marker in 
PDEC. H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised macrophages (MF) for 5 days in normo- or 
hyperglycaemic settings (5 or 25 mM of glucose) and treated with 1 μg/ml of Tocilizumab or Rituximab (ctrl). The 
epithelial cells were separated from direct coculture via CD11b-MACS depletion of M1-MF and used for qPCR 
analysis. The relative gene expression levels of Nestin (A and B) and Nanog (C and D) of both cell lines are depicted, 
normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the equivalent ctrl 
sample. Normally distributed data are presented as mean and standard error of mean, unpaired t-test was performed 
for statistical analysis. Not normally distributed data (indicated via (#)) are shown as median and interquartile range. 
Wilcoxon Signed Rank Test was used for statistical analysis. n=7 
Nestin showed a 1.62-fold elevation in H6c7-pBp cells from normoglycaemic coculture treated with 
Tocilizumab, whereas H6c7-pBp cells from hyperglycaemic coculture were not impacted (Figure 40 A). 
Moreover, gene expression levels of Nanog in the benign PDEC were not influenced by Tocilizumab at all 





































































































































































In the premalignant H6c7-kras cells, Nestin levels were not influenced by Tocilizumab in normoglycaemic 
coculture settings, whereas Nanog levels were slightly increased (1.43-fold elevation compared to 
normoglycaemic control). In hyperglycaemic coculture settings, on the other hand, the premalignant cells 
showed enhanced levels of both Nestin (2.77-fold) and Nanog (2.48-fold) upon Tocilizumab treatment 
(Figure 40 B and D). 
 
Altogether, these data indicate that while benign H6c7-pBp cells were hardly affected by Tocilizumab, 
Tocilizumab predominantly influences H6c7-kras cells when exposed to hyperglycaemic coculture with M1-
polarised macrophages. In these cells, Tocilizumab treatment increases the expression of EMT- and CSC- 
inducing mediators and transcription factors along with the expression of epithelial, mesenchymal and 
stemness markers. Interestingly, these effects were not to be observed in H6c7-kras cells cultivated under 
normoglycaemic inflammatory settings. 
4.4.1.2 Impact of Tocilizumab on the colony formation ability of cocultured PDEC 
Tocilizumab’s impact on the stemness ability of PDEC from normo-and hyperglycaemic coculture with 
M1-polarised macrophages was additionally analysed via colony formation assays. For this, the quantity and 
quality of colonies formed by PDEC treated with either Tocilizumab or with the control antibody under 
the respective conditions were investigated. 
H6c7-pBp cells arising from normoglycaemic settings showed a 1.22-fold increase in the total number of 
colonies formed when treated with Tocilizumab compared to cells treated with the control antibody 
(Figure 41 A). H6c7-pBp cells from hyperglycaemic coculture, on the other hand, formed similar quantities 
of colonies irrespective of the antibody treatment. The fact that cells exposed to high glucose levels 
beforehand showed a decline in the total number of colonies compared to cells cultured in normoglycaemic 
settings (data not shown) is in line with the findings mentioned in section 4.2.3 (Figure 30). 
Normoglycaemic premalignant PDEC treated with Tocilizumab showed a marginal reduction of colonies 
formed compared to the equivalent cells treated with the control antibody (0.94-fold). However, 
hyperglycaemic H6c7-kras cells showed a 1.73-fold increase in the quantity of colonies formed upon 
blockade of IL-6-signalling via Tocilizumab (Figure 41 B). 
Interestingly, Tocilizumab had a more pronounced impact on the type of colonies formed by the benign 
than by the premalignant PDEC. In normoglycaemic H6c7-pBp cells treated with Tocilizumab, a 1.5-fold 
increase in the percentage of holoclones was observed (Figure 41 C). This occurred at the expense of 
meroclones, which showed a 0.88-fold decrease, whereas the proportion of paraclones remained stable. In 
hyperglycaemic H6c7-pBp cells, Tocilizumab predominantly led to a larger amount of paraclones (1.51-fold 
increase compared to the control samples), whereas the percentage of holo- and meroclones was unchanged. 
In the premalignant PDEC Tocilizumab treatment in normoglycaemic setting evoked almost no alterations 
in the composition of the colonies formed (Figure 41 D), while a slight increase in holoclones and no 




Figure 41: Impact of Tocilizumab on the colony formation ability of PDEC arising from normo- or 
hyperglycaemic coculture with M1-polarised macrophages (MF). H6c7-pBp and H6c7-kras cells were cocultured 
with M1-polarised MF for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and treated with 
1 μg/ml Tocilizumab or Rituximab (ctrl).  The epithelial cells were separated from direct coculture with macrophages 
via CD11b-MACS depletion of M1-MF and used for colony formation assays. For this, 800 cells/well were seeded in 
duplicates and cultivated for 8 to 14 days. After fixation and staining, colonies of more than 50 cells were analysed. 
The total number of colonies per well (A and B) and the quality of colonies (C and D) formed under the differing 
treatments are shown. Data are depicted as n-fold compared to the equivalent ctrl sample. Normally distributed data 
are presented as mean and standard error of mean, unpaired t-test was performed for statistical analysis. n=6 
To sum up, Tocilizumab treatment especially impacted on H6c7-pBp cells from normoglycaemic coculture 
and on H6c7-kras cells from hyperglycaemic coculture. In these conditions, Tocilizumab led to an increase 




































































































































































4.4.1.3 Blockade of IL-6 signalling via Tocilizumab reduces the migratory potential of H6c7-kras 
cells arising from hyperglycaemic coculture with M1-polarised macrophages 
To visualise possible changes in the migratory potential of PDEC through the blockade of IL-6 signalling, 
a scratch assay was performed in PDEC treated with either Tocilizumab or Rituximab and cocultured with 
M1-polarised macrophages under normo- or hyperglycaemic conditions. 
 
Figure 42: Blockade of IL-6 signalling via Tocilizumab reduces the migratory potential of H6c7-kras cells 
arising from hyperglycaemic coculture with M1-polarised macrophages (MF). H6c7-pBp and H6c7-kras cells 
were cocultured with M1-polarised MF for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and 
treated with Tocilizumab or Rituximab (ctrl). The migratory potential of PDEC was then evaluated via scratch assay 
using the Lionheart FX Automated Microscope. Scratch closure was assessed at t=0, t=9h and t=24h for normo- and 
hyperglycaemic H6c7-pBp CoM1 (A and C) and H6c7-kras CoM1 (B and D). The percentage of closure was evaluated 
with the Gen5 Data Analysis Software Normally distributed data are presented as mean and standard error of mean; 
unpaired t-test was performed for statistical analysis. n=4 
In H6c7-pBp cells, the blockade of IL-6 signalling led to an increase in their migratory potential irrespective 
of the glucose conditions. 24 hours after the scratch was performed, 35.24% of the scratch were closed by 
the benign PDEC arising from normoglycaemic coculture treated with Tocilizumab, whereas only 20.55% 
were closed by the equivalent cells treated with the control antibody (Figure 42 A). In hyperglycaemic 
coculture conditions, 32.53% of the scratch were closed after 24 hours by benign PDEC treated with 
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Tocilizumab treatment only marginally influenced the migratory potential of H6c7-kras cells from 
normoglycaemic coculture (Figure 42 B). After 9 hours the scratch closure was slightly less pronounced in 
cells treated with Tocilizumab compared to the equivalent control (12.48% and 16.68% of closure compared 
to t=0, respectively). After 24 hours, however, the scratch was closed to roughly 25%, irrespective of the 
antibody treatment. Together, these findings show that Tocilizumab leads to a slower migration of H6c7-
kras cells in normoglycaemic coculture conditions but does not impact on the overall migratory potential. 
In hyperglycaemic coculture conditions, on the other hand, Tocilizumab treatment led to a reduced closure 
of the scratch at both evaluated timepoints, indicating a reduction of migratory potential (Figure 42 D). 
15.61% of the scratch were closed by H6c7-kras treated with Tocilizumab and cocultured with M1-polarised 
macrophages in hyperglycaemic conditions, whereas the equivalent control showed a scratch closure of 
25.68% after 24 hours. 
 
4.4.2 Blockade of IL-6 trans-signalling via sgp130Fc 
4.4.2.1 Impact of IL-6 blockade by gp130Fc on the gene expression levels of EMT- and CSC-
associated genes in cocultured PDEC  
After having evaluated the impact of the blockade of both IL-6 signalling pathways, changes on the gene 
expression level of EMT- and stemness-associated genes in PDEC were now investigated after the exclusive 
blockade of IL-6 trans-signalling. For this, H6c7-pBp and H6c7-kras cells were treated with either sgp130Fc 
or ctrlFc and cocultured with M1-polarised macrophages in normo- or hyperglycaemic conditions for 5 
days. The epithelial cells were then separated from direct coculture via CD11b-MACS depletion of 
macrophages and used for qRT-PCR analysis. Cells arising from the equivalent coculture setting treated 
with ctrlFc served as a control. 
4.4.2.1.1 sgp130Fc increases expression levels of EMT- and CSC-inducing mediators in PDEC 
Both benign and premalignant PDEC were similarly impacted in their gene expression levels of IL-6, IL-8, 
TGF-b1 and TNF-a through the blockade of IL-6 trans-signalling via gp130Fc. 
IL-6 levels were clearly elevated in H6c7-pBp cells arising von normoglycaemic coculture blocked via 
sgp130Fc (6.88-fold elevation compared to the control sample) (Figure 43 A). This effect also occurred but 
was less explicit in H6c7-pBp cells from hyperglycaemic coculture (2.4-fold increase compared to the control 
sample). In H6c7-kras cells, blockade of IL-6 trans-signalling also showed elevated IL-6 expression levels 
irrespective of the glucose level (Figure 43 B). However, the increase was not as pronounced as in the 
H6c7-pBp cells. 
Similarly, gene expression level of IL-8 was clearly elevated in H6c7-pBp cells upon treatment with sgp130Fc 
and this elevation seemed to be independent of the glucose level (2.36- and 2.65-fold elevation compared 
to the equivalent control) (Figure 43 C). In H6c7-kras cells, the blockade of IL-6 trans-signalling led to 
similar results, but again, the elevation in gene expression level was less pronounced than in their benign 
counterpart (Figure 43 D). 
Results 
96 
Gene expression levels of TNF-a were only influenced in PDEC arising from hyperglycaemic coculture 
settings: a 1.65-fold elevation in benign and a 1.63-fold in premalignant PDEC compared to the equivalent 




Figure 43: Blockade of IL-6 trans-signalling via sgp130Fc promotes the expression of EMT- and CSC-
















































































































































































































































Figure 43: Blockade of IL-6 trans-signalling via sgp130Fc promotes the expression of EMT- and CSC-
inducing mediators in PDEC. (continued) H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised 
macrophages (MF) for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and treated with 10 μg/ml 
of sgp130Fc or ctrlFc (ctrl). The epithelial cells were separated from direct coculture via CD11b-MACS depletion of 
M1-MF and used for qPCR analysis. The relative gene expression levels of IL-6 (A and B), IL-8 (C and D), TNF-a 
(E and F) and TGF-b1 (G and H) of both cell lines are depicted, normalised to the housekeeping gene GAPDH and 
presented as n-fold expression compared to the equivalent ctrl sample. Normally distributed data are presented as 
mean and standard error of mean, unpaired t-test was performed for statistical analysis. n=4 
 
The blockade of IL-6 trans-signalling also led to an elevation of mRNA levels of TGF-b1 in the benign 
PDEC, irrespective of the glucose levels (2.32- and 2.11-fold increase compared to the equivalent control 
sample in normo- and hyperglycaemic conditions, respectively) (Figure 43 G). 
Interestingly, TGF-b1 mRNA levels were hardly influenced by blockade of trans-signalling in H6c7-kras 
cells (Figure 43 H). 
 
4.4.2.1.2 sgp130Fc increases the expression of EMT- and CSC-inducing transcription factors in 
PDEC 
In H6c7-pBp cells, the EMT- and CSC-inducing transcription factors Snail, Slug and Zeb1 were all elevated 
through blockade of trans-signalling (Figure 44 A, C and E). 
A 3.01-fold increase in mRNA levels of Snail could be observed in the benign PDEC from normoglycaemic 
coculture upon treatment with sgp130Fc; cells arising from hyperglycaemic coculture showed a 1.92-fold 
elevation compared to the equivalent control (Figure 44 A). Gene expression levels of Slug were more 
pronounced in cells from hyperglycaemic coculture, reaching a 1.83-fold increase compared to the 
equivalent control (Figure 44 C). The effect of treatment with sgp130Fc on Zeb1 expression was glucose 
independent in the benign PDEC: a 2.83-fold and 2.69-fold increase was to be observed in normo- and 
hyperglycaemic coculture settings, respectively, compared to the control (Figure 44 E). 
In H6c7-kras cells, on the other hand, sgp130Fc treatment primarily showed effects in normoglycaemic 
coculture settings. A 1.77-, 1.26- and 1.55-fold increase was to be observed for mRNA levels of Snail, Slug 
and Zeb1 respectively (Figure 44 B, D and F), whereas no changes could be stated upon treatment with 
sgp130Fc in cells arising from hyperglycaemic coculture settings. Once again, this stands in contrast to the 
effects observed upon treatment with Tocilizumab where Zeb1 mRNA levels had been significantly elevated 
















































































































































































































































Figure 44: Blockade of IL-6-trans-signalling via sgp130Fc promotes the expression of Snail, Slug and Zeb1 
in PDEC. H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised macrophages (MF) for 5 days in normo- 
or hyperglycaemic settings (5 or 25 mM of glucose) and treated with 10 μg/ml of sgp130Fc or ctrlFc (ctrl). The 
epithelial cells were separated from direct coculture via CD11b-MACS depletion of M1-MF and used for qPCR 
analysis. The relative gene expression levels of Snail (A and B), Slug (C and D) and Zeb1 (E and F) of both cell lines 
are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold expression compared to the 
equivalent ctrl sample. Normally distributed data are presented as mean and standard error of mean, unpaired t-test 




























































































































































































4.4.2.1.3 Treatment with sgp130Fc increases the expression of both epithelial and mesenchymal 
markers in PDEC 
Whereas the treatment with Tocilizumab had not influenced the gene expression level of epithelial or 
mesenchymal markers in the benign PDEC, treatment with sgp130Fc led to elevated mRNA levels of 
E-Cadherin (Figure 45 A), Vimentin (Figure 45 C) and L1CAM (Figure 45 E). Except for L1CAM, this 
elevation was irrespective of the glucose levels at which the cells were cocultured. Interestingly, treatment 
with sgp130Fc did not show any impact at all on the gene expression level of L1CAM of benign PDEC in 
hyperglycaemic conditions, whereas a 2.87-fold increase was to be observed in normoglycaemic conditions. 
In the premalignant PDEC, treatment with sgp130Fc also led to increased gene expression levels of 
E-Cadherin (Figure 45 B). However, this effect was less pronounced than in the benign PDEC, and more 
pronounced in the normoglycaemic than in the hyperglycaemic setting.  
Intriguingly, the mRNA level of the mesenchymal marker Vimentin was reduced by 50% in H6c7-kras cells 
arising from normoglycaemic conditions treated with sgp130Fc, while no effect was observed upon 
sgp130Fc treatment of cells from hyperglycaemic coculture (Figure 45 D).  
L1CAM gene expression levels were elevated through the blockade of IL-6 trans-signalling in H6c7-kras 




Figure 45: Blockade of IL-6 trans-signalling via sgp130Fc promotes the expression of epithelial and 
mesenchymal markers in PDEC. H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised macrophages 
(MF) for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and treated with 10 μg/ml of sgp130Fc 
or ctrlFc (ctrl). The epithelial cells were separated from direct coculture via CD11b-MACS depletion of M1-MF and 
used for qPCR analysis. The relative gene expression levels of E-Cadherin (A and B), Vimentin (C and E) and L1CAM 
(E and F) of both cell lines are depicted, normalised to the housekeeping gene GAPDH and presented as n-fold 
expression compared to the equivalent ctrl sample. Normally distributed data are presented as mean and standard error 
of mean, unpaired t-test was performed for statistical analysis. n=4 
4.4.2.1.4 Treatment with sgp130Fc impacts heterogeneously on gene expression levels of CSC 
markers in PDEC 
The blockade of IL-6 trans-signalling led to a significant increase in gene expression levels of Nestin in 
H6c7-pBp cells arising from hyperglycaemic coculture (4.90-fold increase compared to the control) 
(Figure 46 A). Interestingly, H6c7-pBp cells arising from normoglycaemic coculture were not impacted at 























































































































































































levels of Nestin irrespective of the glucose level. In H6c7-kras cells, on the other hand, sgp130Fc treatment 
led to increased Nestin expression levels irrespective of the glucose level in coculture settings (Figure 46 B). 
While Tocilizumab did not show any impact on the gene expression level of Nanog in the benign PDEC, 
sgp130Fc led to an 8.03-fold increase in cells arising from normoglycaemic and to a 2.80-fold increase in 
cells from hyperglycaemic coculture (Figure 46 C). 
Nanog showed weak tendencies of decrease in H6c7-kras cells upon treatment with sgp130Fc irrespective 
of the glucose level (Figure 46 D). These results stand in contrast to those obtained by treatment with 
Tocilizumab: both CSC-markers had been elevated in H6c7-kras arising from hyperglycaemic coculture 
(Figure 40 B and D). 
 
Figure 46: Blockade of IL-6-trans-signalling via gp130Fc promotes gene expression level of Nestin in PDEC. 
H6c7-pBp or H6c7-kras cells were cocultured with M1-polarised macrophage (MF) for 5 days in normo- or 
hyperglycaemic settings (5 or 25 mM of glucose) and treated with 10 μg/ml of sgp130Fc or ctrlFc (ctrl). The epithelial 
cells were separated from direct coculture via CD11b-MACS depletion of M1-MF and used for qPCR analysis. The 
relative gene expression levels of Nestin (A and E) and Nanog (C and F) of both cell lines are depicted, normalised to 
the housekeeping gene GAPDH and presented as n-fold expression compared to the equivalent ctrl sample. Normally 
distributed data are presented as mean and standard error of mean, unpaired t-test was performed for statistical analysis. 
*: 0,05>p>0,0332; n=4 
To sum up, sgp130Fc treatment promotes gene expression of EMT- and CSC-inducing mediators and 
transcription factors, especially IL-8, TGF-b1, Slug and Zeb1. These effects were observed in both cell lines, 
however, they were more pronounced in benign than in premalignant PDEC. Furthermore, blocking IL-6 
trans-signalling led to elevated mRNA level of both epithelial and mesenchymal markers in H6c7-pBp cells. 
In H6c7-kras cells, however, the epithelial marker E-Cadherin was also elevated, but the mesenchymal 


































































































































4.4.2.2 Treatment with sgp130Fc impacts on the colony formation ability of PDEC 
Finally, the impact of sgp130Fc on the colony formation ability of PDEC from normo- and hyperglycaemic 
coculture with M1-polarised macrophages was analysed via colony formation assays. For this, the quantity 
and quality of colonies formed by PDEC treated with either sgp130Fc or with the controlFc were analysed. 
 
 
Figure 47: Impact of sgp130Fc on the colony formation ability of PDEC arising from normo- or 
hyperglycaemic coculture with M1-polarised macrophages (MF). H6c7-pBp or H6c7-kras cells were cocultured 
with M1-polarised MF for 5 days in normo- or hyperglycaemic settings (5 or 25 mM of glucose) and treated with 
10 μg/ml of sgp130Fc or ctrlFc (ctrl). The epithelial cells were separated from direct coculture via CD11b-MACS 
depletion of M1-MF and used for colony formation assays. For this, 800 cells/well were seeded in duplicates and 
cultivated for 8 to 14 days. After fixation and staining, colonies of more than 50 cells were analysed. The total number 
of colonies per well (A and B) and the quality of colonies (C and D) formed under the differing treatments are shown. 
Data are depicted as n-fold compared to the equivalent ctrl sample. Normally distributed data are presented as mean 
and standard error of mean, unpaired t-test was performed for statistical analysis. *: 0,05>p>0,0332; n=6 
H6c7-pBp cells arising from normoglycaemic settings showed a 1.29-fold increase in the total number of 
colonies formed upon treatment with sgp130Fc (Figure 47 A). Cells from hyperglycaemic settings, 
however, formed less colonies after treatment with sgp130Fc. A 0.66-fold reduction was to be observed 





























































H6c7-pBp: Type of colony formed













































































H6c7-kras: Type of colony formed
















Normoglycaemic premalignant PDEC treated with sgp130Fc showed a significant 0.61-fold reduction in 
the number of colonies formed compared to their control (Figure 47 B). Hyperglycaemic H6c7-kras cells 
also showed a decrease in colonies formed upon treatment with gp130Fc, but this decrease was less 
pronounced than under normoglycaemic conditions. 
Similar to the effects observed after treatment with Tocilizumab (Figure 41 C), normoglycaemic H6c7-pBp 
cells treated with sgp130Fc showed a 1.4-fold increase in the percentage of holoclones (Figure 47 C). In 
hyperglycaemic H6c7-pBp cells, sgp130Fc did almost not alter the percentage of para-, mero- or holoclones. 
In the premalignant PDEC, on the other hand, sgp130Fc treatment in normoglycaemic setting evoked an 
increase of meroclones (2.25-fold elevation compared to the control) and a slight increase in holoclones 
(1.36-fold increase compared to the control) (Figure 47 D). In hyperglycaemic settings, the effect of 
sgp130Fc was similar to the normoglycaemic settings, albeit less pronounced (1.61-fold increase in mero-, 
and 1.23-fold increase in holoclones compared to the equivalent control). 
To sum up, colony formation abilities of PDEC were slightly altered by treatment with sgp130Fc. The 
decrease in the total number of colonies formed by H6c7-kras cells upon blockade is to be emphasized, as 
is the shift towards more meroclones. In H6c7-pBp cells arising from normoglycaemic coculture, an increase 
in holoclones is to note, which is similar to the results observed upon treatment with Tocilizumab. 
 
 
Altogether, the blockade of IL-6 signalling pathways shows an impact on both EMT- and CSC-properties 
in PDEC. 
Interestingly, the complete blockade of IL-6 signalling via Tocilizumab primarily has an EMT- and CSC-
inducing effect in H6c7-kras arising from hyperglycaemic culture. 
CSC-properties were also impacted in H6c7-pBp cells, especially elevated mRNA levels of Nestin and Nanog 
are to note in this context. Closely linked to this, the elevated capacity of H6c7-pBp cells to form holoclones 
is also important as an indicator for the acquisition of CSC-properties. 
The exclusive blockade of trans-signalling via sgp130Fc, on the other hand, predominantly influenced the 
benign PDEC. A shift towards a more pro-inflammatory, mesenchymal phenotype was to be observed here. 
However, also the epithelial marker E-Cadherin, whose reduction is known to be the milestone in EMT 
induction, showed elevated gene expression levels upon treatment with sgp130Fc. 
In H6c7-kras cells, sgp130Fc also provoked a shift towards a more pro-inflammatory phenotype, however, 
no gain in mesenchymal markers was to be observed. One may therefore suppose that EMT induction is 
reduced through the blockade of IL-6 trans-signalling. Furthermore, H6c7-kras’ colony formation ability is 
reduced. Together with the finding that sgp130Fc decreases mRNA levels of Nanog in the premalignant 




PDAC is among the few tumour entities with increasing incidence and mortality. 80 % of all PDAC patients 
are first diagnosed in late stages of tumourigenesis, leaving palliative treatment as the only option. In the 
last years, a special focus has been laid on the role of the local microenvironment in progression and 
initiation of PDAC as it is generally acknowledged that the high extent to which desmoplasia is present in 
PDAC tissue is characteristic and may be one potential point of attack for screening and treatment methods. 
In this context, an inflammatory stroma – which represents up to 90% of the entire tumour mass (Erkan et 
al., 2012) and comprises macrophages as one important immune cell population – and hyperglycaemia seem 
to play a pivotal role. In line with this, chronic inflammation, obesity and T2DM are considered prominent 
risk factors contributing to the initiation and progression of PDAC (Calle et al., 2003; Liao et al., 2015). 
Infiltration of tumour tissue with macrophages is acknowledged to be associated with poorer prognosis in 
various tumour entities including PDAC (Bingle et al., 2002; Kurahara et al., 2013). The same also applies 
to high blood glucose levels: there are many studies showing that T2DM patients are subject to an increased 
risk to develop one of several cancer entities, e.g. PDAC (Huxley et al., 2005), but also breast cancer (Larsson 
et al., 2007), endometrium cancer (Friberg et al., 2007), colorectal cancer (Larsson et al., 2005) and others. 
Furthermore, Wang et al. could show that pancreatic tumour cell proliferation is promoted in diabetic mice 
(Wang et al., 2016). 
Therefore, the aim of this study was to assess the interplay of macrophages and PDEC in the context of 
high glucose levels and to evaluate whether a T2DM-related inflammatory and hyperglycaemic 
microenvironment further promotes malignancy-associated alterations in PDEC. To assess this question, a 
direct coculture system was chosen to mimic this inflammatory microenvironment of benign or 
premalignant PDEC with macrophages under normo- or hyperglycaemic conditions. In a first step, focus 
was laid on alterations in macrophages themselves; in a second step, the glucose- and inflammation-induced 
impact on EMT and CSC induction in PDEC was evaluated. 
5.1 Impact of  hyperglycaemia and PDEC on macrophages 
To examine macrophages’ potential contribution to PDAC initiation, a direct coculture system of 
macrophages and PDEC was chosen, mimicking an obesity and T2DM-associated microenvironment. First 
findings of our group suggested that elevated TNF-a levels expressed by macrophages upon exposure to 
high glucose levels may influence EMT progression within PDAC development (Plundrich, 2017). This 
interplay between macrophages and PDEC in T2DM-associated hyperglycaemic conditions on 
macrophages themselves was now to be further elucidated. For this purpose, M1-polarised macrophages 
were chosen, as Castoldi et al. could show that macrophages adopt a pro-inflammatory phenotype in the 
state of metabolic disorder (Castoldi et al., 2016). 
We could show highly elevated expression levels of pro- and anti-inflammatory cytokines and growth factors 
in macrophages exposed to PDEC and high glucose levels simultaneously. Especially IL-6 levels were highly 
upregulated, but also IL-8 levels and – in line with previous findings of Plundrich et al. – also TNF-a levels 
were increased. Furthermore, the mRNA levels of VEGF and anti-inflammatory IL-10 were upregulated in 
Discussion 
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macrophages arising from coculture with benign PDEC (Figure 14). Together, these findings highlight the 
role of macrophages as an important source for abundant cytokine expression in inflammatory tissue in 
metabolic disorders (Mantovani et al., 2008; Grivennikov et al., 2011) and also underline the plasticity of 
macrophages: even though macrophages had been polarised towards M1-macrophages according to a well-
established protocol, they showed high levels of cytokines linked to both M1- and M2-associated expression 
profiles after coculture with PDEC and exposure to hyperglycaemia. This, once again, indicates that 
macrophages cannot clearly be categorised into the one or the other extreme. Rather, the polarisation of 
macrophages is influenced by their respective microenvironment (Helm et al., 2014a). 
When further analysed, it turned out that changes in gene expression levels of these cytokines were mainly 
due to the presence of PDEC and only to a lesser extent due to the presence of high glucose levels 
(Figure 15 and Figure 16). Apart from a glucose-dependent elevation of VEGF expression levels in 
macrophages cocultured with premalignant PDEC, hyperglycaemia alone did not show any relevant effect 
on the gene expression levels of the other cytokines analysed. This partly stands in contrast to findings of 
Cheng et al., who could show elevated levels of especially pro-inflammatory cytokines in monocytes upon 
exposure to high glucose levels (Cheng et al., 2015). One possible explanation for this divergence is that 
human monocytes were isolated from blood samples and then differentiated to M1-polarised macrophages 
in vitro in the current study, whereas the group of Cheng et al. examined gene expression levels in monocytes 
prior to specific macrophage differentiation. In line with this, Moganti et al. could show that high glucose 
levels induce TNF-a gene expression in monocytes, but that this effect is no longer to be observed once 
the differentiation from monocytes towards macrophages starts (Moganti et al., 2017). Morey et al. also 
asserted glucose-dependent increases in expression levels of pro-inflammatory cytokines in macrophages 
(Morey et al., 2019). However, already the differentiation from monocytes to macrophages was performed 
under hyperglycaemic conditions in their experimental setup, whereas in our study exposure to 
hyperglycaemia started once macrophages were fully differentiated, attributing a particular importance to 
the glucose level throughout the differentiation process. Supporting this thesis are findings from Pavlou et 
al.: their experimental set up included macrophages differentiated from both monocytes in normoglycaemic 
and monocytes in hyperglycaemic conditions. In the latter, macrophages showed elevated gene expression 
levels of TNF-a and IL-6; gene expression levels of macrophages which had been differentiated under 
normoglycaemic conditions comparable to our study, however, did not respond to high glucose levels 
(Pavlou et al., 2018). In this context, it would be of interest to evaluate the cytokine profile of macrophages 
arising from the pancreata of e.g. diabetic mice, as these are constantly exposed to high glucose levels. 
Furthermore, it is important to keep in mind that the human derived monocytes in our study arise from 
different blood donors. The expression patterns of cells originating from different blood donors were 
shown to vary largely depending on the marker analysed (Moganti et al., 2017). This helps to explain the 
wide range of expression levels obtained throughout the five experiments (and blood donors) and points 
out one limitation of the current study. 
Nevertheless, the current results clearly underline the importance of macrophages in the acquisition of 
malignancy-associated properties in PDAC and with tumour initiation. Soluble mediators of EMT- and 
CSC-properties were highly elevated in macrophages in the concomitant presence of PDEC and high 
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glucose; IL-6, IL-10, TNF-a and VEGF are all known to be pro-tumourigenic factors (Mantovani et al., 
2006; Solinas et al., 2009; Hermano et al., 2014). Furthermore, an immunosuppressive microenvironment is 
fostered by amplified secretion of IL-8, IL-10, and regulation of angiogenesis via VEGF (Kleeff et al., 2007; 
Pandol et al., 2009; Kurahara et al., 2013). Apart from IL-10 levels, all of the above effects were slightly 
more pronounced in macrophages in coculture with premalignant than with benign PDEC, suggesting a 
dependency on kras mutation. In this context, Lesina et al.  and Gukovsky et al. report of kras-dependent 
self-amplifying signalling cascades (Figure 3), which attract macrophages and other immune cells and 
support their secretion of especially IL-6 and TNF-a, promoting invasiveness of PDEC (Lesina et al., 2011; 
Gukovsky et al., 2013). Furthermore, several studies promote the idea that a mutation in the oncogene ras 
is crucial for direct cross-talk between epithelial cells and macrophages (Guerra et al., 2011; Liou et al., 2015; 
Storz, 2015), which could also explain the more pronounced reaction of  macrophages towards premalignant 
PDEC in this study. 
Special attention needs to be paid to the highly elevated IL-6 levels in macrophages upon coculture with 
PDEC (838-fold and 1550-fold elevation in macrophages arising from hyperglycaemic coculture with H6c7-
pBp and H6c7-kras cells, respectively) (Figure 14). High serum levels of IL-6 in PDAC patients have been 
associated with poorer prognosis in several studies (Okada et al., 1998; Scholz et al., 2003; Ebrahimi et al., 
2004) and in line with our findings, Lesina et al. could identify macrophages as main source of IL-6 in 
pancreatic tumourigenesis (Lesina et al., 2011). The interplay of IL-6, macrophages and PDEC will be 
discussed in more detail in chapter 5.5 in the context of the IL-6 blockade experiments. 
Altogether, this current study underlines that macrophages show abundant alterations in expression of 
cytokines known to play a pivotal role in pancreatic tumourigenesis upon interaction with PDEC, which 
can be further amplified in the presence of glucose. To further elucidate which mediators trigger these 
alterations, analysis of cytokines and soluble mediators in the equivalent supernatants are planned in future 
experiments. 
5.2 Exposure to hyperglycaemia and/or high glucose levels induces EMT 
in PDEC 
Further experiments investigated the impact of a T2DM-associated microenvironment on PDEC. H6c7-
pBp and H6c7-kras cells were exposed to M1-polarised macrophages and/or hyperglycaemia in a direct 
coculture system. 
Upon coculture in hyperglycaemic conditions, an induction of the mesenchymal markers Vimentin and 
L1CAM and a loss of the epithelial marker E-Cadherin was visible in both PDEC lines (Figure 19 (mRNA 
level) and Figure 29 (protein level)), indicating an EMT-promotion. Additionally, mRNA levels of the 
EMT-inducing transcription factors Zeb1, Snail and Slug were increased in H6c7-kras and H6c7-pBp cells 
(Figure 18). However, some of these EMT-associated alterations were more prominent in the premalignant 
cells than in their benign counterpart and vice versa; and when further analysed, it turned out that some 
changes were rather triggered by exposure to high glucose levels, others by exposure to macrophages and 
for some, synergistic effects of macrophages and hyperglycaemia were to be observed. Previous studies have 
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revealed that EMT in PDAC is promoted by the presence of macrophages (Helm et al., 2014a) or by 
exposure to hyperglycaemia (Wang et al., 2016), but there are only few studies analysing the combined effect. 
However, these phenomena are closely linked since both are crucial mediators of an inflammatory milieu. 
Last but not least it is known that glucose can also promote a pro-inflammatory phenotype in macrophages 
as described in chapter 5.1 and thereby reinforces their effect. 
Loss in E-Cadherin levels – commonly referred to as the milestone in EMT – was most pronounced in 
H6c7-kras cells exposed to macrophages and hyperglycaemia, underlining a synergistic effect. The 
transcription factor Snail is known to repress E-Cadherin and other epithelial molecules (Batlle et al., 2000); 
in line with this, Snail levels showed a stronger increase in the premalignant than in the benign PDEC upon 
exposure to a T2DM-associated microenvironment. Congruent with our findings, several other studies 
could show that the expression of Zeb1, Slug and Snail is closely intertwined with the repression of E-
Cadherin levels, and enhanced levels thus promote EMT (Peinado et al., 2007; Nieto et al., 2016). That these 
effects were more pronounced in the premalignant PDEC again implies a dependency on kras mutation. 
Coinciding with this hypothesis, several mice models demonstrated that caerulin-induced pancreatic 
inflammation leads to tumour progression exclusively in mice harbouring kras-mutation (Guerra et al., 2007; 
Carrière et al., 2009). Daniluk et al. suggest the idea of an inflammation-induced positive feedback loop via 
NF-kB which is strictly dependent on oncogenic kras causing an amplification of kras levels up to 
pathological levels, thereby promoting tumourigenesis. The group suggests it as a possible target for therapy 
via COX-2-inhibtor or inhibition of the inhibitor of  NF-kB kinase 2 (Daniluk et al., 2012). As already 
mentioned in chapter 5.1, Storz et al. identified kras mutation as a mediator of ICAM-1 upregulation which 
attracts M1-polarised macrophages and promotes secretion of pro-inflammatory cytokines and proteases 
leading to tumour progression (Storz, 2015). Altogether, this might explain the pronounced effect in H6c7-
kras cells in e.g. the loss in E-cadherin levels, where an additional kras-dependent direct crosstalk between 
macrophages and epithelial cells is possible, whereas this additional interaction is missing in the benign 
H6c7-pBp cells. 
However, the upregulation of Vimentin and Zeb1 expression was more prominent in H6c7-pBp than in 
H6c7-kras cells upon exposure to macrophages and hyperglycaemia. Therefore, other mechanisms by which 
EMT is promoted by inflammatory processes also seem to be important and need further investigation. 
TGF-b1 is referred to as one of the most potent EMT inducers in various cancer entities (Jing et al., 2011). 
In previous studies, our group could already identify TGF-b1 as a key player in glucose-dependent EMT 
induction in H6c7-kras and Panc1 cells (Rahn et al., 2018). In the current study, a predominantly glucose-
dependent increase in TGF-b1 level in both PDEC lines could be observed (Figure 21). This points to the 
importance of TGF-b1 as a mediator of EMT initiation in a diabetes-associated microenvironment not only 
in (pre)malignant stages of PDAC but also in benign epithelial cells. The basal expression level of TGF-b1 
was higher in H6c7-kras than in H6c7-pBp cells (data not shown). This is one further possible explanation 
for the more pronounced EMT induction in the premalignant than in the benign PDEC as several studies 
could show autocrine amplification of TGF-b1 signalling in epithelial cells thereby encouraging EMT 
progression (Derynck et al., 2001; Kalluri and Weinberg, 2009; Wu and Derynck, 2009). Furthermore, Oft 
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et al. point out a direct link between EMT induction via activation of autocrine TGF-b signalling loops and 
ras mutation in a human mammary epithelial cells (Oft et al., 1998). Moreover, elevated TGF-b1 expression 
through ERK-activation in dependency on a mutation in the oncogene kras is also reported for some other 
tumour entities (Tsubaki et al., 2011). 
A further important mechanism by which TGF-b1 is linked to EMT in PDAC is described by Geismann et 
al.: upon exposure to myofibroblasts, L1CAM expression is upregulated in a TGF-b-dependent manner in 
PDEC, leading to a more mesenchymal and motile phenotype (Geismann et al., 2009). In the current study, 
we could also observe a coculture-dependent increase on the mRNA level of L1CAM in both PDEC lines 
(Figure 27), however, hyperglycaemia decreased gene expression levels in both cell lines (Figure 23). This 
challenges the hypothesis of its TGF-b1-dependency in our study, as TGF-b1 was upregulated in a glucose-
dependent manner as described above; and points out the context-dependency of the effects caused by 
TGF-b1. Similar to our findings, Mrazkova et al. observed a reduction in L1CAM levels in cancer cells 
cultured in hyperglycaemic conditions (which could be reversed by interfering in the glycolytic metabolism) 
and suggested a link between L1CAM expression and glycolytic energy metabolism of tumour cells 
(Mrazkova et al., 2018). 
Intriguingly, L1CAM was inversely affected on protein compared to mRNA level: coculture and 
hyperglycaemia synergistically increased L1CAM expression in H6c7-pBp cells; in H6c7-kras cells a 
coculture- dependent decrease and glucose-dependent increase were to be observed (Figure 29). 
IL-8 is also described as an initiator of EMT in various cancer entities and IL-8 serum levels have been 
shown to be of prognostic value (Millar et al., 2008; Fernando et al., 2011; Chen et al., 2012; Wen et al., 
2020). In this study, however, decreased levels of IL-8 were observed in H6c7-pBp cells when cocultured 
with macrophages, whereas no relevant changes at all were to be detected in H6c7-kras cells upon exposure 
to macrophages (Figure 17). One possible explanation for the divergence in IL-8 levels in the two cell lines 
might be found in gene expression levels of TNF-a, as IL-8 and TNF-a levels were shown to be directly 
correlated in other tumour entities (Ma et al., 2017). In the current study, TNF-a levels were decreased in a 
coculture-dependent manner in the benign cells, whereas contrary effects were seen in the premalignant 
cells. Furthermore, macrophages showed highly elevated levels of the anti-inflammatory IL-10 when 
exposed to the benign, but not the premalignant PDEC (Figure 16), which can be considered as one 
possible mediator of the coculture-dependent loss in in the expression of pro-inflammatory IL-8 and 
TNF-a in H6c7-pBp cells. However, to further support this hypothesis, supernatants should be analysed to 
verify the contribution of potential mediators to the observed alterations in the expression of EMT markers 
of PDEC upon exposure to a T2DM-associated microenvironment. 
Collectively, the current study reveals that an enhanced inflammatory microenvironment not only leads to 
induction and promotion of EMT in premalignant PDEC already harbouring a kras mutation, but also in 
benign cells even though to a slightly lesser extent. 
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5.3 The acquisition of  CSC-properties in PDEC is promoted by a T2DM-
associated microenvironment 
It is uncontroversial that the microenvironment also influences the CSC-properties of tumour cells (Ye et 
al., 2014; Plaks et al., 2015). In the current study, a gain in stemness-properties in PDEC could be observed 
upon exposure to a T2DM-typical microenvironment by evaluating expression levels of the CSC markers 
Nestin and Nanog and by analysis of colony formation. 
Nestin is known to be involved in the regulation of cell proliferation and to play a crucial role in tumour 
growth, invasiveness and migratory potential of pancreatic cancer cells (Matsuda et al., 2011, 2012; Su et al., 
2013). In our study, Nestin was highly upregulated through combined hyperglycaemia and coculture in the 
premalignant H6c7-kras cells, but only to a much lesser extent and in an exclusively glucose-dependent 
manner in the benign H6c7-pBp cells (Figure 20 and Figure 24). Matsuda et al. were able to link enhanced 
Nestin levels with EMT progression (Matsuda et al., 2014) which coincides with our findings that H6c7-
kras cells showed a greater shift towards a more mesenchymal phenotype upon exposure to T2DM-
associated microenvironment than H6c7-pBp cells. 
Intriguingly, Nanog levels were increased in H6c7-pBp cells through normoglycaemic, but decreased through 
hyperglycaemic coculture with macrophages, whereas in H6c7-kras cells Nanog expression was decreased 
upon both exposure to hyperglycaemia and/or macrophages (Figure 20). This partly stands in contrast to 
observations of Yang et al. who could identify a TAM-dependent increase in Nanog expression levels in 
breast cancer cells promoting their tumourigenicity (Yang et al., 2013). Furthermore, knockdown of Nanog 
and Oct-4 was shown to diminish CSC-properties in pancreatic cancer cells in vitro and in vivo, attributing to 
Nanog an important role in the acquisition of CSC-properties such as proliferation, migration, 
chemoresistance and tumourigenesis in PDAC (Lu et al., 2013). Moreover, there are also studies classifying 
the increase in Nanog expression levels as an early event in tumourigenesis. Wen et al. revealed elevated 
expression of Nanog and Oct-4 (which are co-expressed as Oct-4 is intertwined in the expression of Nanog) 
in non-cancerous pancreatic tissue and in precancerous lesions preceding kras-mutation (Wen et al., 2010). 
This is one possible explanation for the differing impact we observed in benign and premalignant PDEC; 
our findings might therefore attribute a significant role to Nanog in early inflammation-related acquisition 
of malignancy-associated alterations. However, further analysis is necessary here to fully understand the 
underlying mechanisms. 
The pro-inflammatory cytokine TNF-a has been associated with the acquisition of both EMT- and CSC-
characteristics in various tumour entities, including PDAC (Egberts et al., 2008; Storci et al., 2010; C. Li et 
al., 2012; Wang et al., 2013; Zhang et al., 2014). In the current study, TNF-a expression levels were highly 
elevated in a coculture-dependent manner in H6c7-kras cells, whereas they were decreased in the benign 
cells (Figure 25). In macrophages exposed to PDEC, TNF-a levels were also strongly elevated 
(Figure 16) – in a slightly more pronounced manner in macrophages arising from coculture with H6c7-kras 
cells implying a kras-dependency. Bates et al. suggest a link between macrophages’ TNF-a expression and a 
thereby induced autocrine TNF-a production of epithelial cells which is dependent on ERK-activation 
(Bates and Mercurio, 2003). This could explain the higher gene expression level of TNF-a in premalignant 
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than in benign PDEC and further corroborates our findings of a complex crosstalk between macrophages 
and epithelial cells promoting and self-amplifying a favourable inflammatory microenvironment for the 
acquisition of EMT- and CSC-associated properties in PDEC. Storci et al. were able to link the acquisition 
of an aggressive stem cell like phenotype in breast cancer cells to the activation of EMT-associated 
transcription factor Slug via signalling cascades of TNF-a and its downstream target NF-kB (Storci et al., 
2010). In our study, p-p65, the activated subunit of NF-kB, was clearly enhanced on protein level in both 
PDEC lines upon exposure to macrophages (Figure 29), with the basal expression level being substantially 
higher in the premalignant than in the benign PDEC. It is known that NF-kB can be activated in several 
ways, amongst others by pro-inflammatory cytokines secreted by TAMs or cancer cells themselves, or 
through oncogenic activation of kras. This explains the higher expression level of p-p65 in monocultured 
H6c7-kras cells compared to H6c7-pBp cells and leads to the assumption that the coculture-dependent 
induction in these cells is associated with the TNF-a elevation detected on mRNA level, which can in turn 
contribute to an autocrine activation of NF-kB (Gukovsky et al., 2013) and induce stemness features in the 
epithelial cells. In H6c7-pBp cells, however, other mechanisms seem to be responsible for the observed 
acquisition of CSC-properties, as TNF-a levels were contrarily influenced to NF-kB levels upon exposure 
to macrophages and hyperglycaemia. 
Diabetic culture conditions were shown to promote proliferation and invasiveness of pancreatic cancer cells 
via elevated TNF-a and NF-kB levels (Wang et al., 2016). Inhibition of this signalling cascade decreased 
tumour size and ameliorated survival rates in diabetic mice bearing pancreatic tumours. In our study, 
however, glucose alone only marginally impacted on the gene expression level of TNF-a (Figure 21), they 
were predominantly influenced by the presence of macrophages (Figure 25). 
Moreover, enhanced stemness features could be shown in PDEC upon exposure to glucose in colony 
formation assays. We refrained from evaluating the impact of coculture, as preliminary experiments had 
shown that the magnetic cell separation counterfeits an increased gain in CSC-associated properties (data 
not shown). However, hyperglycaemia led to a shift towards more mero- and holoclones at the expense of 
paraclones in both H6c7-pBp and H6c7-kras cells (Figure 30). Whereas the glucose-induced acquisition of 
CSC-associated properties was more pronounced in monocultured benign PDEC than in cocultured ones, 
the premalignant PDEC are similarly impacted under both cultivation conditions. This effect was congruent 
with the glucose-dependent increase of Nestin on mRNA level of PDEC, suggesting a direct link here. This 
is supported by a previous study of our group, in which a knockdown of Nestin in Panc1-Holoclones did 
not only decrease the total number of colonies formed but also induced a loss in the proportion of 
holoclones and a gain in mero- and paraclones (Knaack, 2018). 
Together these findings again point to the importance of an enhanced inflammatory microenvironment and 
elevated glucose levels in the acquisition of malignancy-associated alterations with special regard to stemness 
features. 
However, the experimental setting deserves some discussion. Even though the chosen direct-coculture 
system allows direct interaction between the respective cell populations, it evidently has some limitations. 
For one, it has to be kept in mind, that H6c7-pBp and H6c7-kras cells chosen as an in vitro model for benign 
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and premalignant PDEC were both retrovirally transduced. The possibility cannot be excluded that this 
causes genomic alterations not to be found in vivo. Finally, the chosen experimental setup cannot sufficiently 
represent the complexity of in vivo conditions as other cellular populations are not present in the culture 
system but in vivo. It serves as a simplified model of an inflammatory milieu in precursor lesions of PDAC. 
It is therefore necessary to transfer this into an in vivo, e.g. mouse model. 
5.4 Impairment of  TGF-b1 signalling partly abrogates the induction of  
hyperglycaemia and macrophage mediated EMT- and CSC-
characteristics in PDEC 
Further experiments analysed whether enhanced TGF-b1-expression contributed to the glucose- and 
coculture-dependent acquisition of malignancy-associated properties of PDEC. TGF-b1 is described as a 
mediator of PDAC promotion (Otsuru et al., 2019) and impaired TGF-b1 signalling was already shown to 
inhibit EMT in skin and colorectal cancer (Han et al., 2005; Pino et al., 2011). Indeed, the glucose- and 
macrophage-mediated acquisition of EMT- and CSC-properties was lost after knockdown of TGF-bRII in 
H6c7-pBp cells. This was demonstrated through reduction in gene expression levels of TNF-a and IL-6 
(Figure 31), a gain in E-Cadherin and loss of Vimentin levels (Figure 33) and a decreased proportion of 
holoclones in CFAs (Figure 35). Furthermore, previous experiments of our group had revealed an increase 
in the migratory potential of PDEC arising from a hyperglycaemic and inflammatory surrounding 
(Plundrich, 2017), which we could now show to be reduced upon inhibition of TGF-b1-signalling 
(Figure 36). 
In the premalignant cells, TGF-bRII knockdown also reversed some of the alterations that had been 
observed upon exposure to a T2DM-associated microenvironment. However, EMT was only partially 
reversed, as E-Cadherin levels were elevated, but so were Vimentin levels. Nevertheless, the migratory 
capacity was reduced, suggesting TGF-b as one potential contributor to the acquisition of malignancy-
associated alterations in premalignant PDEC as well. Unexpectedly, Nestin expression was elevated upon 
TGF-bRII knockdown (Figure 34), which partly stands in contrast to previous findings of our group which 
revealed a decrease in Nestin levels when TGF-b signalling was impaired (Rahn et al., 2018). However, cells 
had only been monocultured in the previous study, suggesting that in the current study the presence of 
macrophages promotes the expression of stemness features by activating alternative signalling pathways. 
One possible mediator of this is TNF-a, which showed elevated gene expression levels upon knockdown 
of TGF-bRII in normoglycaemic conditions (Figure 31). In line with this, Slug levels were elevated and 
also the proportion of holoclones formed was higher (Figure 32 and Figure 35). In hyperglycaemic 
conditions, on the other hand, all these markers showed reduced expression levels upon knockdown of 
TGF-bRII, pointing to a loss in CSC-properties. 
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Whereas the efficiency and stability of the TGF-bRII knockdown was verified to guarantee a stable gene 
suppression throughout the duration of the experiments, it still remains to analyse whether down-stream 
signalling is also effectively blocked. 
In summary, we could show that TGF-b1 is at least partly responsible for the alterations in EMT- and CSC-
properties in PDEC in a hyperglycaemic and inflammatory milieu. Especially in benign cells knockdown of 
TGF-bRII could undermine the acquisition of malignancy-associated features. In the presence of the 
oncogene kras, the cells seem to be able to activate alternative pathways to keep up at least some EMT- and 
CSC-characteristics. Further experiments, e.g. analysis of gene expression in macrophages after blockade of 
TGF-b signalling and assessment of secreted cytokines in the supernatants of all culture settings, are 
necessary to fully understand the underlying mechanisms. Nevertheless, these first experiments suggest 
TGF-b1 to be closely intertwined in the complex crosstalk between macrophages, hyperglycaemia and 
PDEC promoting acquisition of malignancy-associated alterations of the latter. 
5.5 Induction of  EMT- and CSC-characteristics in premalignant PDEC 
can partially be attributed to IL-6 trans-signalling 
IL-6 is a pro-inflammatory cytokine known to be elevated in T2DM-patients and it is even attributed a 
prognostic value concerning the risk of T2DM onset (Spranger et al., 2003; Kristiansen and Mandrup-
Poulsen, 2005). Similarly, elevated IL-6 serum levels were shown to be associated with a poorer prognosis 
in various cancer entities (Ebrahimi et al., 2004; Gao et al., 2007; Storci et al., 2010). As IL-6 gene expression 
was strongly modulated in macrophages upon exposure to PDEC and glucose, IL-6 signalling was blocked 
to determine whether this cytokine is a mediator of the EMT- and CSC-associated alterations in PDEC. 
The complete blockade of IL-6 signalling via Tocilizumab (classic and trans-signalling impaired) 
predominantly induced EMT- and CSC-characteristics in H6c7-kras cells arising from hyperglycaemic 
conditions. Besides elevated levels of IL-8, TGF-b1 and IL-6 (Figure 37), the mesenchymal markers 
Vimentin and L1CAM were increased. However, the epithelial E-Cadherin was also upregulated, and the 
migratory capacity reduced upon Tocilizumab treatment, implying a partial EMT reversion. The acquisition 
of stemness features was reflected by elevated expression levels of Zeb1, Nestin and Nanog (Figure 38 and 
Figure 40), as well as by an increase in the share in holoclones (Figure 41). 
H6c7-pBp cells were hardly impacted through Tocilizumab treatment; only slight induction tendencies of 
CSC-features mirrored by an increase in Nestin expression level and, in line with this, an increase in 
holoclones were to be noted (Figure 40). Furthermore, the migratory potential of H6c7-pBp cells was 
elevated upon Tocilizumab treatment (Figure 42). However, these results need to be regarded with care as 
scratch assays were performed in cocultured PDEC, and it can thus not completely be guaranteed that 
migration of exclusively epithelial cells was evaluated and macrophages were not mistaken for epithelial 
cells. Moreover, cytokeratin stainings, which were performed in cocultured PDEC 24 hours after the scratch 
(and with this after termination of scratch assay analysis), revealed that the spatial distribution of the 
equivalent epithelial cells was not as dense as would be ideal for a scratch assay (data not shown), pointing 
out a further limitation of our current experimental setup. 
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The impact of Tocilizumab treatment observed on PDEC partly stands in contrast to findings of Wan et al. 
Their group attributed a great importance to elevated TAM-derived IL-6 levels in the context of invasiveness 
and acquisition of stemness features of hepatocellular carcinoma cell lines. They could show a reversion of 
these effects in vitro and reduced tumour growth in a xenograft mouse model upon Tocilizumab treatment 
(Wan et al., 2015). However, Wunderlich et al. revealed that the complete impairment of IL-6 signalling in 
hepatocytes can cause systemic inflammation. Levels of TNF-a and other pro-inflammatory cytokines were 
elevated upon blockade of IL-6 signalling in their study (Wunderlich et al., 2010), which is in line to the 
results we obtained in the hyperglycaemic premalignant cells (Figure 37). There are several other studies 
attributing IL-6 an important role not only in pro-inflammatory activities but also in the regulation of 
metabolic homeostasis. Haemostatic activities are attributed to classic signalling, whereas trans-signalling is 
responsible for the promotion of a pro-inflammatory environment. They show that a simultaneous blockade 
of classic and trans-signalling predominantly negatively impacts on the metabolic equilibrium (Matthews et 
al., 2010; Rose-John, 2012; Mauer et al., 2014; Kraakman et al., 2015). These studies are consistent with the 
shown findings in the premalignant cells treated with Tocilizumab. However, it remains to be elucidated 
why the benign PDEC are hardly impacted through Tocilizumab. Possibly, IL-6 classic signalling is of lesser 
importance for haemostatic activities in benign PDEC, thus its blockade is of lesser consequence. Possibly, 
the interplay of benign PDEC and macrophages counterbalances the Tocilizumab-dependent promotion of 
inflammation through anti-inflammatory mediators whose effect become more pronounced in the absence 
of IL-6 (which is not possible anymore in the premalignant cells harbouring a kras-mutation). Future 
experiments will have to further elucidate this issue. 
The exclusive blockade of trans-signalling via sgp130Fc, on the other hand, predominantly influenced the 
benign PDEC. A shift towards a more pro-inflammatory, mesenchymal phenotype was observed. In H6c7-
kras cells, sgp130Fc also provoked a shift towards a more pro-inflammatory phenotype, however, no gain 
in mesenchymal markers was to be observed (Figure 43 and Figure 45). In normoglycaemic conditions, 
blockade of IL-6 trans-signalling even resulted in a reduced EMT induction. Furthermore, H6c7-kras cells’ 
colony formation ability and mRNA levels of Nanog were decreased (Figure 46 and Figure 47), suggesting 
a sgp130Fc-dependent loss in CSC-properties. Consistent with this are findings of Lesina et al. who could 
show that PanIN progression is promoted via IL-6 signalling in a kras-dependent manner. The group also 
demonstrated that IL-6 trans-signalling leads to an activation of STAT3 (whereas classic signalling does not) 
and that impaired STAT3 signalling stops PanIN progression but not its initiation (Lesina et al., 2011). This 
might explain why we could observe a loss in EMT- and CSC-characteristics through treatment with 
sgp130Fc in H6c7-kras cells but not in H6c7-pBp cells. Similarly, Brooks et al. report kras-driven lung 
carcinogenesis to be dependent on IL-6 trans-signalling and reversible through equivalent blockade in both 
in vitro and in vivo experiments (Brooks et al., 2016). The group of Grivennikov describes TNF-a levels to 
be directly linked to IL-6 trans-signalling, as blockade led to reduced, and treatment with Hyper-IL-6 to 
elevated TNF-a levels in mice bearing colitis-associated cancer (Grivennikov et al., 2009). The group 
promotes the idea of a cross-regulation between IL-6 and TNF-a which is reliant on trans-signalling 
pathways and causes enhanced chronic inflammation and tumourigenesis. As TNF-a was not reduced upon 
blockade of trans-signalling in our current study, the importance of glucose and macrophages, promoting 
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the expression of pro-inflammatory cytokines also in absence of IL-6 is underlined. Future experiments 
should therefore also tend to the analysis of gene expression levels in macrophages upon blockade of IL-6 
signalling and to the analysis of supernatants from the equivalent coculture conditions to assess the secreted 
cytokines. 
Overall, the results of this study reveal that IL-6 is indeed closely intertwined with the progression of EMT 
and the acquisition of CSC features in PDEC. Blockade of IL-6 trans-signalling which has been reported to 
be effective as anti-tumour therapy in other cancer entities (Selander et al., 2004; Grivennikov et al., 2009; 
Brooks et al., 2016), might be one possible point of attack to undermine malignant progression, although, 
not to prevent tumour onset in PDAC patients. In very early precancerous stages, it might be of greater 
importance to target the inflammatory milieu which hyperglycaemia and obesity promote via recruitment of 
macrophages and self-amplifying pro-inflammatory signalling cascades. 
5.6 Outlook  
Overall, the current study corroborates the complex interplay of macrophages and hyperglycaemia as an 
important contributor to the acquisition of malignancy-associated alterations in PDEC. A T2DM- and 
obesity-associated hyperglycaemic and inflammatory microenvironment promotes a gain in EMT- and CSC-
features in PDEC. Partially, these alterations were more evident in the premalignant PDEC already 
harbouring a kras mutation, but benign H6c7-pBp cells acquired malignancy-associated properties through 
the presence of macrophages and/or hyperglycaemia, underlining the relevance of early prevention options. 
The observed alterations could partially be attributed to TGF-b signalling and partially to IL-6 signalling. 
Based on these findings, further experiments should be undertaken to reveal whether these cytokines and 
signalling cascades represent suitable target structures for the prevention of PDAC. Furthermore, the in vitro 
findings should be validated in an in vivo study, e.g., a diabetic mouse model, as coculture experiments are 
only a rough approximation and cannot fully mimic the complex in vivo microenvironment.  
Especially in high-risk patients, such as patients suffering from obesity or T2DM, an anti-inflammatory 





With less than 4 %, pancreatic ductal adenocarcinoma (PDAC) represents a small share in newly detected 
cancers but is among the few tumour entities with increasing incidence and mortality. By the year of 2030, 
PDAC is predicted to be the second most lethal neoplasia in western countries. Due to the lack of specific 
early symptoms, 80% of the patients are diagnosed in late tumour stages, leaving palliative treatment as the 
only therapeutic option. 
Besides chronic inflammation, obesity and type 2 diabetes mellitus (T2DM) - both associated with 
hyperglycaemia - are risk factors contributing to the initiation and progression of PDAC. However, 
underlying mechanisms are not yet fully understood. It is known that already precursor lesions are 
characterised by an inflammatory stroma. Macrophages, representing one of the largest immune cell 
populations within this stroma, impact on pancreatic ductal epithelial cells (PDEC) by promoting their 
malignant progression. Previous studies showed that high glucose levels influence the phenotype of 
macrophages, leading to the question whether these changes in macrophages’ phenotype in a T2DM-related 
inflammatory and hyperglycaemic microenvironment further facilitate malignancy-associated alterations in 
PDEC. In order to address this question, both, macrophages differentiated from human monocytes and 
H6c7-pBp and H6c7-kras cells mimicking benign and premalignant PDEC, were analysed after direct 
coculture under hyperglycaemia and compared to normoglycemic conditions. 
In macrophages, IL-6 levels were most strongly elevated, along with other pro-inflammatory cytokines such 
as IL-8 and of TNF-a. In PDEC, the pro-inflammatory hyperglycaemic microenvironment enhanced the 
acquisition of tumourigenesis-associated alterations: Epithelial-Mesenchymal-Transition (EMT) and the 
acquisition of cancer stemness properties were promoted; and common soluble mediators of these two 
phenomena were increased in their expression levels as well. Many of these alterations were slightly more 
pronounced in H6c7-kras cells, however, also benign PDEC cells were shown to be driven into malignant 
progression through the complex interplay of an inflammatory hyperglycaemic surrounding. This underlines 
the importance of early intervention options in high-risk patients. Blockade of TGF-b signalling partially 
reversed the above-mentioned changes in PDEC, as did the blockade of IL-6 trans-signalling via sgp130Fc, 
suggesting a partial involvement of these factors in inflammation and hyperglycaemia driven acquisition of 
malignancy-associated alterations and pointing to possible therapeutic points of attack. 
Overall, the current study corroborates the importance of the interplay of macrophages and hyperglycaemia 
as a leading contributor to the acquisition of malignancy-associated alterations in PDEC. It gives a new 
understanding of how metabolic disorders such as T2DM and obesity might initiate and promote PDAC. 
A better understanding of this is essential to foster ideas for potential early therapeutic intervention in high-
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